Elastin-like polypeptides in protein nanotechnology by Eldijk, M.B. van
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://repository.ubn.ru.nl/handle/2066/128473
 
 
 
Please be advised that this information was generated on 2017-03-09 and may be subject to
change.
Elastin-like polypeptides in protein 
nanotechnology  
 
 Mark B. van Eldijk
Elastin-like polypeptides in protein nanotechnology                                            M
ark van Eldijk
  
 
Elastin-like polypeptides in 
protein nanotechnology 
 
Proefschrift 
 
ter verkrijging van de graad van doctor aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus prof. mr. S.C.J.J. Kortmann, 
volgens besluit van het college van decanen in het openbaar te verdedigen 
op donderdag 3 juli 2014 om 14.30 uur precies 
 
 
door 
 
Mark Bernardus van Eldijk 
geboren op 28 augustus 1985  
te Veghel 
  
 
 
 
 
 
 
 
 
 
 
 
 
Promotor 
Prof. dr. ir. J.C.M. van Hest 
 
Manuscriptcommissie   
Prof. dr. G.J.M. Pruijn  
Prof. dr. M.A. Cohen Stuart (Wageningen University) 
Dr. M. Merkx (Technical University Eindhoven) 
 
Paranimfen 
Sanne Schoffelen 
Nanda Smits 
 
 
 
 
The research presented in this thesis forms part of the research programme of the Dutch 
Polymer Institute (DPI), project #693 
 
 
 
Omslagontwerp:  Tessa van Eldijk 
Druk:   Ipskamp Drukkers B.V., Enschede 
ISBN:   978-94-6259-223-0 
  
 
 
 
 
 
 
 
 
 
Table of contents 
 
 
4 
 
 
 
 
 
 
 
 
 
Table of contents 
List of abbreviations   8 
1 − Elastin-like polypeptides  13 
1.1. Introduction  14 
1.2. Elastin biosynthesis  14 
1.3. General properties of elastin and tropoelastin  18 
1.4. Development and properties of elastin-like polypeptides  20 
1.5. Applications of elastin-like polypeptides  23 
1.5.1. Temperature-triggered purification  23 
1.5.2. Drug delivery  28 
1.5.3. Tissue engineering  36 
1.5.4. Hybrid materials  38 
1.6. Aim of research and outline of thesis  41 
1.7. References  42 
 
2 − Thermodynamic investigation of the interaction  49 
between elastin-like polypeptide fused to a 
minimized binding domain Z33 and antibodies   
2.1. Introduction  50 
2.2. Results and discussion  52 
2.2.1. Protein design, production and purification  52 
2.2.2. Characterization of the fusion proteins  53 
2.2.3. Thermodynamic analysis of binding characteristics  54 
2.3. Prospects for application  59 
2.4. Acknowledgements  61 
2.5. Experimental section  61 
2.6. References  66 
 
 
 
 
 
 
 
 
 
 
Table of contents 
 
 
5 
 
 
 
 
 
 
 
 
 
3 – An elastin-like polypeptide fusion protein for selective  69 
purification of antibodies 
3.1. Introduction  70 
3.2. Results and discussion  72 
3.2.1. Protein design, production and purification  72 
3.2.2. Characterization of Z33-ELP  73 
3.2.3. Release conditions  76 
3.2.4. Antibody capture, precipitation and release  77 
3.2.5. Selective purification of human antibodies  80 
3.3. Conclusion  81 
3.4. Acknowledgements  82 
3.5. Experimental section  82 
3.6. References  85 
 
4 – Synthesis and self-assembly of elastin-like polypeptide –   89 
poly(ethylene glycol) conjugates 
4.1. Introduction  90 
4.2. Results and discussion  92 
4.2.1. Production and characterization of elastin-like polypeptides  92 
4.2.2. Metal-free and pH-controlled introduction of azides into proteins  95 
4.2.3. Synthesis of BCN-poly(ethylene glycol) 100 
4.2.4. Conjugation of elastin-like polypeptides and poly(ethylene glycol) 101 
4.2.5. Self-assembly of ELP-PEG 103 
4.2.6. Encapsulation of 1-anilinonapthalene-8-sulfonic acid 104 
4.3. Conclusion 106 
4.4. Acknowledgements 106 
4.5. Experimental section 106 
4.6. References 114 
 
  
 
 
 
 
 
 
 
 
 
Table of contents 
 
 
6 
 
 
 
 
 
 
 
 
 
5 – Designing two self-assembly mechanisms into one viral  117 
capsid protein 
5.1. Introduction 118 
5.2. Results and discussion 119 
5.2.1. Protein design, production and purification 119 
5.2.2. pH-induced assembly of virus-like particles 120 
5.2.3. ELP-induced assembly of virus-like particles 123 
5.3. Conclusion 129 
5.4. Acknowledgements 130 
5.5. Experimental section 130 
5.6. References 135 
 
6 – Towards construction of well-defined nanoreactors 139 
6.1. Introduction 140 
6.2. Results and discussion 141 
6.2.1. Covalent modification of capsid proteins 141 
6.2.2. Non-covalent approach for encapsulation of enzymes in VLPs 145 
6.3. Conclusion and outlook 150 
6.4.  Acknowledgements 151 
5.5. Experimental section 151 
5.6. References 158 
 
7 – Conclusions and perspective 161  
7.1. Elastin-like polypeptides: from structural elucidation to application 162 
7.1.1. Protein purification 163 
7.1.2. Nanocarriers 163 
7.2. Outlook 164 
7.3. References 166 
 
 
 
 
 
 
 
 
 
 
Table of contents 
 
 
7 
 
 
 
 
 
 
 
 
 
 
Summary 168 
Samenvatting 172 
Dankwoord 176 
About the author 179 
List of publications and patent applications 180 
 
 
 
 
 
 
 
 
 
 
List of abbreviations 
 
 
8 
 
 
 
 
 
 
 
 
 
List of abbreviations 
Aha  azidohomoalanine 
aECM  artificial extracellular matrix 
Ala  alanine 
AF4  asymmetric-flow field-flow fractionation 
ATRP  atom transfer radical polymerization 
BCN  bicyclo[6.1.0]nonyne 
BDNF  brain-derived neurotrophic factor 
BMPs  bone morphogenetic proteins 
BSA  bovine serum albumin 
CalB  Candida antarctica lipase B 
CCMV  cowpea chlorotic mottle virus 
cDNA  complementary DNA 
CP  capsid protein 
CPP  cell penetrating peptide 
Cys  cysteine 
DCM  dichloromethane 
DLS  dynamic light scattering 
DMF  dimethylformamide 
DNA  deoxyribonucleic acid 
Dox  doxorubicin 
EBP  elastin-binding protein 
EDP  elastin-derived peptide 
EDTA  ethylenediaminetetraacetic acid 
EGFP  enhanced GFP 
ELP  elastin-like polypeptide 
EMAC  ELP-mediated affinity capture 
EPR  enhanced permeability and retention 
ESI-TOF electrospray ionization – time-of-flight 
Fab  fragment antigen-binding 
Fc  fragment crystallizable 
FDA  food and drug administration 
FITC  fluorescein isothiocyanate 
 
 
 
 
 
 
 
 
 
List of abbreviations 
 
 
9 
 
 
 
 
 
 
 
 
 
GFP  green fluorescent protein 
Gly  glycine 
HRP  horseradish peroxidase 
Hyp  hydroxyproline 
ICP-MS  inductively coupled plasma mass spectrometry 
Ig  immunoglobulin 
Ile  isoleucine 
IMAC  immobilized metal affinity chromatography 
IPTG  isopropyl β-D-1-thiogalactopyranoside 
ITC  inverse transition cycling  
ITC  isothermal titration calorimetry 
Ka  association constant 
Kd  dissociation constant 
LCST  lower critical solution temperature 
mAbs  monoclonal antibodies 
MALDI-TOF matrix-assisted laser desorption/ionization – time-of-flight 
MALLS  multi-angle laser light scattering 
Met  methionine 
MQ  milliQ water 
mRNA  messenger RNA 
MTS  membrane translocating signal 
MW  molecular weight 
mYFP  monomeric yellow fluorescent protein 
NTA  nitrilotriacetic acid 
PBS  phosphate buffered saline 
PDB  protein data bank 
PDI  polydisperisity index 
PEG  poly(ethylene glycol) 
Pen  penetratin 
Phe  phenylalanine 
PNIPAM poly-N-isopropylacrylamide 
polyHIPE polymerized high internal phase emulsions 
Pro  proline 
RAFT  reversible addition-fragmentation chain transfer polymerization 
 
 
 
 
 
 
 
 
 
List of abbreviations 
 
 
10 
 
 
 
 
 
 
 
 
 
RER  rough endoplasmic reticulum 
RNA  ribonucleic acid 
ROMP  ring-opening metathesis polymerization 
SDS-PAGE sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
SEC  size exclusion chromatography 
SELP  silk elastin-like polypeptide 
SpA  Protein A from Staphylococcus aureus  
SPAAC  strain-promoted alkyne–azide cycloaddition 
SrtA  Sortase A 
TEM  transmission electron microscopy 
THF  tetrahydrofuran 
THPP  β-[tris(hydroxymethyl)phosphino]-propionic acid 
TNFα  tumor necrosis factor alpha 
TRITC  tetramethylrhodamine isothiocyanate 
Tt  transition temperature 
Tyr  tyrosine 
Val  valine 
VLP  virus-like particle 
4CL2  4-coumarate:CoA-ligase 2 
ΔCp  heat capacity 
  
 
 
 
 
 
 
 
 
 
List of abbreviations 
 
 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Elastin-like polypeptides 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part of this chapter has been published: 
M. B. van Eldijk, C. L. McGann, K. L. Kiick and J. C. M. van Hest, Top. Curr. Chem., 2012, 310, 71-116  
1 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
 
14 
 
 
 
 
 
 
 
 
 
1.1. Introduction 
Elastomeric polypeptides are a class of very interesting biopolymers which are 
characterized by rubber-like elasticity, large extensibility before rupture, reversible 
deformation without loss of energy and high resilience upon stretching. Their useful 
properties have motivated their use in a wide variety of materials and biological 
applications. The most well-known elastomeric protein is elastin; this structural protein is 
one of the main components of the extracellular matrix, which provides structural 
integrity to the tissues and organs of the body. This highly cross-linked and therefore 
insoluble protein is the essential element of elastic fibers, which induce elasticity to tissue 
of lung, skin and arteries. In these fibers, elastin forms the internal core which is 
interspersed with microfibrils.[1-2] Not only elastin but also its precursor material, 
tropoelastin, has inspired the materials science society for many years already. The most 
interesting characteristic of the precursor is its ability to self-assemble under physiological 
conditions, thereby demonstrating a lower critical solution temperature (LCST) behavior. 
This specific property has led to the development of a new class of synthetic polypeptides 
which mimic elastin in its composition and are therefore also known as elastin-like 
polypeptides (ELPs). 
 This chapter will discuss the basic aspects of elastin and will address its biological role, 
biochemical processing and properties. Then the development and characteristics of 
elastin-like polypeptides will be described, followed by an overview of elastin-like 
polypeptide-based materials and the applications thereof. Finally an outline of the thesis 
will be provided. 
1.2. Elastin biosynthesis 
Elastin is a heavily cross-linked biopolymer which is formed in a process named 
elastogenesis. In this section, the role of elastin and the different steps of elastin 
production will be described, starting with transcription of the gene and processing of the 
primary transcript, followed by translation into the elastin precursor protein and its 
transport to the extracellular matrix. Finally, the cross-linking and fiber formation, which 
result in the transition from tropoelastin to elastin are described.  
 Tropoelastin is the soluble precursor of elastin and consists of alternating hydrophobic 
and hydrophilic peptide domains. The most common amino acids in the hydrophobic 
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domains are Gly, Val, Ala and Pro, which are often present in repeats of tetra-, penta- and 
hexapeptides, such as Gly-Gly-Val-Pro, Gly-Val-Gly-Val-Pro, Gly-Val-Pro-Gly-Val and 
Gly-Val-Gly-Val-Ala-Pro, respectively.[3-4] The hydrophilic domains are mainly composed 
of lysines interspersed by alanines.  
 Tropoelastin is encoded by a single copy gene and the alternating hydrophobic and 
hydrophilic domains are generally encoded by different expressed regions, or exons 
(Figure 1.1). Those exons are alternated by introns (intragenic regions), which are not 
present in the final transcript. Even though a single gene is coding for tropoelastin, 
various types (isoforms) of tropoelastin exist due to extensive alternative splicing.[5-6] Six 
exons were shown to be subject to this process in a cassette-like fashion in which an exon 
is either included or excluded, and this results in at least 11 human isoforms (Figure 1.2 
arrows).[7] The elastin genes of human, bovine, chicken and rat have been sequenced and 
the amino acid sequences were determined.[8] Even though a strong similarity was found 
between tropoelastins from different sources, some variation does exist. Some exons are 
specific for a certain species, for example exon 26A is only present in human elastin. This 
exon is rich in charged and polar amino acids and is thought to influence the structural 
and biological functions of elastin.[6]  
 After mRNA splicing, the tropoelastin mRNA is translated at the surface of the rough 
endoplasmic reticulum (RER) in a variety of cells: smooth muscle cells, endothelial and 
microvascular cells, chondrocytes and fibroblasts. The approximately 70 kDa precursor 
protein (depending on isoform) is synthesized with an N-terminal 26-amino-acid signal 
peptide. This nascent polypeptide chain is transported into the lumen of the RER, where 
the signal peptide is removed cotranslationally.[9] 
 
Figure 1.1. Primary structure of human tropoelastin isoform 3 (EBI accession no. P15502). The signal peptide, 
hydrophobic domains and cross-linking domains are indicated and are based on Daamen et al.[2] 
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Figure 1.2. cDNA structure of human tropoelastin. The alternating hydrophobic and hydrophilic domains are 
generally encoded by different exons, shown in white and black, respectively. The arrows indicate the six exons 
that are subject to alternative splicing in a cassette-like fashion. Reproduced from Vrhovski et al.[8] with 
permission from John Wiley and Sons © 1998 
 Very few post-translational modifications have been found on tropoelastin. However, 
hydroxylation of 25% of the proline residues is observed.[10] The enzymatic modification 
of proline to hydroxyproline (Hyp) is performed by prolyl hydroxylase.[11] The purpose of 
this hydroxylation remains unclear and it is even proposed that hydroxyprolines in 
tropoelastin are a by-product of collagen hydroxylation as this occurs in the same cellular 
compartment.[8] 
 Once the tropoelastin is synthesized, it is bound by the elastin-binding protein (EBP). 
This binding of EBP to tropoelastin is believed to prevent intracellular aggregation and to 
protect it from proteolytic degradation.[12] EBP is a 67 kDa multifunctional peripheral 
membrane protein and is part of the elastin-receptor.[13] The two other subunits of the 
receptor complex are transmembrane proteins of 61 kDa and 55 kDa.[14] EBP is also 
equipped with a binding site for β-galactosaccharides, and binding of these sugars 
allosterically leads to reduced affinity for tropoelastin and results in dissociation of EBP 
from the 61 kDa and 55 kDa membrane proteins. While complexed with EBP, elastin is 
transported from the RER to the cell-surface via the Golgi apparatus. Upon reaching the 
cell surface, it is secreted from the cell. Galactosugar moieties on microfibrils at the cell-
surface are then bound by EBP, which leads to release of tropoelastin (Figure 1.3). 
 The microfibrils act as a scaffold onto which the tropoelastin molecules are deposited. 
In order for tropoelastin to be incorporated into the elastic fibers it needs to be cross-
linked. To facilitate the cross-linking these elastin precursors must associate and align. This 
alignment is thought to proceed via the process of coacervation. This process occurs via 
an inverse temperature transition which induces the aggregation of tropoelastin. At low 
temperatures tropoelastin is soluble in aqueous solutions; upon raising the temperature the 
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solution becomes cloudy because the tropoelastin molecules aggregate and become 
ordered by the interactions between their hydrophobic domains. This phenomenon is 
completely reversible (by cooling) and is thermodynamically controlled. This process is 
also known as lower critical solution temperature (LCST) behavior and can be influenced 
by protein concentration, salt concentration and pH. 
 
 
 
Figure 1.3. The elastin receptor consists of a 67 kDa peripheral subunit (EBP) with two transmembrane proteins 
of 61 and 55 kDa. The 67 kDa protein binds tropoelastin and galactosugars through two separate sites. a) 
Tropoelastin binds to the intact EBP complex. b) Upon binding of a galactosugar, the EBP loses its affinity for both 
tropoelastin and the membrane-bound protein, which leads to the release of tropoelastin. Adapted from 
Vrhovski et al.[8] with permission from John Wiley and Sons © 1998 
 After the self-assembly process, the tropoelastin molecules are enzymatically cross-
linked via the lysine residues in the hydrophilic domains. In this last step of the 
elastogenesis, lysyl oxidase converts the amines of the lysine residues to aldehydes 
(allysine) via oxidative deamination (Scheme 1.1). Lysyl oxidase is a copper-dependent 
amine oxidase. In the following spontaneous condensations allysine can react with another 
allysine or with lysine to form di-, tri- and tetrafunctional cross-links, to eventually yield 
desmosine and isodesmosine linkages.[15] The interchain cross-linking and the high 
number of hydrophobic residues immediately lead to insolubility of the elastin.  
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Scheme 1.1. Structures and formation routes of cross-links in elastin. In the first step lysine is catalytically 
converted to allysine by lysyl oxidase; all subsequent condensation steps are spontaneous. 
 
1.3. General properties of elastin and tropoelastin 
Research into elastin, its properties and the fiber formation was for a considerable period 
of time hindered due to its insolubility. However, the discovery of the soluble tropoelastin 
precursor made new investigations possible. The tropoelastin protein can be isolated from 
copper-deficient animals. However, this is a very animal-unfriendly, low yielding process.[2] 
Therefore it is preferred to obtain tropoelastin from overexpression in microbial hosts 
such as E. coli. Most studies are thus based on tropoelastin obtained via bacterial 
production. 
 The main biological function of elastin is to provide elasticity to organs and tissues. 
However, it has been shown that elastin and peptides derived from elastin also have 
additional biological properties. Elastin can be degraded by several protein-degrading 
enzymes, such as elastases, matrix metalloproteinases and cathepsins. The resulting elastin-
derived peptides (EDP) can interact with other extracellular matrix proteins to induce a 
broad range of biological activities. EDPs are chemotactic for various cells, such as 
fibroblasts and monocytes, by binding to the EBP.[16-17] The consensus sequence GXXPG 
(X being any natural amino acid) of EDPs was proposed to be critical for the interaction 
with the EBP.  
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 The coacervation of tropoelastin plays a crucial role in the assembly into elastic fibers. 
This coacervation is based on the LCST behavior of tropoelastin, which causes 
tropoelastin’s structure to become ordered upon raising temperature. The loss of entropy 
of the biopolymer is compensated by the release of water from its chain.[2, 18-19] This 
release of water results in dehydration of the hydrophobic side chains and this is the onset 
of the self-assembly leading to the alignment of tropoelastin molecules. 
 Weiss and coworkers intensively investigated the coacervation behavior of a single 
isoform of tropoelastin. They produced tropoelastin by overexpression in E. coli and the 
coacervation was then assayed by monitoring turbidity while varying protein 
concentration, NaCl concentration and pH. All these factors influence the temperature at 
which the coacervation was initiated. A typical tropoelastin coacervation curve is shown in 
Figure 1.4. Increasing tropoelastin concentration resulted in a shift towards lower 
temperatures and a reduction of the temperature range over which coacervation took 
place. Also for the NaCl concentration a lowering of coacervation temperature was found 
upon increasing concentration. It is suggested that this is caused by NaCl decreasing the 
effective concentration of water by binding it in hydration shells, which therefore leads to 
an increase in protein concentration. Impurities that are able to bind the hydrophobic 
domains of the tropoelastin also had a major influence on the coacervation.[20] 
 
 
 
Figure 1.4. Coacervation curve of 40 mg/ml tropoelastin in 10 mM sodium phosphate pH 7.4, 150 mM NaCl. 
Maximal coacervation was obtained at 37 °C. This figure is reproduced from Vrhovski et al.[20] with permission 
from John Wiley and Sons © 1997  
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 This coacervation process forms the basis for the self-assembly, which takes place 
prior to the cross-linking. The assembly of tropoelastin is based on an ordering process, in 
which the polypeptides are converted from a state with little order to a more structured 
conformation.[8] Via the enzymatic cross-linking of tropoelastin, which is described in the 
previous section, the insoluble elastic fiber is formed. Various models are proposed to 
explain the mechanism of elasticity of the elastin fibers. The major models are described in 
a review by Vrhovski and Weiss.[8] For ideal elastomers in the extended mode all the 
energy resides on the backbone and can therefore be recovered upon relaxation.[18] 
Generally, it is believed that the mechanism of elasticity is entropy-driven, thus the 
stretching decreases the entropy of the system and the recoil is then induced by a 
spontaneous return to the maximal level of entropy.[8] 
 
1.4. Development and properties of elastin-like polypeptides 
In order to obtain a better understanding of the origin of the interesting characteristics of 
elastin and its precursor several groups have investigated model polymers with elastin-
based sequences. Urry et al. performed pioneering work in this field. They were the first to 
synthesize the repetitive peptides, their oligomers and polymers that were found in the 
hydrophobic domains of elastin. Via this approach they determined the conformation and 
interactions of these domains. Of particular interest proved to be the repeat sequence of 
Val-Pro-Gly-Xaa-Gly, where the fourth residue can be any natural amino acid except 
proline. They observed that polymers of this pentapeptide repeat coacervate in a similar 
way to tropoelastin. Polypeptides containing this type of sequence were coined elastin-like 
polypeptides (ELPs).[21] In some articles and reviews the terms elastin-mimetic 
polypeptides or elastin-like recombinamers are used instead of elastin-like polypeptides, 
however in this thesis we will refer to these polymers as elastin-like polypeptides (ELPs). 
 Poly(VPGVG) (Figure 1.5a) has been studied most thoroughly and it was shown that it 
exhibits an inverse phase transition. The biopolymer undergoes phase separation from 
solution upon increasing temperature, resulting in a β-spiral structure and simultaneous 
release of water molecules associated with the polymer chain (Figure 1.5).  
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Figure 1.5. a) Chemical structure of poly(Val-Pro-Gly-Val-Gly). b) The recurring β-turn found in poly(VPGVG). c) 
Detailed representation of the β-spiral structure adopted by the poly(VPGVG) upon raising the temperature 
above the inverse transition temperature. Reprinted from Urry et al.[22] with permission from Elsevier © 1992 
 
Figure 1.6. a) The effects of varying amino acid at the fourth position in ELP[V8X2] b) Extrapolation of transition 
temperature for other ratios of Val:Xaa a) and b) Reprinted with permission from Urry et al.[24] American 
Chemical Society © 1993 c) Molecular weight dependence of transition temperature. Reprinted from Chilkoti et 
al.[23] with permission from Elsevier © 2002 
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 The effects of varying the fourth amino acid and the biopolymer length have 
extensively been investigated and models have been proposed.[23-26] ELP constructs are 
usually described using the notation ELP[XiYjZk-n], where the capital letters between the 
brackets indicate the single letter amino acid code for the Xaa replacing residue in the 
pentapeptide Val-Pro-Gly-Xaa-Gly. The subscript stands for the ratio of the guest 
residues and the n represents the total number of pentapeptide repeats. 
 Figure 1.6a shows the turbidity measurements for different guest residues in 
ELP[V8X2]. Lower transition temperatures (Tt) correlate with increased hydrophobicity of 
the guest residue.[24-25] This data was extrapolated to other ratios of Val:Xaa (Figure 1.6b). 
The transition temperature could also be influenced by the molecular weight of the ELP. 
The Tt was shown to increase with decreasing polymer length (Figure 1.6c).[23, 26] 
 ELPs can be produced via chemical synthesis and biosynthetically. For chemical 
synthesis via solid phase peptide synthesis, the attainable polymer length is however 
limited, and if long polymers with a defined length are required the biosynthetic approach 
is more appropriate. An advantage of chemical synthesis is, however, that it enables the 
facile introduction of functional residues in the polypeptide.[27] In the biosynthetic 
approach, protein expression in E. coli[27], yeast[28-29] and plants[30-31] has been employed. 
This approach requires the construction of genes encoding for these repetitive 
polypeptides. Different methods for gene construction have been published: 
multimerization,[32] recursive directional ligation[33] and recursive directional ligation via 
plasmid reconstruction.[23, 34] 
 Several studies were performed on the optimization of expression levels of ELP 
proteins in E. coli. In an example the expression protocol was optimized for an ELP 
fusion with green fluorescent protein (GFP). This fusion protein was expressed and 
purified in a yield of 1.6 g/L of bacterial culture, which finally yielded ~400 mg of GFP 
per L of bacterial culture. This extremely high yield was found after uninduced expression 
in nutrient-rich medium supplemented with phosphate, glycerol and certain amino acids, 
such as proline and alanine.[35] The influence of fusion order was also examined and it was 
found that positioning the ELP at the C-terminus of the target protein resulted in 
significantly higher expression levels.[36] 
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1.5. Applications of elastin-like polypeptides 
1.5.1. Temperature-triggered purification 
After expression of poly(VPGXG) genes, the biopolymer can easily be purified from a 
cellular lysate via a simple centrifugation procedure, because of the inverse temperature 
transition behavior. This causes the ELPs to undergo a reversible phase transition from 
being soluble to insoluble upon raising temperature above the Tt and then back to soluble 
by lowering the temperature below Tt (Scheme 1.2). The insoluble form can be induced 
via addition of salt.[27] The inverse transition can be assayed by monitoring the solution 
turbidity as function of temperature. The complete purification process is called inverse 
transition cycling (ITC), which is achieved by repeated centrifugation while alternating the 
temperature above and below the Tt.[33] 
 The inverse transition temperature of the elastomeric polypeptide motivated Meyer 
and Chilkoti to design ELP fusion proteins. They hypothesized that the temperature-
dependent inverse transition of the free biopolymer could be transferred to the fusion 
protein and would allow non-chromatographic separation of recombinant fusion proteins 
via the ITC procedure.[33] This hypothesis was furthermore supported by the results of  
 
  
Scheme 1.2. Purification of ELPs by ITC is based on the reversible inverse phase transition. a) Protein purification 
via direct ELP fusions. A soluble ELP fused to a target protein becomes reversibly insoluble upon increasing 
temperature above Tt. b) Protein purification via ELP coaggregation. An excess of free ELPs enhances the 
aggregation of trace quantities of ELP-fusions. c) Purification via ELP-mediated affinity capture (EMAC). ELPs are 
fused to capture proteins, which bind specifically and reversibly to a target protein. This target protein can then 
be aggregated at temperatures above the Tt. Scheme is adapted and reprinted from Floss et al.[39] with 
permission from Elsevier © 2010 
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previous studies on protein conjugates of poly(N-isopropylacrylamide), a synthetic 
polymer that undergoes a similar thermally-driven phase transition, which showed that the 
transition behavior of the free polymer is retained in the conjugate.[37-38] This founded the 
use of ELPs for purification of primarily recombinant proteins but also other molecules. 
The ELP-mediated purification procedures can be sorted in three categories: protein 
purification via direct ELP fusions (Scheme 1.2a), protein purification via ELP 
coaggregation (Scheme 1.2b) and purification via ELP-mediated affinity capture (EMAC, 
Scheme 1.2c).  
Protein purification via direct ELP fusion 
As an example of purification via the ELP fusion approach Meyer and Chilkoti (Scheme 
1.2a) purified the proteins thioredoxin and tendamistat. For this purpose these target 
proteins and ELP were genetically fused via a short peptide sequence that included a 
thrombin cleavage site which allows the removal of the ELP tag after the purification is 
completed. The general outline of the purification procedure is depicted in Scheme 1.3. 
They showed that ELPs could be used for purification of target proteins with technical 
simplicity, low cost, ease of scale-up, and capacity for multiplexing.[33] 
 In a subsequent study the effect of reducing the ELP molecular weight on the 
expression and purification of a fusion protein was investigated. Two ELPs, ELP[V-20] 
and ELP[V5A2G3-90], both with a transition temperature at ~40 °C in phosphate buffered 
saline (PBS) with 1 M NaCl, were applied for the purification of thioredoxin. Similar yields 
were observed for both fusion proteins, resulting in a higher thioredoxin yield for the 
ELP[V-20] fusion, since the ELP fraction was smaller here. However, a more complex 
phase transition behavior was observed for this ELP and therefore a selection of an 
appropriate combination of salt concentration and solution temperature was required.[40] 
 The ELP expression system was compared to the conventional oligo-histidine fusion 
which is traditionally applied for purification by immobilized metal affinity 
chromatography (IMAC). Both techniques were shown to give a similar yield of the 
purified recombinant protein. The temperature-triggered approach offers a fast and 
inexpensive non-chromatographic separation with the possibility for larger scale 
purification. Although the ELP expression system may not be applicable to all types of 
recombinant proteins, numerous examples have already been shown.[41] 
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Scheme 1.3. Inverse transition cycling (ITC) purification overview. The target proteins are genetically fused to an 
ELP via a short peptide linker that includes a protease cleavage site. After expression, the fusion protein is 
separated from the other proteins in the cellular lysate by inducing the ELP inverse temperature phase transition. 
The solution is then centrifuged at elevated temperature to pellet the aggregated fusion protein. The pellet is 
resolubilized by cooling below the Tt and the solution is centrifuged at low temperature to remove the remaining 
insoluble matter. This cycle of heated and cooled centrifugation is repeated several times to obtain higher purity. 
The target protein can then be liberated from the ELP via proteolytic cleavage and the cleaved ELP is then 
removed with another round of ITC. This figure is reproduced from Meyer et al.[40] with permission from John 
Wiley and Sons © 2001  
 In the previous examples, protease-dependent cleavage was used to remove the ELP-
tag and to obtain the purified target protein. However, several problems are associated 
with the use of a protease-dependent cleavage: additional cost of the purification process, 
an additional purification step to separate the protease from the target protein and 
possible cleavage sites in the target protein. Therefore the methodology was optimized by 
introducing self-cleaving inteins for protease-independent cleavage of the target protein. 
Both Wood and coworkers[42] and the research groups of Chilkoti and Filipe[43] 
simultaneously reported on this self-cleaving ELP-tag. The latter demonstrated this 
approach by the use of the mini-intein from Mycobacterium xenopi GyrA gene to purify 
thioredoxin.[43] Wood and coworkers published several extensive protocols describing 
every aspect of how to use cleavable elastin-like polypeptide-tags.[44-45] Some other 
proteins were also expressed as a direct ELP fusion protein and were then purified by 
ITC.[46-47] 
 Another route to circumvent the additional purification step to separate the protease 
from the target protein, is the use of a protease with an ELP-tag which is pelleted from 
the solution simultaneously with the ELP-tag of the target protein. This approach was 
combined with the transpeptidase activity of Staphylococcus aureus Sortase A (SrtA). SrtA 
enzymatically exchanges the C-terminal site of an LEPTG sequence with an N-terminal 
tri- or oligoglycine. This enables the simultaneous site-specific covalent coupling of a 
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triglycine-tag functionalized with a small molecule of interest to the purified target protein 
and the release of the ELP tag (Scheme 1.4).[48] 
Protein purification via ELP coaggregation 
The previous ELP fusions are examples of protein purification in which the ELP is 
covalently connected to the protein of choice. This approach is suited for the purification 
of recombinant proteins that are expressed to high levels, but at very low concentrations 
of ELP the recovery becomes limited. Therefore this approach is not applicable for 
proteins expressed at micrograms per liter of bacterial culture, such as toxic proteins and 
complex multidomain proteins. An adjusted variant of ITC was designed to solve this 
problem. This variant makes use of coaggregation of free ELPs with ELP fusion proteins. 
In this coaggregation process, an excess of free ELP is added to a cell lysate to induce the 
phase transition at low concentrations of ELP fusion protein (Scheme 1.2b). It was shown 
that picomolar levels of ELP fusion proteins could be purified via ELP coaggregation.[49-
50] The value of this technique was shown by the purification of an anti-atrazine 
antibody.[51] 
Purification via ELP-mediated affinity capture (EMAC) 
The third purification procedure is based on the combination of temperature-triggered 
aggregation and affinity capture and has been used to not only purify proteins[52-58] but 
also other molecules,[59-60] and for the removal of pollutants from a solution.[61-63] For this 
procedure ELP is conjugated to a capture reagent, which can be done either genetically or 
chemically. This procedure eliminates the need for cleavage of ELP after purification and 
introduces the potential to recycle the ELP. 
 Various purification systems of this type were developed by Chen and coworkers, such 
as a new plasmid purification method. This system is based on the interaction between a 
DNA-binding protein and its cognate DNA sequence harbored on the target plasmid. 
Thus, an ELP is genetically fused to a DNA-binding protein. After binding of the fusion 
protein to the plasmid via the recognition sequence, the complex can be collected by 
triggering the inverse phase transition of ELP. Subsequently, the plasmid can be eluted 
from the DNA binding protein by heating to ~60°C, after which the ELP-DNA binding 
protein is removed and recycled via centrifugation to obtain the purified plasmid in 
solution. A schematic overview of the plasmid purification via temperature-triggered 
affinity capture is depicted in Scheme 1.5.[59-60] 
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Scheme 1.4. Purification of target proteins using ELPs in tandem with the Sortase A (SrtA) transpeptidase 
provides a method for chromatography-free purification of recombinant proteins and optional, site-specific 
conjugation of the target protein to a molecule equipped with a triglycine-tag. Figure was reproduced from 
Bellucci et al.[48] with permission from Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
 
 
Scheme 1.5. Principle of temperature-triggered affinity purification of plasmid DNA. An ELP fused to a DNA 
binding protein (ELP-DNA binding protein) was used to bind a plasmid. The ELP-DNA binding protein-plasmid 
complex is aggregated by increasing temperature and is then collected by centrifugation. Subsequently the 
plasmid is eluted from the DNA binding protein by mild heating after which the ELP-DNA binding protein is 
removed and recycled via centrifugation to obtain the purified plasmid in solution. Adapted by permission from 
Macmillan Publishers Ltd: Nature Protocols, Lao et al.[60], © 2007 
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 In a similar way, proteins were purified, for example antibodies. For this purpose, 
ELPs were combined with antibody-binding proteins, such as Protein G, Protein L, 
Protein A[52-54, 56]  or binding domains derived from Protein A.[57-58] The antibodies can be 
bound via the ELP-antibody binding domain fusion and then those complexes can be 
purified via temperature-triggered precipitation. Also histidine-tagged proteins were 
purified by temperature-triggered purification. An ELP with repeating sequences of 
[(VPGVG)2(VPGKG)(VPGVG)2]21 was chemically modified by reacting the amino 
groups of the lysines with imidazole-2-carboxaldehyde to introduce metal-binding ligands. 
Subsequently, the biopolymer was charged with Ni2+ to enable binding of his-tagged 
proteins. This combined the advantages of his-tag purification with inverse transition 
cycling.[55] Similarly, another affinity tag was genetically fused to a target protein, which 
could then directly be purified using ELP equipped with a capturing domain. 
Incorporation of a self-cleaving intein domain between the target protein and the affinity 
tag enabled rapid removal of the affinity tag, which was then removed by another cycle of 
ITC.[64] 
 The last example of EMAC also makes use of metal-binding groups, although here 
they are used to remove heavy metal contaminants. The first report on temperature-
triggered removal of cadmium made use of histidine-tagged ELPs, because they strongly 
bind Cd2+.[61] In a later report, ELP was fused to a metal-binding domain, which was 
shown to bind Cd2+ more effectively and selectively than the his-tagged ELPs.[63] A similar 
approach was followed with the construction of ELP-MerR, where an ELP was fused to 
the metalloregulatory protein MerR, which is responsible for regulating expression of the 
mercury detoxification pathway. This fusion protein was used for specific removal and 
recycling of mercury.[62] 
1.5.2. Drug delivery 
Numerous experimental therapeutics have shown potency in vitro, however when they are 
tested in vivo, they often lack significant efficacy. This is often attributed to unfavorable 
pharmacokinetic properties and systemic toxicity, which limit the maximum tolerated 
dose. These limitations can be overcome by use of drug carriers. Two general types of 
carrier systems have been designed: drug conjugation to macromolecular carriers, such as 
polymers and proteins, and drug encapsulation in nanocarriers, such as vesicles and 
micelles. 
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 Over the past decades, ELPs have also been applied in drug delivery as both 
macromolecular carriers and nanocarriers. The ELP-based carrier systems combine the 
advantages of drug carriers with the properties of ELPs. In addition to these carrier 
systems, ELP-based drug depots for controlled release have been designed, such as drug 
releasing gels and drug-eluting films. 
 ELPs with different transition temperatures have been employed for drug delivery. 
These can typically be divided into three categories: (1) soluble ELPs with a Tt above the 
body temperature, (2) stimulus-responsive ELPs with a Tt in the region where phase 
transition can be triggered in vivo, thus slightly above body temperature and (3) insoluble 
ELPs with a Tt below body temperature. This final class of ELPs is used in nanocarriers 
and in drug depots. In this section the emphasis will be on systems that have been tested 
in vivo, and some recent developments in the area of ELP-assisted drug delivery which are 
very promising. 
Macromolecular carriers 
In macromolecular drug delivery systems, drugs are attached to polymeric compounds, 
such as synthetic polymers,[65] dendrimers[66] and antibodies,[67] in order to enhance the 
delivery of the active substance to the diseased tissue and to reduce the toxicity to healthy 
tissue. The use of macromolecular delivery systems provides several advantages: extension 
of the half-life of the drug, the ability to introduce targeting moieties into the carrier, the 
possibility of triggered drug release and the aforementioned reduced cytotoxicity.  
 In cancer treatment, passive targeting of macromolecular carriers to tumors is a 
commonly used approach. This passive targeting is based on the enhanced permeability 
and retention (EPR) effect, which leads to an accumulation of the high molecular weight 
carrier in the tumor tissue. The EPR effect arises from the different physiology of tumor 
vasculature, where the vessel walls are highly porous and lack the tight junctions which are 
present in healthy tissue. As a result, macromolecular carriers extravasate and accumulate 
preferentially in tumor tissue relative to normal tissues.[68-69] 
 All the aforementioned advantages and several additional features apply to ELP-based 
macromolecular carriers. First, ELP-based carriers are thermally responsive. Second, ELP 
is a biopolymer and therefore is biodegradable and non-toxic. Third, the gene-based 
synthesis of ELP allows the creation of genetic fusions with functional peptides and 
proteins, such as targeting sequences. 
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Scheme 1.6. a) The structure of ELP[VA8G7-160] conjugated to doxorubicin via the cysteine residues. b) 
Schematic representation of the self-assembly of ELP-Dox to form nanoparticles. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Materials, MacKay et al.[70], © 2009 
 Recently, Chilkoti and coworkers showed the effective use of self-assembled ELP-drug 
conjugates in the treatment of solid tumors in mice. For this purpose ELP[VA8G7-160] 
with a transition temperature of >>37°C was equipped with a conjugation-site for 
hydrophobic molecules, for example therapeutics. This conjugation segment consisted of 
eight cysteine residues, interspersed with diglycine spacers. Doxorubicin (Dox), a rather 
hydrophobic and clinically effective drug, was modified with a terminal maleimide via an 
acid-labile hydrazone linker and then coupled to the thiols of the Cys residues via the 
maleimide-thiol reaction. This macromolecular carrier spontaneously assembled into 
micellar nanoparticles of ~40 nm diameter (Scheme 1.6). The half-life, the maximum 
tolerated dose and the anti-tumor activity of these nanoparticles in mice were evaluated by 
administering the drug conjugates systemically. It was found that the ELP-Dox 
formulation allowed a higher dose than the free drug, which is likely to be caused by the 
shielding of ELP to limit the toxicity of Dox to healthy tissue. With a single injection, at 
the maximum tolerated dose, ELP-Dox outperformed the free drug in reducing tumor 
volume and this led to a substantial increase in animal survival.[70] 
 The previous example of application of ELPs in drug delivery does not exploit their 
thermal responsiveness. In most other examples the ELP phase transition is used to target 
ELP-drug conjugates towards tumors by applying local heating of tissue (local 
hyperthermia). Chilkoti and coworkers were the first to successfully employ this principle. 
They developed a method for targeting of intravenously injected ELPs towards solid 
tumors by local hyperthermia. In addition, mild hyperthermia also enhances the delivery of 
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drugs to solid tumors, due to the increase of vascular permeability at temperatures 
between 40 °C and 45 °C.[71] Two ELPs were synthesized, ELP[V5A2G3-150] with a Tt of 
41 °C, which is between the body temperature and the mild hyperthermic temperature, 
and the control ELP[VA8G7-160] with a Tt well above 55 °C, which is unresponsive at the 
mild hyperthermic temperature. These biopolymers were labeled with either rhodamine or 
with radioactive iodine for in vivo fluorescence video-microscopy and radiolabel 
distribution studies in nude mice with implanted human tumors. Thermally targeting of 
ELP[V5A2G3-150] led to an increase in tumor localization compared to the control ELP 
with hyperthermia and to the same polymer without hyperthermia.[72-73] In the previously 
described labeling studies, the amines in the ELPs were labeled, in another study 14C 
radiolabels were incorporated into the backbone of both ELPs during protein expression. 
This was used to minimize the influence of the labeling while studying the biodistribution 
and pharmacokinetics and to prevent release of the radiolabel.[74-75] Next Dox was 
conjugated to ELP[V5A2G3-150] via an acid-labile hydrazone linker, but this lowered the 
Tt to below the body temperature, thus this ELP could not be employed for in vivo 
thermally triggered targeting.[76] In a subsequent study to minimize perturbation of the 
linker on the phase transition behavior and to provide an efficient and quantitative release 
of Dox, the chain length and the hydrophobicity of the hydrazone linker were 
optimized.[77] Also the targeting of ELP towards the tumor via local hyperthermia was 
further optimized by thermal cycling of the tumor. This method relies on heating and 
cooling cycles of the tumor tissue, where the hyperthermia causes an increased vascular 
concentration of the ELP[V5A2G3-150] aggregates adhering to the vessel walls in the 
tumor, which upon return to normal temperature leads to an increase in transvascular 
transport.[78] A review by Chilkoti and coworkers gives a comprehensive overview on their 
efforts in the field of ELP-assisted drug delivery.[79] 
 Generally, the plasma membrane of eukaryotic cells is impermeable to macromolecular 
carriers. Therefore, Raucher and coworkers improved the ELP-assisted drug delivery by 
fusing a cell penetrating peptide (CPP) to the ELP carrier to facilitate its cellular uptake.[80-
81] CPPs are short peptides which are capable of efficiently crossing the cellular plasma 
membrane and entering the cell’s cytoplasm. CPPs have been shown to deliver a variety of 
cargos across the cell membrane.[82] Various CPPs, such as penetratin (Pen) derived from 
Drosophila transcription factor Antennapaedia, the Tat peptide derived from the HIV-1 Tat 
protein, the hydrophobic membrane translocating sequence (MTS) from the Kaposi 
fibroblast growth factor and the cationic Bac peptide derived from the bactenecin 
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antimicrobial peptide, were fused to the N-terminus of the ELP (for sequences see Figure 
1.7).[83-84] In addition to the use of this system for delivery of Dox, therapeutic peptides 
were fused to the C-terminus of the CPP-ELP (Figure 1.7). This design was examined for 
a therapeutic peptide that inhibits the oncogenic transcription factor c-Myc[83, 85] and for 
cell cycle inhibitory peptides.[84, 86-87] The CPP-ELP conjugate with the peptide inhibitor of 
c-Myc was shown to be delivered effectively to brain tumors in a rat model.[88]  
 
Figure 1.7. Schematic representation of the ELP carrier N-terminally fused to a cell penetrating peptide and C-
terminally fused to a therapeutic peptide. The amino acid sequences for the cell penetrating peptides are given 
in the table. Reprinted from Bidwell et al.[89] with permission from Elsevier © 2010 
 
 
 
Scheme 1.7. Hyperthermia-triggered multivalency. Block copolymers consisting of two ELP blocks, a hydrophilic 
ELP[VA8G7-n] block (in yellow) and a hydrophobic ELP[V5-n] block (in blue) were designed. The N-terminal 
hydrophilic block was modified with a peptidic ligand (green triangle) by gene fusion and the design also allows 
introduction of a drug or imaging agent at the C-terminus (lightning bolt). Reprinted in part with permission from 
Dreher et al.[90] © 2008 American Chemical Society 
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 Another approach that also employs the thermal responsiveness of ELPs for drug 
delivery is the hyperthermia-triggered multivalency. To this end, block copolymers of two 
ELP regions were synthesized (ELP[VA8G7-n]-ELP[V5-n]) , where one of the blocks 
would have its transition temperature at the hyperthermic temperature of the tumor and 
the other block would be insensitive in this temperature range. The end of the insensitive 
block was furthermore genetically modified with a peptidic ligand which targets a specific 
cellular receptor or membrane protein that is upregulated by tumor cells. Normally, the 
effectiveness of this type of peptides is limited due to their systemic toxicity, however in 
this approach the block copolymer was triggered by the hyperthermia in the tumor to 
assemble into a drug delivery vehicle displaying multiple ligands. This triggered 
multivalency is supposed to increase the binding affinity of the ligand-ELP in tumor tissue 
without increasing the accumulation in healthy tissue. A schematic overview of the design 
and rationale is given in Scheme 1.7.[90-91] 
Nanocarriers 
Micellar nanocarriers have already been applied successfully for delivery of hydrophobic 
drugs [92]. These carriers are usually the product of self-assembled block copolymers, 
consisting of a hydrophilic block and a hydrophobic block.[93] Generally, an ELP with a 
transition temperature below body temperature is used as hydrophobic block and the 
hydrophilic block can be an ELP with a transition temperature above body temperature or 
another peptide or protein (Scheme 1.8). The EPR effect also directs these types of 
carriers towards tumor tissue.  
 
Scheme 1.8. General design principle illustrating the formation of ELP nanocarrier micelles. An ELP block 
copolymer containing a hydrophobic and a hydrophilic block self-assembles into micelles upon heating above the 
Tt of the hydrophobic block. Reprinted in part with permission from Hassouneh et al.[94] © 2012 American 
Chemical Society 
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 In 2000, the first example on ELP diblock copolymers for reversible stimulus-
responsive self-assembly of nanoparticles was reported and their potential use in 
controlled delivery and release was suggested.[95] Later, these type of diblock 
copolypeptides were also covalently cross-linked through disulfide bond formation after 
self-assembly into micellar nanoparticles. In addition, the encapsulation of 1-
anilinonaphthalene-8-sulfonic acid, a dye which fluoresces in hydrophobic environment, 
was used to investigate the capacity of the micelle for hydrophobic drugs.[96] This work 
was expanded by encapsulation of dipyridamole, a lipophilic anti-inflammatory 
compound, into the hydrophobic core of the micelles, which increased the drug’s water 
solubility by 60- to 70-fold. In vitro drug release studies showed a rapid initial release in the 
first hours, followed by an extended release in the next days.[97] Chaikof and coworkers 
also showed the applicability of these micellar nanoparticles for in vivo imaging.[98-99] 
 An ELP diblock copolymer with a pH-sensitive hydrophobic ELP block, could be 
obtained by incorporation of histidine residues (ELP[VG7A8-80]-ELP[VH4-100]). These 
ELP diblock copolymers were shown to self-assemble in response to three triggers: 
temperature, pH and cosolutes.[100] The controlled disassembly at low pH, for instance in 
tumor tissue or upon internalization into the endosomes of cells, makes them particularly 
interesting. Furthermore, the hydrophobic ELP block can also be sensitized to calcium by 
interspersing the ELP with calcium binding sequences.[101] ELPs have also been fused with 
other hydrophilic blocks, such as poly aspartic acid,[102] targeting domains[94], and 
oligonucleotides.[103]  
 Besides diblock systems also ELP-based triblock copolypeptides have been used to 
produce stimulus-responsive micelles, and Chaikof and coworkers envisioned the possible 
application of these micelles as controlled drug delivery vehicles. These amphiphilic 
triblock copolymers were constructed from two identical hydrophobic ELP end-blocks 
and a hydrophilic ELP mid-block. Below the transition temperature, loose and 
monodispersed micelles were formed which upon heating reversibly contracted, leading to 
more compact micelles with a reduced size.[104] 
 Rodríguez-Cabello and coworkers reported a modified elastin-like polypeptide, in 
which the glycine at the third position of the repetitive sequence was replaced for an 
alanine. These biopolymers consisting of VPAVG-repeats also showed a reversible phase 
transition, however strong undercooling was needed to resolubilize this ELP.[105] This 
biopolymer, (VPAVG)220, has already been used to encapsulate the model drug 
dexamethasone phosphate,[106] and bone morphogenetic proteins (BMPs) in ELP-based 
 
 
 
 
 
 
 
 
 
Elastin-like polypeptides 
 
35 
 
 
 
 
 
 
 
 
 
nanoparticles for drug delivery. BMPs are signaling proteins that are capable of promoting 
new bone formation, and the developed delivery system was shown to be effective in an in 
vitro cell assay.[107]  
 The previous examples describe micellar assemblies, however, ELP-based vesicular 
structures were recently also reported.[108] These vesicle-like structures were obtained by 
using amphiphilic triblock copolypeptides, with appropriate block arrangements and 
lengths. 
Drug depots 
ELP-assisted local delivery of drugs is realized via several strategies. In the first strategy 
soluble ELPs are injected and their coacervation is triggered by the body temperature. 
Here, the drug can be covalently attached to the ELP or it can just be mixed with the 
ELP. In another approach, cross-linked ELP depots containing a drug can be produced 
and can then be implanted to generate a stable release of the drug. 
 This first strategy was used by Setton and coworkers to trigger the in situ formation of 
an ELP-based drug depot for sustained release. Biodistribution studies of radiolabeled 
ELPs with a Tt below body temperature were performed after intra-articular injection in 
rats.[109] Later, drug depots of ELPs with covalently attached immunomodulator 
therapeutics[110] and anti-TNFα therapeutics[111] were created using ELP[V-120] and 
ELP[V-60], respectively. These two biopolymers have their transition below body 
temperature.  
 The Chilkoti group applied the local injection approach for intratumoral drug delivery. 
ELP[V-120] with a transition at 27 °C was designed and labeled with 14C, 125I or 131I for 
radiotherapy. The first two labels were used to monitor tumor retention of the ELP and 
the last label was introduced to equip the ELP with anti-tumor activity. It was found that 
mice treated with 131I-labeled ELP[V-120] experienced a significantly prolonged survival 
over those treated with saline.[112] 
 For the second type of drug release from depots, ELPs were cross-linked prior to 
implantation. In an investigation on the controlled release of the antibiotics cefazolin and 
vancomycin, ELP[KV16-102] was used. This ELP was cross-linked via the amines on the 
lysine residues using β-[tris(hydroxymethyl)phosphino]-propionic acid (THPP) to enable a 
high degree of antibiotic entrapment. The functionality of this approach was only shown 
in vitro.[113] Another example of this methodology is the production of drug-loaded ELP 
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microspheres which are cross-linked with glutaraldehyde. The ELP temperature-
responsiveness was then used to open and close the pores of these microspheres.[114] 
 In clinical trials using adenoviral vectors for gene delivery, it was shown that selective 
delivery of sufficient number of therapeutic gene copies remains difficult and the lack of 
this selectivity caused acute toxicity and immunogenicity for the healthy tissue. Cappello 
and Ghandehari applied silk elastin-like polypeptide (SELP)[32] hydrogels to overcome the 
challenges of cancer gene therapy in head and neck cancer.[115] They found that 
intratumoral injection of adenoviruses with SELPs enhanced gene expression in tumors 
up to 10 fold compared to viral injection without the biopolymer.[116-118] In mouse models, 
the SELPs efficiently controlled the duration and extent of transfection in tumors for up 
to 5 weeks with no detectable spread to the liver. This resulted in a five-fold greater 
reduction in tumor volume compared to intra-tumoral injection of adenoviruses without 
the biopolymer.[119-120] 
1.5.3. Tissue engineering 
In the field of tissue engineering, the principles of engineering and life sciences are applied 
for the development of functional substitutes for damaged tissue. To this extent 
biomaterials have been used to replace, restore or enhance organ function. Therefore the 
material needs to be able to match the characteristics of the tissue it is replacing, such as 
shape, physical properties and support in cellular processes.[121] 
 The application of ELPs in tissue engineering is attractive for several reasons: first, 
ELPs are based on elastin, which is a main component of the extracellular matrix. As a 
result they are non-immunogenic, biocompatible and biodegradable.[122] ELPs can 
furthermore be produced in high yields in host cells, such as bacteria, and this type of 
polymer synthesis provides control over the exact amino acid sequence and polymer 
length. ELPs can also easily be purified by exploiting their inverse temperature transition. 
For these reasons, ELPs were used and modified to form hydrogels, films and fibers for 
various tissue engineering applications, such as cartilaginous, vascular, ocular and liver 
tissue regeneration. 
 Setton and Chilkoti applied ELPs as a three-dimensional matrix to entrap 
chondrocytes. In their study, ELP[V5G3A2-90] with a transition temperature of 35 °C at 
50 mg/mL in PBS was used. This biopolymer can be used to generate a suspension with 
cells, which upon injection into a defect site will form a scaffold. They showed that in vitro 
the resulting ELP gel supported the viability of chondrocytes and the synthesis and 
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accumulation of cartilage-specific extracellular matrix material. This suggested that ELPs 
indeed could be used for in situ formation of a scaffold for cartilaginous tissue repair.[123] 
Later, they also demonstrated that ELP-gels could induce and support chondrocytic 
differentiation of human adipose-derived adult stem cells in vitro, without the addition of 
chondrocyte-specific growth factors.[124] Haider et al. also demonstrated the potential of 
silk-elastin-like polypeptides (SELPs)[32] as scaffold for the encapsulation and 
chondrogenesis of human mesenchymal stem cells. These SELPs irreversibly form 
hydrogels upon triggering the transition.[125] One significant problem is that the shear 
modulus of uncross-linked ELPs is several orders lower than of articular cartilage. In 
order to increase the load-bearing capabilities of ELP gels, glutamine- and lysine-
containing ELPs that could be enzymatically cross-linked via transglutaminase were 
developed.[126] Even though the shear modulus was increased and the ability to promote 
the synthesis and retention of cartilage tissue was retained, the cross-linking reaction 
proceeded over a long time, which prevented its clinical use. Therefore a chemical cross-
linking method that would proceed within a shorter time was developed. For this method, 
several lysine-containing ELPs were cross-linked with THPP.[127-129] ELP[V6K1-224] was 
then used as an injectable scaffold for cartilage repair in a goat model of an osteochondral 
defect. It was shown that the ELP cross-linker solution was easily delivered and resulted in 
a stable, well-integrated gel that supported cell infiltration and matrix synthesis, but 
unfortunately this gel was prone to rapid degradation.[130] In a recent study, many lysine-
containing ELPs were evaluated for their mechanical properties to optimize the ELP 
formulation for in vivo application.[131] 
 Tirrell and coworkers designed artificial extracellular matrix (aECM) proteins for small-
diameter vascular grafts. For vascular grafts, both mechanical integrity and biological 
interaction with host tissue are important properties. Therefore the aECM proteins 
contained alternating CS5 binding domains and elastin-like polypeptide domains (Figure 
1.8, aECM 3). The fibronectin CS5 domains provide cell adhesion signals whereas the 
ELP domains give these materials elasticity and mechanical integrity. The aECMs also 
contained lysine residues, either incorporated into the ELP domains or near the C- and N-
termini, to allow cross-linking without interrupting the CS5 binding domains.[132-134] It was 
shown that these cross-linked films of aECMs resembled the properties of the natural 
elastin.[135] In another study, aECMs with RGD binding domains were produced (Figure 
1.8, aECM 1) and compared to the CS5 domains. Here, it was found that the cellular 
response to aECM proteins can be modulated through choice of binding domain and that 
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those with the RGD sequence showed rapid cell spreading and matrix adhesion.[136] 
Subsequently, variation in ligand density was accomplished by mixing two aECMs (1 and 
2, Figure 1.8) in different ratios prior to cross-linking. Via this method cell adhesion and 
spreading could be modulated.[137] Incorporation of full-length cell-binding fibronectin 
domains in aECM proteins instead of the RGD peptides was shown to promote faster cell 
spreading, tighter integrin binding and faster wound healing.[138] 
 
Figure 1.8. Amino acid sequences of aECM proteins. Each protein contains a T7 tag, a histidine tag, a cleavage 
site and elastin-like domains with lysine residues for cross-linking. The RGD cell-binding domain is found in aECM 
1, whereas aECM 3 contains the CS5 cell-binding domain. aECM 2 and aECM 4 are the negative controls with 
scrambled binding domains for aECM 1 and aECM 3, respectively. Reprinted with permission from Liu et al.[136] © 
2004 American Chemical Society 
1.5.4. Hybrid materials 
In the previous sections it was demonstrated that the stimulus-responsive behavior of 
ELP was transferred to ELP fusion proteins and even to non-covalently bound moieties, 
such as proteins, plasmids and heavy metals, mostly for biomedical and biotechnological 
applications. The ability of ELPs to reversibly switch their polarity is also of great interest 
for the development of stimulus-responsive hybrid materials. Many approaches have 
therefore recently been undertaken to integrate ELPs with for example polymers, particles 
and surfaces.  
 In 2003, the van Hest group produced elastin-based side-chain polymers.[139] This 
research was motivated by the demonstration of the occurrence of inverse temperature 
transition in a single repeat of VPGVG.[140] A methacrylate-functionalized VPGVG was 
synthesized and used as a monomer to perform atom transfer radical polymerization 
(ATRP) to produce homopolymers (Figure 1.9b) or ABA block copolymers (Figure 1.9a), 
in which the A blocks are based on the methacrylate-functionalized VPGVG and the B 
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block is a bifunctional poly(ethylene glycol) ATRP macroinitiator. It was shown that these 
polymers exhibited behavior similar to linear poly(VPGVG).[139, 141] Later, Cameron and 
coworkers used another type of controlled radical polymerization (reversible addition-
fragmentation chain transfer polymerization, RAFT) to produce homopolymer elastin-
based side-chain polymers (Figure 1.9c).[142] They found that binary mixtures of well-
defined elastin-based side-chain polymers showed a single transition temperature, which 
depended on the blend composition.[143] Additionally, they immobilized these elastin-
based side-chain polymers on polymerized high internal phase emulsions (polyHIPE), to 
demonstrate the potential of this methodology to reversibly immobilize biomolecules, 
such as enzymes.[144] Also ring-opening metathesis polymerization (ROMP) was used to 
prepare elastin-based oligopeptides of low molecular weight and low polydispersity.[145] 
More recently, random copolymers of elastin-based monomers and oligo(ethylene glycol)-
based monomers were generated using ROMP.[146] 
 
 
Figure 1.9. Various types of elastin-based side-chain polymers. a) ABA block copolymer produced via ATRP, b) 
homopolymer produced via ATRP, c) homopolymer produced via RAFT polymerization 
 Inspired by the elastin-based side-chain polymers, Lemieux et al. prepared elastin-
based stimulus-responsive gold nanoparticles. To this end, gold particles were capped with 
a layer of a single repeat of thiol-functionalized VPGVG peptides (Scheme 1.9a). These 
nanoparticles showed LCST behavior which was modulated by varying the pH of the 
solution.[147] Similarly, short ELPs were displayed on filamentous phage particles. 
However, in this case, the density of the surface-displayed ELPs was insufficient to drive 
thermally induced aggregation.[148] 
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Scheme 1.9. a) Schematic representation of elastin-based stimulus-responsive gold nanoparticles Illustration is 
reproduced from Lemieux et al.[147] by permission of The Royal Society of Chemistry b) Schematic overview of 
functionalization of a glass surface with ELP. In the first step the glass surface is aminosilylated with N-2-
(aminoethyl)-3-aminopropyltrimethoxysilane, then modified with glutaraldehyde. Subsequently, the stimulus-
responsive biopolymer is covalently immobilized using reductive amination. Illustration is reproduced from 
Teeuwen et al.[149] by permission of The Royal Society of Chemistry  
 Besides short ELPS, longer ELPs have also been conjugated to synthetic polymers. In 
one approach Cu(I)-catalyzed azide-alkyne cycloaddition click chemistry was applied. For 
this purpose, ELPs were functionalized with azides or alkynes via incorporation of 
azidohomoalanine and homopropargyl glycine, respectively, using residue-specific 
replacement of methionine in ELP via bacterial expression.[150]  
 In another investigation, ELP[V5L2G3-90] with three lysines in the N-terminal region 
was immobilized on a glass surface in a microreactor to enable temperature-controlled 
positioning of ELP fusion proteins. For this purpose the glass surface was first 
functionalized with N-2-(aminoethyl)-3-aminopropyltrimethoxysilane, followed by 
glutaraldehyde treatment and reductive amination to immobilize the biopolymer on the 
surface (Scheme 1.9b).[149] 
 Hybrid materials of poly(VPGVG)s and gold were also conveniently produced. 
ELP[V5A2G3-180] was adsorbed onto colloidal gold particles via electrostatic 
interactions.[151] Subsequently, these ELPs were covalently immobilized on the gold 
surface, by reacting the amines in the ELP with N-hydroxysuccinimide-activated carboxyl 
groups attached to gold. These stimulus-responsive particles were subsequently used to 
capture and release biomolecules.[152] 
 Huang et al. were able to synthesize optically responsive hybrid materials. They used 
the block copolymer ELP[V-40]-ELP[V4C1-10], which was assembled onto gold nanorods 
via the thiol-moieties of the cysteines. Exposure of the ELP-functionalized gold nanorods 
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to near-infrared light led to heating of the gold due to surface plasmon resonance. This 
resulted in phase transition and aggregation of the ELP-functionalized gold nanorods.[153] 
Also the group of Rodriguez-Cabello published on similar hybrid materials based on ELP-
functionalized gold nanoparticles.[154-155] 
1.6. Aim of research and outline of thesis  
As reviewed in this Chapter, elastin is a structural protein with outstanding properties, and 
therefore it has inspired many investigations, with special interest for its elastomeric 
properties. This behavior could be mimicked with elastin-like polypeptides and those have 
found wide application in bioengineering, biomedicine and nanobiotechnology. It has 
been shown that the inverse phase transition of ELPs could be transferred to almost any 
type of material, such as biopolymers, small molecules, synthetic polymers, metals and 
inorganic particles. A wide variety of applications for ELPs have been explored, such as 
drug delivery and affinity precipitation for purification.  
 In this thesis we explore the unique features of hybrid ELP-based block copolymers 
for the development and characterization of materials with novel emergent functionalities. 
We focus on construction of well-defined assemblies and supramolecular aggregates with 
application potential in the biotechnological and biomedical fields. 
 In Chapter 2 and 3 we pursued the application of ELPs in the purification of 
antibodies. There is a growing interest in antibodies, since they are widely applied as 
detection probes, purification ligands and targeting moieties in research and medicine. 
Currently, antibodies are purified by several column chromatography steps. The 
bottleneck in this downstream processing is found in the Protein A-based affinity capture 
chromatography. We realized that purification by affinity precipitation, using ELPs, is an 
interesting alternative to affinity chromatography. This required an antibody-binding 
domain which could be coupled to the ELP. Therefore we studied the interaction between 
antibodies and Z33, a minimized antibody-binding domain derived from Protein A of only 
33 amino acids, fused to ELP and GFP. The thermodynamic parameters for the 
interaction of the fusion proteins with antibodies from various species were determined 
and a difference in Z33 binding affinity of several orders of magnitude was observed 
between human and bovine antibodies (Chapter 2). This finding was further explored in 
Chapter 3, in which the application of the Z33-ELP fusion protein in the purification of 
antibodies by affinity precipitation is described. The observed selectivity towards human 
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IgGs was employed for the efficient and selective ELP-mediated purification of human 
IgGs from mixtures containing bovine IgGs and other proteins. 
 As described in this Chapter, ELPs have been used to generate self-assembled 
nanocarriers which can be applied in drug delivery. Many of the described self-assembled 
structures consist of amphiphilic ELP diblock copolypeptides. We imagined the use of an 
alternative amphiphilic diblock copolymer for the production of self-assembled 
nanocarriers, in which a stimulus-responsive ELP block was combined with a hydrophilic 
poly(ethylene glycol) (PEG) following a click chemistry approach. The choice for PEG 
was rationalized by its ability to provide stealth and steric protection for encapsulated 
materials and because of its low toxicity. Furthermore, it has been approved for internal 
applications by regulatory agencies (Chapter 4).  
 Chapter 5 reports the construction and assembly properties of a block copolymer in 
the form of a fusion protein, ELP–CP, consisting of the capsid protein of cowpea 
chlorotic mottle virus and an N-terminal short ELP block. This design combines the 
properties of the two blocks: the ability of the capsid protein to form nanocapsules with 
well-defined morphologies and the stimulus-responsive character of the ELP fragment. 
Surprisingly, this protein-based block copolymer could be self-assembled via two 
mechanisms into two different, well-defined nanocapsules: (1) pH-induced assembly 
yielded 28 nm nanocapsules, and (2) ELP-induced assembly yielded 18 nm nanocapsules. 
 Subsequently, Chapter 6 discusses our efforts towards the encapsulation of enzymes 
into these well-defined nanocapsules in order to create a nanoreactor. Furthermore, we 
demonstrate that self-assembly of these ELP–CPs can also be efficiently triggered by the 
addition of NiCl2, probably as a result of the synergistic effect of nickel complexation by 
the his-tags of the CPs and interactions between the ELP domains. 
 Chapter 7 reflects on the progress in ELP-based materials with respect to the work 
described in this thesis. Furthermore, an outlook for the application of ELPs is provided 
and, in a broader view, the expectations for the development of protein nanotechnology 
are discussed. 
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2.1. Introduction 
In nature, many important processes, ranging from signal transduction and immune 
response to enzymatic cascades, are controlled by protein-protein interactions. Quite often 
these interactions are facilitated by specific protein binding domains. Based on systems 
found in nature, a wide variety of peptide motifs harbouring multivalent binding domains 
have been developed, such as leucine zippers,[1] collagen-like peptides,[2] and the 
calmodulin binding peptide.[3] Peptide-based binding motifs have been employed both in 
the field of supramolecular chemistry to control self-assembly at the nanometer level,[4-5] 
as well as in recombinant protein expression technology as purification tags.[6] 
 An important class of peptide-binding domains, are motifs capable of interacting with 
immunoglobulin G (IgG) (Figure 2.1a), the most abundant class of antibodies. IgGs are 
widely applied as detection probes, purification ligands, and targeting moieties in research 
and medicine. With respect to the latter, antibodies have become one of the fastest 
growing classes of therapeutics, with currently more than 25 FDA-approved monoclonal 
antibodies for treatment of diseases.[7] 
 Protein A from Staphylococcus aureus (SpA),[8] a multidomain protein, is the most-studied 
motif capable of specific binding to the Fc-portion of mammalian immunoglobulins. SpA 
consists of five homologous domains, which each can bind to IgGs, and is therefore 
currently industrially employed in SpA-based affinity capture as the first chromatography 
step in the purification of antibodies.[9-10]  
 
Figure 2.1. Ribbon structures of (a) IgG (from PDB: 1IGY) showing the Fc-domain and the Fab-domain and (b) 
three-helix bundle Z domain (2SPZ)[11]. (c) Ribbon diagram of Z domain interacting with the Fc-domain of an 
immunoglobulin G. For this purpose the Z domain is superimposed onto the B domain in PBD: 1FC2.[12] 
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 Not the entire structure of SpA is required for effective binding, as each domain 
separately is already able to interact with immunoglobulins. The SpA structure can 
therefore be minimized to the so-called Z-domain, which is a single domain consisting of 
58 residues that forms a three-helix bundle structure, and which shows comparable 
binding affinity as SpA (Figure 2.1b).[13] From crystallographic analysis it was furthermore 
determined that the first two helices of the Z domain bind in the three β‐turns of the 
CH2‐CH3 junction of the Fc fragment to interact with IgG and that the third helix 
stabilizes the scaffold (Figure 2.1c).[11-12] Braisted and Wells recognized the opportunity to 
further minimize the SpA-derived binding domain by removing the third helix and by 
introducing stabilizing mutations in the two remaining helices, resulting in a truncated 33 
residue Z-peptide (Z33 = FNMQQQRRFYEALHDPNLNEEQRNAKIKSIRDD).[14] 
This minimized domain was shown to bind to human IgG1 with a dissociation constant 
(Kd) of 43 nM. The two-helix domain could be further stabilized through the formation of 
a disulfide bridge and through backbone ligation.[15-16] This 33-residue peptide was 
efficiently conjugated to other molecules, such as proteins, and subsequently tagged with 
antibodies which targeted the cargo to specific tissue sites.[17-19]  
 In this chapter we systematically study for the first time the thermodynamics of 
binding of the Z33-domain to various IgGs by isothermal titration calorimetry (ITC). The 
Z33-domain was fused to two interesting proteins to equip them with antibody-binding 
functionality, without perturbing the properties of both the target protein and the Z33-
domain (Scheme 2.1). The first protein was a stimulus-responsive elastin-like polypeptide 
(ELP),[20-21] which can be applied in purification of antibodies by affinity precipitation. 
ELPs are well-defined protein-based polymers, which can be switched from an extended 
water soluble to a collapsed hydrophobic state in response to increasing temperature. This 
completely reversible phenomenon is also known as lower critical solution temperature 
(LCST) behavior. The application of the Z33-ELP fusion will be described in Chapter 3. 
Secondly, the Z33-domain was fused to a fluorescent protein, which can be of interest for 
application in supramolecular chemistry and immunochemistry. 
 
 
 
Scheme 2.1. The two-helix Z33-domain can easily be fused to any target protein to introduce antibody-binding 
functionality, without perturbing the properties of both the target protein and the Z33-domain. The antibody-
graphics in this scheme were reproduced and adjusted with permission from iStockphoto.com. 
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2.2. Results and discussion 
2.2.1. Protein design, production and purification 
To investigate the opportunity to use the Z33-peptide as an antibody binding tag for 
proteins, two different fusion proteins were produced: a stimulus-responsive elastin-like 
polypeptide (ELP) fusion and an enhanced green fluorescent protein (EGFP) fusion. To 
generate the required genes, a synthetic gene fragment encoding for Z33 was genetically 
fused with genes encoding ELP[V5L2G3-90][22] and EGFP[23] (for ELP nomenclature, see 
Experimental section). The resulting genes were expressed in E. coli.  
 After the expression of Z33-ELP[V5L2G3-90], the cells were lysed and the protein was 
easily purified via inverse transition cycling.[24] This process entails repeated centrifugation 
while alternating above and below the ELP transition temperature (Tt), soluble and 
insoluble contaminants are removed. This purification was checked by SDS-PAGE 
(Figure 2.2a). In the first cycle most of the bacterial proteins were removed during the 
“hot spin”. After two cycles a single band around 40 kDa was observed, which 
corresponded to the theoretical molecular weight (MW) of the fusion protein. This 
indicated that only two cycles of inverse transition cycling were required to obtain pure 
protein (Figure 2.2a, lane 7). The purified protein was freeze-dried and an expression yield 
of 90-115 mg/L of bacterial culture was determined. 
 For Z33-EGFP a different purification strategy was needed. For that reason the protein 
was equipped with a C-terminal histidine tag which was used to first purify the fusion 
protein via Ni-NTA affinity chromatography. Subsequently, size exclusion 
chromatography was performed to afford the purified protein with a MW of 
approximately 30 kDa and a yield of 14 mg/L of culture (Figure 2.2d). 
 The MWs of the fusion proteins could already be estimated from SDS-PAGE, but 
electrospray ionization time-of-flight (ESI-TOF) mass spectrometry was employed for an 
exact determination. Mass analysis of Z33-ELP[V5L2G3-90] produced a multiply charged 
ion series, which showed a large number of charges and a broad charge-state distribution 
(Figure 2.2b), and a deconvoluted total mass spectrum was produced (Figure 2.2c). The 
observed MW of Z33-ELP[V5L2G3-90] was 41708.6 Da, which nicely matched with the 
calculated MW of 41709.2 Da. The deconvoluted mass of Z33-EGFP (32772.9 Da) 
corresponded with the calculated value of 32772.7 Da (Figure 2.2f). 
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Figure 2.2. Purification and analysis of Z33-ELP and Z33-EGFP. (a) Coomassie-stained SDS-PAGE of Z33-ELP 
purification; total cell lysate (lane 1), supernatant of “hot spin 1” (lane 2), resuspended pellet of “hot spin 1”  
(lane 3), supernatant of “cold spin 1” (lane 4), supernatant of “hot spin 2”  (lane 5), resuspended pellet of “hot 
spin 2” (lane 6), product after last “cold spin” (lane 7). (b) Multiply-charged ion series of ESI-TOF mass 
spectrometry of purified Z33-ELP. (c) deconvoluted total mass spectrum of purified Z33-ELP. (d) Coomassie-stained 
SDS-PAGE of Z33-EGFP after Ni-NTA purification (lane 1) and after SEC purification (lane 2). (e) Multiply-charged 
ion series of ESI-TOF mass spectrometry of purified Z33-EGFP. (f) Deconvoluted total mass spectrum of purified Z-
33-EGFP. 
 
2.2.2. Characterization of the fusion proteins 
To show that the properties of the proteins which are fused to the Z33-domain were 
unmodified, their characteristics were investigated. Z33-ELP was purified by taking 
advantage of the LCST behavior of the ELP domain. To further characterize this 
behavior, the Tt was investigated by measuring turbidity as a function of temperature using 
a spectrophotometer with temperature control. For comparison, ELP[V5L2G3-90] without 
the antibody-binding domain was used. The Tt determined at 50% of the maximal 
turbidity change in phosphate buffered saline (PBS) was 41 °C and 40 °C for Z33-
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ELP[V5L2G3-90] and ELP[V5L2G3-90], respectively (Figure 2.3a). The influence of the 
antibody-binding domain on the transition temperature of ELP was shown to be minimal, 
which is in line with other ELP fusion proteins.[24-25] 
 To establish the influence of the Z33-domain on the fluorescent properties of EGFP, 
the excitation and emission spectrum of the fusion protein were measured. The spectral 
properties were found to be unaffected by the introduction of the antibody-binding 
domain, with the excitation and emission maxima at 480 nm and 510 nm, respectively 
(Figure 2.3b).[23]  
 
Figure 2.3. Characterization of Z33-ELP and Z33-EGFP. (a) Normalized turbidity measured at 600 nm as function of 
temperature of Z33-ELP[V5L2G3-90] (dashed lines) and ELP[V5L2G3-90] (solid lines) in PBS. (b) Excitation and 
emission spectrum of Z33-EGFP. 
2.2.3. Thermodynamic analysis of binding characteristics 
ITC was employed for thermodynamic investigation of the binding properties of the Z33-
fusion proteins to IgGs. For the ITC investigation four IgGs from different origins were 
selected: human IgG1, bovine IgG and two rabbit IgGs with different fluorescent labels, 
FITC and TRITC. All experiments were performed at 20 °C, 25 °C and 30 °C. Figure 2.4a 
and Figure 2.4b show typical thermograms and binding isotherms for binding of 
respectively Z33-ELP and Z33-EGFP to human IgG1 at 20 °C. The thermodynamic 
parameters for binding of the fusion proteins to the different IgGs are shown in Table 2.1. 
For all binding experiments large enthalpy-driven binding, which was compensated by 
unfavorable entropy, was observed. These results are in good agreement with results 
reported for the molecular interaction of complete SpA with human IgG1 and human 
IgG4.[26] As expected, the thermodynamic binding parameters of both batches of rabbit 
IgGs were very similar. 
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Figure 2.4. Thermograms and binding isotherm for the interaction between human IgG1 and (a) Z33-ELP and (b) 
Z33-EGFP at 20 °C in phosphate buffered saline. Plots of ΔH as function of temperature for the interaction 
between IgGs and (c) Z33-ELP and (d) Z33-EGFP. Different IgGs were investigated: bovine IgG (green), human IgG1 
(blue), TRITC-labeled rabbit IgG (black) and FITC-labeled rabbit IgG (red). 
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Table 2.1. Thermodynamic parameters for binding of Z33-fusion proteins to various IgGs 
IgG type Temp 
(°C) 
Kd ΔG 
(kcal·mol-1) 
ΔH 
(kcal·mol-1) 
-TΔS 
(kcal·mol-1) 
n [a] 
Z33-ELP       
Bovine 20 2.8 µM -7.5 -17.1 9.6 1.75 
 25 4.2 µM -7.3 -19.5 12.2 1.65 
 30 6.5 µM -7.2 -21.0 13.8 1.62 
Human 20 11 nM -11.1 -24.6 13.5 1.88 
 25 26 nM -10.3 -26.8 16.5 1.90 
 30 61 nM -10.1 -29.0 18.9 1.91 
Rabbit-TRITC 20 140 nM -9.3 -18.6 9.3 1.87 
 25 204 nM -9.2 -20.9 11.7 1.76 
 30 385 nM -8.9 -24.2 15.3 1.64 
Rabbit-FITC 20 79 nM -9.5 -17.1 7.6 1.87 
 25 141 nM -9.4 -20.1 10.7 1.78 
 30 262 nM -9.2 -22.4 13.2 1.72 
       
Z33-EGFP       
Bovine 25 3.3 µM -7.4 -15.1 7.7 1.70 
Human 20 20 nM -10.4 -25.2 14.8 1.73 
 25 68 nM -10.2 -28.5 18.3 1.63 
 30 116 nM -9.6 -33.1 23.5 1.68 
Rabbit-TRITC 20 96 nM -9.4 -17.2 7.8 1.71 
 25 177 nM -9.2 -22.9 13.7 1.65 
 30 301 nM -9.1 -24.5 15.4 1.66 
Rabbit-FITC 20 88 nM -9.5 -17.2 7.7 2.03 
 25 147 nM -9.3 -20.2 10.9 1.62 
 30 467 nM -8.8 -24.5 15.7 1.65 
       
Protein A       
Bovine 25 48 nM -9.9 -59.1 49.2 0.28 
Human 25 0.5 nM -11.1 -112.3 99.4 0.26 
[a] Binding stoichiometry of Z33-fusion protein or Protein A to IgG 
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 The dissociation constants (Kd) for the fusion proteins were in the nanomolar range 
for all investigated IgGs with exception of bovine IgG, which was observed to bind in the 
micromolar range. Even though a similar difference in binding affinity has also been 
detected for SpA (Table 2.1), this is the first time it is shown that the binding selectivities 
for various IgGs are maintained in a minimized domain.[27-29] The highest binding affinity 
was observed for human IgG1, with a Kd value as low as 11 nM for Z33-ELP at 20 °C. 
This is even lower than the Kd of 43 nM reported for the free Z33-peptide.[14] However, in 
that case, the binding was studied by surface plasmon resonance (SPR). The binding 
affinity was shown to be temperature-dependent, with an increased affinity at lower 
temperatures. This observation is remarkable since this was not observed for Protein A.[26] 
Possibly, the small binding domain is more flexible, resulting in lower binding affinity at 
elevated temperature. 
 Theoretically, binding stoichiometry (n) is 2:1 for Z33:IgG, because both Fc fragments 
can be bound by one Z33-fusion protein. However, a lower binding stoichiometry of 1.6 -
1.9 was observed for both fusion proteins. It is unlikely that the concentrations of both 
fusion proteins were overestimated, since the Z33-ELP concentration was determined by 
dry-weight and the Z33-EGFP concentration was determined by UV-VIS spectroscopy 
using the extinction coefficient. For further evaluation of the binding stoichiometry, size 
exclusion chromatography with an in-line multi-angle laser light scattering detector (SEC-
MALLS) was employed to determine the molecular weight of the Z33-ELP-IgG complex 
(Figure 2.5). A clear shift of the antibody-peak in the presence of an excess of Z33-ELP 
was observed. The determined MW indicated a binding stoichiometry of 1.7:1, which 
supported the ITC results. Possibly this deviation of n was caused by inaccessibility of the 
second Fc-domain due to steric hindrance by the readily bound Z33-ELP, or by lower 
concentrations of functional IgGs in the ITC cell, which however does not influence the 
observed binding parameters. The concentration of functional IgG may have been 
decreased by 10-20% due to denaturation or due to loss during sample preparation. 
 The change in heat capacity (ΔCp) upon binding of IgGs to the Z33-fusion proteins 
was calculated using the enthalpy changes in a temperature range from 20 °C to 30 °C 
(Figure 2.4c, Figure 2.4d and Table 2.2). For the interaction of both fusion proteins with 
all IgGs, large negative ΔCps were observed, which implies that binding results in burial of 
a large hydrophobic surface area. This observation was supported by structural 
investigation of the interaction, which showed that the binding is predominantly 
hydrophobic, together with the occurrence of two salt bridges and four hydrogen 
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bonds.[12, 26] The dipeptide Phe14-Tyr15, which is located on the first helix of Z33, forms 
the hydrophobic core, around which the salt bridges and hydrogen bonds are distributed 
(see Figure 2.6). Ile253 is the main contributor to the hydrophobic interaction on the IgG 
side. In total, an intersurface area of about 400 Å2 is involved in the interaction.[30] 
 
 
Figure 2.5. Size exclusion chromatograms of human IgG1 (black traces), Z33-ELP (red traces) and mixture of human 
IgG1 with an excess of Z33-ELP (blue traces). The solid traces show the absorbance at 280 nm, and the dotted lines 
show the molecular masses. 
 
Table 2.2. Values of heat capacities (ΔCp) for binding of Z33-fusion proteins to IgGs. 
IgG Type ΔCp 
kcal·mol-1·K-1 
R2 [a] 
Z33-ELP   
 Bovine -0.39 0.96 
 Human -0.48 0.99 
 Rabbit TRITC-labeled -0.56 0.98 
 Rabbit FITC-labeled -0.53 0.99 
Z33-EGFP   
 Human -0.79 0.98 
 Rabbit TRITC-labeled -0.73 0.80 
 Rabbit FITC-labeled -0.74 0.98 
[a] Quality of linear fit 
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Figure 2.6. (a) Ribbon diagram of Z33 domain interacting with Fc-domain of IgG (from PDB: 1OQO). The 
hydrophobic side chains of Z33-residues (in red) involved in the interaction with the IgG (in blue) are shown, to 
illustrate the burial of a large hydrophobic area. (b) The amino acid sequence of Z33, the numbering starts at 
position 6 to comply with numbering of the full length Z-domain. The boxed amino acids depict the two helices. 
 
2.3. Prospects for application 
Two proteins, EGFP and ELP, were genetically fused to the Z33-domain, a minimized 
antibody-binding domain derived from Protein A, to equip them with antibody-binding 
functionality. The thermodynamics of interaction of the Z33-domain, with various IgGs 
was investigated by ITC. Tight binding was observed, which was enthalpically favorable 
and entropically unfavorable. From the large negative change in heat capacity it was 
determined that binding of Z33-fusion proteins to IgGs resulted in burial of a large 
hydrophobic surface area. Furthermore, similar Kd values were observed as reported for 
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the free Z33-domain.[14-16] However, binding of the Z33-domain to bovine IgGs was shown 
to be several orders of magnitude weaker than to human IgGs. 
 These results illustrate that the Z33-peptide is a very promising antibody-binding motif, 
which could even find its application in the field of supramolecular chemistry, in which 
assembly at the nanometer level is mediated by specific antibodies. We recently 
demonstrated this concept, in which Z33-fusion proteins were non-covalently assembled 
onto well-defined virus particle nanoscaffolds (Scheme 2.2). The Z33-peptide was fused to 
two different proteins, the monomeric yellow fluorescent protein (mYFP) and the enzyme 
4-coumarate:CoA-ligase 2 (4CL2). The Z33-tag allowed their patterning on the surface of 
zucchini yellow mosaic virus by means of specific antibodies directed against the coat 
protein of the virus. This approach was validated by affinity assays and correlative 
microscopy. Fluorescence and enzymatic activity were fully retained after assembly. The 
principle of using the combination of a scaffold-specific antibody and Z33-fusion proteins 
can be extended to a wide variety of proteins/enzymes and antigenic scaffolds which can 
facilitate the creation of functional “biochips” with optical or catalytic properties.[31] 
 
Scheme 2.2. Overview of the construct in which Z33 is used to position proteins on a well-defined virus particle 
nanoscaffold. In this approach, a protein of interest (green) is genetically fused to Z33 (red), which binds to the Fc 
region of an antibody raised against the virus particle.[31] The image of the virus particle was adjusted with 
permission from www.cronodon.com and the antibody graphics in this scheme were reproduced and adjusted 
with permission from iStockphoto.com. 
 The fluorescent Z33-EGFP can potentially find its application in immunoassays as a 
substitute to labeled secondary antibodies. A similar approach has already been 
demonstrated for fusions of fluorescent proteins and complete antibody-binding 
domains.[32-33] In a proof-of-principle experiment we demonstrated that Z33-EGFP can be 
utilized to visualize antibodies and antibody-targets in immunoblotting (Figure 2.7). 
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 Peptide-based binding motifs are also very attractive for recombinant protein 
expression technology as purification tags. In the next Chapter of this thesis we describe 
the application of the Z33-ELP fusion protein for the purification of antibodies. 
 
 
Figure 2.7. Results of proof-of-principle experiment to show that the fluorescent Z33-EGFP can be used to 
substitute labeled secondary antibodies. (a) Unlabeled rabbit antibody was directly immobilized on a 
nitrocellulose membrane; subsequently, Z33-EGFP was applied to visualize the immobilized antibody. (b) Brain-
derived neurotrophic factor (BDNF) antigen was immobilized on a nitrocellulose membrane and then visualized 
in a two-step labeling approach. First polyclonal anti-BDNF antibodies were used to target BDNF, and in the 
second step Z33-EGFP was applied to visualize the antibodies. 
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2.5. Experimental section 
Materials 
Restriction enzymes (NcoI, XhoI, BamHI, NdeI and HindIII), ligase (T4 DNA Ligase), Antarctic 
Phosphatase and DNA polymerase (Phusion® Hot Start DNA Polymerase) were obtained from New 
England Biolabs. Ampicillin and chloroamphenicol were purchased from MP Biomedicals. Lysozyme and 
isopropyl β-D-1-thiogalactopyranoside (IPTG) were obtained from Sigma-Aldrich. 
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Elastin-like polypeptide nomenclature 
ELP constructs are usually described using the notation ELP[XiYjZk-n], where the capital letters between 
the brackets indicate the single letter amino acid code for the residues at the Xaa position in the 
pentapeptide Val-Pro-Gly-Xaa-Gly. The subscript stands for the ratio of the guest residues and the n 
represents the total number of pentapeptide repeats. 
Construction of expression vectors 
All cloning techniques were performed according to standard molecular biology protocols. For 
construction of pET15b-Z33-ELP[V5L2G3-90] two complementary 5’-phosphorylated oligos encoding for 
the Z33 domain (FNMQQQRRFYEALHDPNLNEEQRNAKIKSIRDD) with restriction site overhangs 
(NcoI and XhoI) were designed and then synthesized by Biolegio (Nijmegen, The Netherlands). The 
forward oligo (5’- 
CATGGGCTTCAACATGCAGCAGCAGCGTCGTTTCTACGAAGCGCTGCACGACCCGAACCT
GAACGAAGAACAGCGTAACGCGAAAATCAAATCTATCCGTGACGACGGCC-3’) and the 
reverse oligo (5’- 
TCGAGGCCGTCGTCACGGATAGATTTGATTTTCGCGTTACGCTGTTCTTCGTTCAGGTTCG
GGTCGTGCAGCGCTTCGTAGAAACGACGCTGCTGCTGCATGTTGAAGCC-3’) were annealed. 
Then the previously described pET15b-ELP[V5L2G3-90] vector[22] was digested with NcoI and XhoI and 
the annealed oligos were ligated into the digested vector to yield pET15b-Z33-ELP[V5L2G3-90]. This 
plasmid was transformed into E. coli XL1 Blue cells and then the DNA was extracted and the correct 
insertion of the oligos was confirmed by DNA sequencing. For the construction of pET21a(+)-Z33-
EGFP-H6 two complementary 5’-phosphorylated oligos encoding for the Z33 domain with restriction 
overhangs (NdeI and BamHI) were designed and then synthesized by Biolegio (Nijmegen, The 
Netherlands). The forward oligo (5’-
TATGGGCTTCAACATGCAGCAGCAGCGTCGTTTCTACGAAGCGCTGCACGACCCGAACCT
GAACGAAGAACAGCGTAACGCGAAAATCAAATCTATCCGTGACGACGGCGGTGGTG-3’) 
and the reverse oligo (5- 
GATCCACCACCGCCGTCGTCACGGATAGATTTGATTTTCGCGTTACGCTGTTCTTCGTTCA
GGTTCGGGTCGTGCAGCGCTTCGTAGAAACGACGCTGCTGCTGCATGTTGAAGCCCA-3’) 
were annealed. The pET21a(+) expression vector (Novagen) was linearized with NdeI and BamHI and 
the annealed oligos were inserted to create pET21a(+)-Z33-H6. Subsequently, the EGFP gene (Clontech) 
was modified by PCR using primers (Biolegio) with overhangs. The forward primer (5’-
TATTAGGATCCATGGTGAGCAAGGGCGAGGAGCTGT-3’) was used to introduce a BamHI 
restriction site and the reverse primer was used to introduce a HindIII restriction site (5’-
GGCATGGACGAGCTGTACAAGCTTGACGAG-3’). The PCR product and the pET21a(+) 
expression vector (Novagen) were then digested with BamHI and HindIII. After dephosphorylation of 
the vector, the digested PCR product was ligated into the vector to yield pET21a(+)-Z33-EGFP-H6. This 
plasmid was transformed into E. coli XL1 Blue cells, the DNA was extracted and the sequence was 
confirmed by DNA sequencing.  
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Protein sequences 
Z33-ELP 
GFNMQQQRRFYEALHDPNLNEEQRNAKIKSIRDDGLEKREAEAGPVPGGGVPGVGVPGVGV
PGGGVPGLGVPGVGVPGVGVPGVGVPGGGVPGLGVPGGGVPGVGVPGVGVPGGGVPGLGVP
GVGVPGVGVPGVGVPGGGVPGLGVPGGGVPGVGVPGVGVPGGGVPGLGVPGVGVPGVGVPG
VGVPGGGVPGLGVPGGGVPGVGVPGVGVPGGGVPGLGVPGVGVPGVGVPGVGVPGGGVPGL
GVPGGGVPGVGVPGVGVPGGGVPGLGVPGVGVPGVGVPGVGVPGGGVPGLGVPGGGVPGVG
VPGVGVPGGGVPGLGVPGVGVPGVGVPGVGVPGGGVPGLGVPGGGVPGVGVPGVGVPGGGV
PGLGVPGVGVPGVGVPGVGVPGGGVPGLGVPGGGVPGVGVPGVGVPGGGVPGLGVPGVGVP
GVGVPGVGVPGGGVPGLGVPGGGVPGVGVPGVGVPGGGVPGLGVPGVGVPGVGVPGVGVPG
GGVPGLGVPGGGA 
 
Z33-EGFP 
GFNMQQQRRFYEALHDPNLNEEQRNAKIKSIRDDGGGGSMVSKGEELFTGVVPILVELDGD
VNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHD
FFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQ
SALSKDPNEKRDHMVLLEFVTAAGITLGMDELYKLAAALEHHHHHH 
Expression, purification and characterization of proteins 
Z33-ELP 
pET15b-Z33-ELP[V5L2G3-90] was transformed into the BLR(DE3) E. coli strain. A single colony was 
used to inoculate 50 mL 2xYT medium supplemented with ampicillin (100 mg/L). The culture was 
grown overnight at 37 °C while shaking (200 RPM). The next day the culture was used to inoculate 1 L 
2xYT medium supplemented with ampicillin (100 mg/L) for uninduced expression at 37 °C.[34] After 24h 
of expression, the cells were harvested by centrifugation (4 °C, 30 min, 2700 g). Subsequently, the cell 
pellet was resuspended in 50 mL cold phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4·2H2O, 1.0 mM KH2PO4, pH 7.4) and incubated with lysozyme (1 mg/mL) for 30 min on 
ice. The cells were further lysed by ultrasonic disruption. The cell lysate was centrifuged (15000 g at 4 °C 
for 30 min, Sorvall HB-4) and the cleared lysate was obtained. The protein was purified from the cleared 
lysate via two cycles of inverse transition cycling,[24] which is achieved by repeated centrifugation while 
alternating the temperature above and below the transition temperature (Tt) of the elastin-like 
polypeptide. The phase transition temperature was decreased by the addition of salt. NaCl was added up 
to 2 M to the cleared lysate and a turbid solution was obtained. In “hot spin 1”, this solution was 
centrifuged at 15000 g for 15 min at 20 °C. The pellet was redissolved in 15 mL cold PBS and then 
centrifuged at 15000 g for 15 min at 4 °C (“cold spin 1”). NaCl was added to the supernatant and the 
resulting turbid solution was centrifuged at 15000 g for 15 min at 20 °C (“hot spin 2”). The pellet was 
then redissolved in 6.5 mL cold PBS and centrifuged at 15000 g for 15 min at 4 °C (“cold spin 2”). An 
SDS-PAGE analysis was performed to check the purification (Figure 2.2). After purification the protein 
was freeze dried. First the salts were removed by two more cycles of ITC and resuspension in water 
(MilliQ). The protein was obtained in a yield of 90-115 mg/L of bacterial culture and the purity was 
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verified by SDS-PAGE. ESI-TOF (JEOL AccuTOF): Z33-ELP[V5L2G3-90] calculated 41709.2 Da, found 
41708.6 Da. For control experiments, ELP[V5L2G3-90] without the Z33 domain was expressed and 
purified as described above using pET15b-ELP[V5L2G3-90]. The protein was obtained in a yield of 95-
120 mg/L of bacterial culture and the purity was also verified by SDS-PAGE. ESI-TOF (JEOL 
AccuTOF): calculated 39670.9 Da, found 39671.5 Da.  
The transition temperatures of the ELPs were determined by turbidity measurements, where the optical 
absorbance at 600 nm was measured as a function of temperature (5-50 °C). These measurements were 
performed in a quartz cuvette with a path length of 0.1 cm on a Jasco J-815 Circular Dichroism 
Spectrometer equipped with a Peltier temperature controller (band width: 1 nm, response: 1 sec., 
sensitivity: standard, temperature slope: 1 °C/min).  
Z33-EGFP 
For a typical expression, 20 mL LB medium, supplemented with ampicillin (100 mg/L) and 
chloroamphenicol (50 mg/L), was inoculated with a single colony of E. coli BLR(DE3)pLysS (Novagen, 
MERCK) containing pET21a(+)-Z33-EGFP-H6 and was incubated at 37 °C overnight. This overnight 
culture was used to inoculate 500 mL of 2xYT medium supplemented with ampicillin (100 mg/L) and 
chloroamphenicol (50 mg/L). The culture was grown at 37 °C and protein expression was induced during 
logarithmic growth (OD600 = 0.4-0.6) by addition of IPTG up to 1 mM. After 5 h of expression at 30 °C, 
the cells were harvested by centrifugation (4000 g at 4 °C for 20 min) and the pellet was stored at -20 °C 
overnight. After thawing, the cell pellet was resuspended in 10 mL lysis buffer (50 mM NaH2PO4, 10 mM 
imidazole and 300 mM NaCl, pH 8.0). Then the cells were lysed by ultrasonic disruption. The lysate was 
centrifuged (12000 g at 4 °C for 20 min, Sorvall HB-4) to remove the cellular debris. The supernatant was 
incubated with 0.75 mL Ni-NTA agarose beads (Qiagen) for 1 h at 4 °C. Subsequently, the suspension 
was loaded onto a column, the flow-through was collected and the column was washed twice with 5 mL 
wash buffer (50 mM NaH2PO4, 20 mM imidazole and 300 mM NaCl, pH 8.0). Finally, the Z33-EGFP 
was eluted from the column using 5 mL elution buffer (50 mM NaH2PO4, 250 mM imidazole and 300 
mM NaCl, pH 8.0). The volume of the protein solution was reduced to 200 µL using centrifugal filtration 
(Amicon Ultra-0.5 mL, 10 kDa). The protein was then further purified and the buffer was exchanged to 
PBS via size exclusion chromatography (Superdex 200 HR 10/300 GL, 0.5 mL/min on an Amersham 
Ettan LC system equipped with a fraction collector from GE Healthcare). 300 µL fractions were 
collected and analyzed by SDS-PAGE. The fractions containing the Z33-EGFP were combined and 1 mg 
aliquots were flash frozen and stored at -20 °C. The protein yield was determined to be 14 mg/L of 
culture by UV-VIS spectroscopy using the theoretical extinction coefficients.[35] The purity was verified 
by SDS-PAGE. ESI-TOF (JEOL AccuTOF): calculated 32772.7 Da, found 32772.9 Da. Z33-EGFP 
emission and excitation spectra were recorded on a Perkin Elmer LS55 Fluorescence Spectrometer using 
a quartz cuvette.  
Mass spectrometry 
Protein mass characterization was performed by electrospray ionization time-of-flight (ESI-TOF) on a 
JEOL AccuTOF. Deconvoluted mass spectra were obtained using MagTran 1.03b2. Isotopically averaged 
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molecular weights were calculated using the “Protein Calculator v3.3” at 
http://www.scripps.edu/~cdputnam/protcalc.html. 
Isothermal titration calorimetry 
All ITC experiments were conducted on a fully automated isothermal titration calorimeter (Microcal 
Auto-iTC200, GE Healthcare). The following commercially obtained IgGs were used: bovine IgG 
(Sigma-Aldrich, I5506), human IgG1 (Sigma-Aldrich, I5029), TRITC-labeled polyclonal rabbit anti-mouse 
IgG (Dako, R0270) and FITC-labeled polyclonal rabbit anti-mouse IgG (Dako, F0261). The solutions of 
IgGs were diluted in PBS to a final concentration of 2 μM or 20 μM and dialysed against the same buffer 
to minimize the buffer differences during the ITC measurements. Z33-ELP and Z33-EFGP were 
dissolved in the same buffer used in the dialysis of IgGs at a final concentration of 40 μM (for ITC 
experiments with human and rabbit IgGs) or 400 μM (for ITC experiments with bovine IgG). Protein A 
(Pierce, 77673) was dissolved in the same buffer used in dialysis of IgGs at a final concentration of 8 μM 
(for ITC experiments with human IgGs) or 80 μM (for ITC experiments with bovine IgG). Titrations 
comprised of 19 injections (2 µL) of Z33-ELP, Z33-EGFP or Protein A from the syringe into solutions of 
IgGs (2 μM for human IgG, 2 μM for rabbit IgG, and 20 μM or bovine IgG). For determination of 
values of heat capacity (ΔCp), experiments were conducted at 20 °C, 25 °C, and 30 °C. The raw data were 
analyzed using commercial software (Origin 6.0, Microcal). Nonlinear curve fitting using a model of 
single site binding gave values of stoichiometry of binding, the association constant, the enthalpy of 
binding, and entropy of binding. 
Size exclusion chromatography 
The size exclusion chromatography – multi-angle laser light scattering (SEC-MALLS) experiments were 
performed on a Shimadzu LC-20A Prominence system (Shimadzu, ‘s Hertogenbosch, The Netherlands) 
using a Superdex 200 10/300 GL column in-line with a Wyatt DAWN HELEOS II light scattering 
detector using a laser operating at 658 nm, a Wyatt Optilab Rex refractive index detector and a Shimadzu 
SPD20A. Overnight flushing of the system was performed to pre-equilibrate the column with PBS, 
followed by normalisation using Bovine Serum Albumin. Weight-averaged molecular weight calculations 
were performed using ASTRA 6.0.6.13, using a dn/dc value of 0.1850 for PBS. For each analysis, 100 μL 
of sample was separated on the column with a flow rate of 0.5 mL/min. Three samples were analyzed: 1) 
12.0 nmol Z33‐ELP, 2) 0.7 nmol human IgG1 (Sigma-Aldrich, I5029) and 3) a mixture of 12.0 nmol 
Z33‐ELP and 0.7 nmol human IgG1 which was incubated 30 min at room temperature. The elution was 
monitored at 280 nm. 
Immunoblot assay 
Polyclonal rabbit IgG (0.4 mg/mL, Santa Cruz sc-2027) and BDNF antigen (0.4 mg/mL, peptide 
epitope, Alomone Labs) were applied onto two separate nitrocellulose membranes (1 µL spots). Then the 
membrane was blocked with BSA (5% BSA in PBS with 0.1% Tween 20). For BDNF, the membrane 
was incubated with 2 µg/mL rabbit polyclonal anti-BDNF antibody (ANT-010, Alomone Labs) in 2 mL 
PBS with 0.1% Tween 20 and 0.5% BSA for 1 hour. After washing the membrane twice with PBS with 
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0.1% Tween 20 and 0.5% BSA, Z33-EGFP was applied to both membranes (20 µg/mL) in 2 mL PBS 
with 0.1% Tween 20 and 0.5% BSA. After 30 min incubation, the membranes were washed and then 
analyzed on a fluorescence imager (Syngene, G:BOX Chemi-XT4, blue LEDs/SW06 filter). 
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3.1. Introduction 
Antibodies, also known as immunoglobulins (Igs), are widely applied as detection probes, 
purification ligands and targeting moieties in research and medicine. Monoclonal 
antibodies (mAbs) have become one of the fastest growing classes of therapeutics, with 
currently more than 25 FDA-approved mAbs for treatment of diseases.[1] This has 
resulted in increasing demand for antibodies, requiring large-scale antibody production 
and purification. Therapeutic antibodies are produced in mammalian cell cultures with 
high titers, whereas polyclonal antibodies, which are often used as diagnostics, are 
obtained from immunized animals. In both cases the antibody needs to be purified from a 
complex mixture of cellular proteins and other molecules. A typical industrial purification 
process involves two or three chromatography steps. In both cases the first step is an 
affinity capture chromatography step, followed by one or two chromatographic polishing 
steps.[1-2] 
 Since antibody titers have increased from a few milligrams to 27 grams per liter of 
culture, alternative, more straightforward and cost efficient purification methods are 
required.[3-4] Currently, the bottleneck in the downstream processing is found in affinity 
capture chromatography, which accounts for more than 70% of the downstream costs due 
to extensive use of purification media and long cycle times.[5-6] This affinity 
chromatography step is based on immobilized Protein A (SpA), which is a bacterial cell 
wall protein from Staphylococcus aureus, capable of specifically binding to the Fc region of 
immunoglobulin G (IgG), the most abundant class of antibodies. SpA-based purification 
is a highly efficient process, as it already provides >98% purity in a single step,[1] therefore 
alternatives to chromatography that still take advantage of the SpA-antibody interaction 
are preferred. 
 We realized that purification by affinity precipitation is an interesting alternative to 
affinity chromatography. In this method, an affinity domain, which is coupled to a 
stimulus-responsive polymer, can specifically bind to its target. Then the stimulus-
responsive polymer is triggered to undergo a phase separation, resulting in precipitation of 
the entire complex. The soluble contaminants can then be removed and finally the 
product is released. A major advantage of affinity precipitation is that binding takes place 
in a homogeneous phase, where it is not limited by hindrance of the column material. 
 Affinity precipitation for the purification of antibodies has been demonstrated by using 
conjugates of antibody-binding domains, such as SpA, with various stimulus-responsive 
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polymers, for instance poly-N-isopropylacrylamide (PNIPAM)[7] and elastin-like 
polypeptide (ELP).[8-9] ELPs are thermally-responsive protein-based polymers composed 
of pentapeptide repeats of Val-Pro-Gly-Xaa-Gly (Xaa= any natural amino acid except 
proline). These biopolymers are soluble in water below their transition temperature (Tt), 
and become insoluble in response to increasing temperature above their Tt, resulting in 
aggregation. This completely reversible phenomenon is also known as lower critical 
solution temperature (LCST) behavior.[10-11] The LCST behavior of ELP has also been 
applied to purify ELP-fusion proteins, and has been used in affinity capture of proteins.[12-
15] 
 To further improve the efficiency of IgG capture the binding domain has been 
minimized, as not the entire structure of SpA is required for effective binding. This has 
been the starting point for the development of the Z-domain, a single domain consisting 
of 58 residues that forms a three-helix bundle structure.[16] The three-helix Z-domain 
proved to be efficient in affinity precipitation studies when fused to ELP.[17-18] As 
described in the previous chapter, Braisted and Wells further minimized the SpA-derived 
binding domain by removing one of the three helices and by introducing stabilizing 
mutations in the two remaining helices, resulting in the 33 residue Z-domain (Z33).[19] In 
chapter 2 we studied the interaction of Z33 with antibodies from various species and we 
showed that the binding was enthalpically driven and entropically unfavorable. A 
difference in Z33 binding affinity of several orders of magnitude was observed between 
human and bovine antibodies. 
 In this chapter we describe a generally applicable method for antibody purification by 
using a fusion protein of ELP and the Z33-domain. This polypeptide is, due to its small 
size, an interesting alternative to SpA or any other antibody-binding protein, since it can 
conveniently be genetically fused to proteins and it is less likely to be denatured.[20-23] The 
Z33-ELP fusion protein was used for purification of antibodies via affinity capture, 
precipitation of the complex and release of the antibodies from the complex under basic 
conditions, while maintaining their biological activity. Furthermore, the selectivity towards 
human IgGs was employed in an efficient and selective purification of human IgGs from 
mixtures containing bovine IgGs and other proteins by affinity precipitation (as shown in 
Scheme 3.1). 
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Scheme 3.1. Schematic representation of affinity capture, precipitation and release by Z33-ELP for purification of 
antibodies. Human IgGs (orange) are captured (step 1) and precipitated by Z33-ELP (step 2). At this point soluble 
contaminants, such as bovine IgGs (green), can be removed, then the precipitated complexes are redissolved and 
the purified antibodies are released under basic conditions (step 3). To obtain higher purity, the washing can be 
repeated. The antibody graphics in this scheme were reproduced and adjusted with permission from 
iStockphoto.com. 
 
3.2. Results and discussion 
3.2.1. Protein design, production and purification 
For purification of proteins, it is important that triggering of the phase transition of the 
ELP does not result in denaturation of the protein. The Tt of ELPs can be influenced by 
changing the fourth residue of the pentapeptide repeat, the number of repeats and salt 
concentration. The first two factors are controlled in the design of the polypeptide, 
whereas the third factor can be used to control the Tt of the ELP externally. We decided 
to use ELP[V5L2G3-90], which is composed of 90 pentapeptide repeats (Val-Pro-Gly-Xaa-
Gly), with guest residues Val (V), Leu (L), and Gly (G) at a ratio of 5:2:3. This polypeptide 
should have its Tt in temperature and salt concentration ranges where antibodies are 
stable.  
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 To generate the stimulus-responsive ELP with the small antibody-binding domain 
(Z33), a synthetic gene fragment encoding for this 33 amino acid binding-domain 
(FNMQQQRRFYEALHDPNLNEEQRNAKIKSIRDD) was genetically fused with 
ELP[V5L2G3-90] via a small peptide linker. The resulting Z33-ELP[V5L2G3-90] gene was 
expressed in E. coli using hyperexpression.[24] The Z33-ELP was easily purified via inverse 
transition cycling.[12] The detailed process of purification and characterization is described 
in Chapter 2. 
3.2.2. Characterization of Z33-ELP 
The influence of the antibody-binding domain on the transition temperature of ELP was 
shown to be minimal, which is in line with other ELP fusion proteins.[12, 25] Therefore, the 
Tt was determined by measuring turbidity as a function of temperature. For comparison, 
ELP[V5L2G3-90] without the antibody-binding domain was used. The Tt, determined at 
50% of the maximal turbidity change in phosphate buffered saline (PBS), was 41 °C and 
40 °C for Z33-ELP[V5L2G3-90] and ELP[V5L2G3-90], respectively (Figure 3.1a, black 
traces). 
 
 
Figure 3.1. (a) Normalized turbidity as function of temperature of Z33-ELP[V5L2G3-90] (dashed lines) and 
ELP[V5L2G3-90] (solid lines) in PBS supplemented with 0.0M (black), 0.5M (red), 1.0M (blue), 1.5M (green) and 
2.0M (yellow) NaCl measured at 600 nm. (b) Transition temperatures of Z33-ELP[V5L2G3-90] (black triangles) and 
ELP[V5L2G3-90] (red triangles) plotted against the NaCl concentration added to PBS. A linear relationship between 
Tt and NaCl concentration was observed as can be concluded from the linear fit (R2>0.99 for both ELPs).  
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 Exposure of biologically active molecules, such as antibodies, to high temperatures 
may result in loss of activity due to denaturation, so therefore the Tt of Z33-ELP needs to 
be reduced. Because the Tt can be influenced by salt concentration, the measurements 
were performed in PBS supplemented with increasing NaCl concentrations (0.5-2.0 M 
NaCl).  This showed that the Tt of Z33-ELP was already reduced to 25 °C in PBS 
supplemented with 1.0 M NaCl, which is a feasible temperature to work with antibodies. 
Addition of more NaCl (1.5 M NaCl and 2.0 M NaCl) resulted in a decrease of Tt to below 
room temperature (Figure 3.1a). The Tt of non-functionalized ELP was comparable to 
Z33-ELP at all NaCl concentrations. A linear decrease in Tt as a function of the NaCl 
concentration was observed for both Z33-ELP and the control ELP (Figure 3.1b), which is 
in accordance with the effect of NaCl as described in literature.[26-27] In case from an 
industrial perspective lower salt concentrations are required, different ELPs with more 
hydrophobic residues at the fourth position of the pentapeptide could be employed, or 
alternatively, other salts could be used.[11, 26] 
 To demonstrate that the Z33 fusion protein can bind to a wide variety of antibodies, an 
affinity experiment was performed. In this experiment a dot blot analysis with 
immobilized Z33-ELP was carried out using fluorescently-labeled polyclonal antibodies 
from different origins (Figure 3.2a). This showed affinity for IgGs from multiple sources, 
especially from guinea pig, mouse, rabbit and Syrian hamster. The variation in 
fluorescence intensity is not necessarily caused by difference in affinity, but is also due to 
variation in fluorescent labeling of the antibodies themselves. It is noteworthy that no 
affinity was detected for bovine IgGs, rat IgGs, goat IgGs and chicken IgYs, which is in 
line with data from literature, and our own observations as described in Chapter 2.[28-30]  
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Figure 3.2. Characterization of Z33-ELP binding properties. (a) Dot blot analysis using polyclonal antibodies from 
different origins. (b) Coomassie-stained SDS-PAGE gel showing that Z33-ELP and polyclonal rabbit antibody can be 
coprecipitated, as no protein is observed after precipitation and centrifugation (lane 1). Resuspending the pellet 
resulted in redissolving Z33-ELP and the antibody as after centrifugation both were observed (lane 2). (c) 
Normalized turbidity as function of temperature of Z33-ELP[V5L2G3-90] in presence (black line) and absence (gray 
line) of rabbit antibodies in PBS supplemented with 1.5M NaCl. 
 Following up on the previous experiment, in which Z33-ELP was immobilized on a 
surface, we studied binding in solution, which was determined by size exclusion 
chromatography (SEC). Three SEC experiments were performed: two controls, in which 
either only Z33-ELP (black traces), or polyclonal rabbit antibody (red traces) was present, 
and an experiment containing a pre-incubated mixture of antibody with a 10-fold molar 
excess of Z33-ELP (blue traces); in all cases the absorbance at 214 nm and 280 nm was 
measured (Figure 3.3). The absorbance at 214 nm detects both Z33-ELP and the antibody; 
at 280 nm only antibody can be detected, as Z33-ELP only has a limited number of 
aromatic residues, which results in negligible absorbance at 280 nm. Both Z33-ELP and 
the antibody eluted at 1.3 mL, whereas the complex eluted at 1.1 mL. From the shift of 
the antibody peak from 1.1 mL to 1.3 mL in the 280 nm trace, it can be concluded that all 
antibody was bound by the excess of Z33-ELP. A more in-depth analysis of the binding 
parameters for Z33-ELP and various IgGs has been provided in Chapter 2. 
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Figure 3.3. Size exclusion chromatograms of Z33-ELP (black traces), polyclonal rabbit antibody (red traces) and 
mixture of polyclonal rabbit antibody with a 10-fold molar excess of Z33-ELP (blue traces) measuring absorbance 
at (a) 214 nm and (b) 280 nm. The small peak at 0.9 mL was probably a result of a small fraction of denatured 
antibody. 
 Subsequently, it was investigated whether the binding was preserved during the inverse 
phase transition and whether this did not result in irreversible precipitation of the 
antibody. Therefore an excess of Z33-ELP was added to polyclonal rabbit antibodies and 
the mixture was incubated, then the ELP phase transition was triggered by adding NaCl 
until the solution turned turbid (approximately 1.5 M). Subsequently the precipitate was 
pelleted by centrifugation and the supernatant was loaded on SDS-PAGE gel (Figure 3.2b, 
lane 1). As expected, almost no protein was present in this fraction. Then the pellet was 
redissolved in PBS and the mixture was again centrifuged. Now, no precipitate was 
observed and the supernatant was analyzed on SDS-PAGE gel (Figure 3.2b, lane 2). In 
this fraction, both Z33-ELP (41.7 kDa) and antibody (25 and 50 kDa, light and heavy 
chains, respectively) were observed. This showed that the affinity was preserved during the 
phase transition and that the antibody could be redissolved and centrifuged, indicating that 
no irreversible precipitation occurred. The Tt of Z33-ELP complexed with antibody was 
investigated. Satisfyingly, the Tt of Z33-ELP was not influenced in presence of antibody 
when mixed in a 2:1 molar ratio (Figure 3.2c).  
3.2.3. Release conditions 
After determining the conditions for binding and precipitation of antibodies, the release 
conditions were investigated. Hence, a series of buffers and solutions were used. Most 
commonly, acidic elution is used for SpA-based affinity chromatography. Therefore it was 
expected that these conditions could be transferred to affinity precipitation. In this 
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experiment fluorescently-labeled polyclonal rabbit anti-mouse IgGs were bound and 
pelleted using Z33-ELP. This pellet was redissolved in different release solutions and after 
short incubation Z33-ELP was precipitated by addition of NaCl and pelleted by 
centrifugation. Both the supernatant and the pellet were analyzed on SDS-PAGE and the 
fluorescence intensity was used to quantify the release (Table 3.1). Unexpectedly, almost 
no elution was observed under acidic conditions. However, under basic conditions (50 
mM NaOH), up to 93% of release was observed within 5 minutes.  
Table 3.1. Percentage of release calculated using fluorescence intensity from SDS-PAGE 
Release solution  Percentage of release (%)[a] 
50 mM NaOH 
 
 93 
 50 mM piperidine buffer pH 11.0  34 
50 mM diethanol amine buffer pH 9.0  6 
50 mM citrate buffer pH 3.5  0 
100 mM glycine·HCl  1 
100 mM HCl 
 
 1 
 
0.5 M arginine pH 3.8  55 
[a] The percentage of release is calculated using the quantified fluorescence 
intensity from SDS-PAGE analysis  
 
 In the study by Chen and coworkers, reporting ELP fusions with one and two 
complete SpA-derived binding domains (ELP-Z and ELP-ZZ), it was also shown that 
release was inefficient under acidic conditions and that a solution of 0.5 M arginine with a 
pH of 3.8 was required to get efficient release.[17] To this end, we also investigated the 
release of antibody after treatment with the same solution (0.5 M arginine, pH 3.8). This 
resulted in release of 55% of antibody after 5 minutes incubation. Possibly the difference 
in elution efficiency is related to the weaker binding of ELP-Z (Kd =  768 nM) and ELP-
ZZ (Kd = 68 nM).[17]  
3.2.4. Antibody capture, precipitation and release 
After determining the optimal binding, precipitation and release conditions, they were 
applied to quantify the Z33-ELP assisted purification of FITC-labeled polyclonal rabbit 
anti-mouse IgGs. In each step of the assay, samples were taken and analyzed on SDS-
PAGE gel (Figure 3.4a and b). First the Z33-ELP was incubated with the antibody at room 
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temperature to allow binding. Then the phase separation of ELP was triggered by addition 
of NaCl. The precipitate was pelleted by centrifugation and the supernatant was removed 
(lane 1). The pellet was then resuspended and shortly incubated in the optimal release 
solution (50 mM NaOH). To remove the Z33-ELP, NaCl was added and the precipitate 
was pelleted. The supernatant, containing the eluted antibodies, was obtained and 
neutralized (lane 2) and the pelleted Z33-ELP was resuspended (lane 3). To quantify the 
purification, the assay was repeated in four-fold and the fluorescence intensities of the 
antibody bands were measured (Table 3.2). As can be concluded from Table 3.2, 83.2 ± 
1.0% of the antibody was recovered. However, this may even be higher if unlabeled IgGs 
are used, since the position of the fluorescent label can negatively influence the binding. 
Also isothermal titration calorimetry showed incomplete binding as indicated by a binding 
stoichiometry of 1.6-1.9 Z33-ELP per IgG, which indicated that possibly not all IgG can 
be recovered. Further washing of the pellet after elution could also increase the recovery. 
To show that binding was really due to the Z33-domain, an ELP without this binding 
domain was also used in this assay. In this case, virtually all antibody (98.2 ± 0.8%) 
remained in the wash fraction (lane 4, 5, 6). 
Table 3.2. Average fluorescence intensities during each purification step 
Step  Percentage of rabbit IgG (%)[a] 
Z33-ELP wash 
 
 12.4 ± 1.2 
 
Z33-ELP elution  83.2 ± 1.0 
Z33-ELP pellet  4.3 ± 1.4 
ELP wash  98.2 ± 0.8 
ELP elution  1.7 ± 0.9 
ELP pellet   0.1 ± 0.1 
[a] This assay was performed in four-fold and the fluorescence intensities of the 
antibody bands were measured and used to calculate the percentage of IgG in 
each fraction. 
 A dot blot analysis was performed to demonstrate that the antibodies still retained 
their function after the purification procedure with elution under basic conditions. 
Therefore mouse IgGs were immobilized on a nitrocellulose membrane and the purified 
FITC-labeled rabbit anti-mouse antibodies were used to visualize them. As can be seen in 
Figure 3.4c, a sufficient amount of IgG still remained active to be visualized on the dot 
blot assay. 
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Figure 3.4. Fluorescently-imaged (a) and coomassie-stained (b) SDS-PAGE analysis of antibody capture, 
precipitation and release assay performed with Z33-ELP (lane 1, 2 and 3) and with ELP (control experiment, lane 4, 
5 and 6): wash fraction (lane 1 and 4), elution fraction (lane 2 and 5) and resuspended pellet (lane 3 and 6). Dot 
blot analysis (c) to demonstrate activity of purified antibodies. Analysis of purification of fluorescently-labeled 
antibodies from an artificial mixture containing bovine serum albumin (BSA, 66 kDa, 3.5 mg/mL), horseradish 
peroxidase (HRP, 40 kDa, 1.0 mg/mL), Candida antarctica lipase B (CalB, 34 kDa, 0.7 mg/mL) and lysozyme (14 
kDa, 1.6 mg/mL); fluorescently-imaged (d) and coomassie stained (e) SDS-PAGE analysis: wash fraction 1 (lane 1), 
wash fraction 2 (lane 2), elution fraction (lane 3), resuspended pellet (lane 4). 
 Having shown that polyclonal rabbit anti-mouse IgGs can be captured, precipitated 
and released while maintaining their biological activity, we then investigated whether this 
purification method could also be used in more complex systems. The previously 
described procedure was therefore repeated, but now using an artificial protein mixture 
containing the fluorescently-labeled rabbit IgGs and four commercially available proteins 
(bovine serum albumin, horseradish peroxidase, Candida antarctica lipase B and lysozyme), 
and introducing a second washing step prior to elution. The IgGs were obtained pure with 
similar recovery (86%), as was determined by SDS-PAGE and quantification of 
fluorescence (Figure 3.4d and e). 
 The reusability of Z33-ELP was demonstrated in recycling experiments. Therefore, the 
same Z33-ELP was recycled for three cycles of purification of FITC-labeled polyclonal 
rabbit IgGs. The recovery of antibody was analyzed by SDS-PAGE and subsequent 
quantification of fluorescence (Figure 3.5). This showed similar recovery of the antibody 
in every cycle (87-88%), without loss of Z33-ELP as it was only detected in the final pellet 
fraction. 
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Figure 3.5. Fluorescently-imaged (a) and silver-stained (b) SDS-PAGE analysis of Z33-ELP recycling experiment. 
Wash fraction 1 (lane 1), elution fraction 1 (lane 2), wash fraction 2 (lane 3), elution fraction 2 (lane 4), wash 
fraction 3 (lane 5), elution fraction 3 (lane 6), recovered Z33-ELP (lane 7). 
3.2.5. Selective purification of human antibodies 
The systematic thermodynamic investigation of the binding properties of the Z33-fusion 
proteins as described in Chapter 2 showed that a more than 100-fold difference in binding 
affinity was observed for bovine IgG and human IgG1. Now we aimed to demonstrate 
the application of Z33-ELP in the purification of IgGs using affinity precipitation, while 
taking advantage of the observed selectivity towards IgGs from different origins. A 
mixture of fluorescently-labeled bovine IgG (1.6 µM), unlabeled human IgG (1.6 µM) and 
bovine serum albumin in PBS was prepared. Contrary to the large excess of Z33-ELP used 
in the previous purification experiments, now only 2.5 µM Z33-ELP was used, and 25 µM 
ELP without the binding domain was added as a coaggregant in order to still be able to 
induce precipitation.[31] After triggering the phase separation by addition of NaCl, the 
precipitate was pelleted by centrifugation and the supernatant was removed (Figure 3.6a 
and b, lane 1). The pellet was then resuspended and this cycle was repeated twice to 
improve purification (lane 2 and 3). Finally, the captured IgGs were released (lane 4) and 
Z33-ELP was precipitated and pelleted (lane 5). The amount of bovine IgG in each 
fraction was quantified by the fluorescence intensity (see Table 3.3). The unlabeled human 
IgG1 was found in the purified fraction, which was practically free of the fluorescently-
labeled bovine IgG. As opposed to affinity column chromatography, the affinity 
precipitation allowed us to operate at a very low concentration of Z33, preventing binding 
to bovine IgG, which underlines the advantage of this approach. 
 
 
 
 
 
 
 
 
 
An ELP fusion protein for selective purification of antibodies 
 
 
81 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Analysis of samples taken during purification of human IgG1 from a mixture with fluorescently-
labeled bovine IgGs and BSA. (a) fluorescently-imaged and (b) Coomassie stained SDS-PAGE analysis. Wash 
fraction 1 (Lane 1), wash fraction 2 (lane 2), wash fraction 3 (lane 3), elution fraction (lane 4), recovered ELP/Z33-
ELP (lane 5). 
Table 3.3. Percentage of fluorescence intensity during each purification step 
Step  Percentage of bovine IgG (%)[a] 
Wash 1 
 
 96.4 
 
Wash 2  1.8 
Wash 3  0.4 
Elution  0.9 
Pellet  0.5 
[a] The percentage of release is calculated using the quantified fluorescence 
intensity from SDS-PAGE analysis 
 
3.3. Conclusion 
A generally applicable antibody purification platform was developed by using Z33-ELP for 
affinity capture, precipitation and release of antibodies. Z33-ELP is a fusion protein of 
ELP with a small binding domain derived from SpA. The major advantage of the small 
binding domain of 33 amino acids is that it can easily be fused with ELP, while binding is 
still dependent on the same interaction as with the complete protein. Furthermore, the Z33 
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domain has a decreased risk of denaturation and degradation. Therefore this methodology 
can easily substitute the industrially-applied SpA-based affinity chromatography 
procedure. Z33-ELP can also be reused, since it is obtained pure after the release of the 
antibodies. Even though antibodies are normally released from SpA-columns under acidic 
conditions, it was shown that release of antibodies from Z33-ELP could only be observed 
after short treatment with base, which did not affect the functionality of the antibody. 
 In Chapter 2, it was shown that binding of the Z33-domain to bovine IgGs was several 
orders of magnitude weaker than binding to human IgGs. This selectivity towards human 
IgGs was employed in an efficient and selective purification of human IgGs from mixtures 
containing bovine IgGs and other proteins by affinity precipitation. Potentially, this means 
that monoclonal antibody production does not necessarily need to be performed in 
medium with low bovine IgG content, such as serum-free medium or medium containing 
fetal calf serum.[32]  
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3.5. Experimental section 
Elastin-like polypeptide nomenclature 
ELP constructs are usually described using the notation ELP[XiYjZk-n], where the capital letters between 
the brackets indicate the single letter amino acid code for the residues at the Xaa position in the 
pentapeptide Val-Pro-Gly-Xaa-Gly. The subscript stands for the ratio of the guest residues and the n 
represents the total number of pentapeptide repeats. 
Construction of expression vector, and expression, purification and characterization of 
Z33-ELP 
The construction of pET15b-Z33-ELP[V5L2G3-90] was described in Chapter 2. Protein expression in 
BLR(DE3) E. coli (Novagen, MERCK), purification and characterization was performed as described in 
Chapter 2. Freeze dried Z33-ELP[V5L2G3-90] was obtained in a yield of 90-115 mg/L of bacterial culture 
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and the purity was verified by SDS-PAGE. ESI-TOF (JEOL AccuTOF): Z33-ELP[V5L2G3-90] calculated 
41709.2 Da, found 41708.6 Da. For control experiments, ELP[V5L2G3-90] without the Z33 domain was 
expressed and purified as described in Chapter 2 using pET15b-ELP[V5L2G3-90]. The protein was 
obtained in a yield of 95-120 mg/L of bacterial culture and the purity was also verified by SDS-PAGE. 
ESI-TOF (JEOL AccuTOF): calculated 39670.9 Da, found 39671.5 Da. 
Mass spectrometry 
Protein mass characterization was performed by electrospray ionization time-of-flight (ESI-TOF) on a 
JEOL AccuTOF. Deconvoluted mass spectra were obtained using MagTran 1.03b2. Isotopically averaged 
molecular weights were calculated using the “Protein Calculator v3.3” at 
http://www.scripps.edu/~cdputnam/protcalc.html. 
Transition temperature 
The transition temperatures of the ELPs were determined by turbidity measurements, where the optical 
absorbance at 600 nm was measured as a function of temperature (5-50 °C). These measurements were 
performed in a quartz cuvette with a path length of 0.1 cm on a Jasco J-815 Circular Dichroism 
Spectrometer equipped with a Peltier temperature controller (band width: 1 nm, response: 1 sec., 
sensitivity: standard, temperature slope: 1 °C/min). For these measurements, 400 µL of 1.0 mg/mL ELP 
in phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·2H2O, 1.0 mM 
KH2PO4, pH 7.4) was prepared. For the experiment in presence of antibody, a mixture of 100 µg of Z33-
ELP (2.4 nmol) with 184 µg of FITC-labeled polyclonal rabbit anti-mouse IgGs (1.23 nmol, Dako, 
F0261) in 400 µL PBS was prepared. 
Analysis of affinity by dot blot 
The affinity of Z33-ELP for antibodies from different origins was assayed by a dot blot assay. The FITC-
labeled control IgGs and chicken IgY used in this assay were purchased from Santa Cruz, Biotechnology. 
Z33-ELP was applied to a nitrocellulose membrane (1 µL of 10 mg/mL). After further blocking of the 
membrane with BSA (5% BSA in PBS with 0.1% Tween 20), it was incubated with 8 µg FITC-labeled 
antibody in 2 mL of PBST + BSA (PBS with 0.1% Tween 20 and 0.5% BSA) for two hours. The 
membrane was washed twice with PBST + BSA and was then analyzed on a fluorescence imager 
(Syngene, G:BOX Chemi-XT4, blue LEDs/SW06 filter). 
Size exclusion chromatography 
The SEC measurements were performed on an Amersham Ettan LC system (GE Healthcare, Diegem, 
Belgium) equipped with a fraction collector using a Superdex 200 PC 3.2/30 column (GE Healthcare). 
For each analysis, 20 µL of sample was separated on the column with a flow rate of 0.050 mL/min of 
PBS. Three samples were analyzed: 1) 1.9 nmol Z33-ELP, 2) 0.1 nmol polyclonal rabbit IgG (Santa Cruz, 
sc-2027) and 3) a mixture of 1.9 nmol Z33-ELP and 0.1 nmol polyclonal rabbit IgG which was incubated 
2 hours at room temperature. The elution was monitored at 214 nm and 280 nm.  
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Release conditions 
The release of antibodies from Z33-ELP was assayed. For each release solution which was tested, 34.5 µg 
of FITC-labeled polyclonal rabbit anti-mouse IgGs (Dako, F0261) were mixed with 100 µg of Z33-ELP in 
40 µL of PBS. After 30 min incubation at 20 °C the antibody/Z33-ELP complex was precipitated and 
pelleted by addition of NaCl upto 1.7 M (from 5 M NaCl stock solution) and centrifugation (15000 g for 
15 min at 20 °C). The supernatant was removed and the pellet was resuspended in 20 µL of the release 
solution. After 5 min of incubation at 20 °C, Z33-ELP was precipitated and pelleted by addition of NaCl 
upto 2.5 M (from 5M NaCl stock solution) and centrifugation (15000 g for 10 min at 20 °C). The 
supernatant was collected and 20 µL of PBS was added. Then the pellet was resuspended in 60 µL of 
PBS. For each release condition, an equal fraction of the supernatant and the pellet were loaded on an 
SDS-PAGE gel, which was then analyzed on a fluorescence imager (Syngene, G:BOX Chemi-XT4, blue 
LEDs/SW06 filter). ImageJ 1.38x was used to quantify the amount of antibody present in each fraction. 
Antibody capture, precipitation and release 
FITC-labeled polyclonal rabbit anti-mouse IgGs (Dako, F0261) were incubated with puriﬁed Z33-
ELP[V5L2G3-90] for 30 min at room temperature in the PBS. After incubation, NaCl was added to a final 
concentration of 1.7 M (from 5 M NaCl stock solution) and the mixture was centrifuged (15000 g for 10 
min at 20 °C). The pellet was resuspended in 50 mM NaOH and the supernatant was stored for SDS-
PAGE analysis. After 5 min of incubation at 20 °C the antibody/Z33-ELP complex was precipitated and 
pelleted by addition of NaCl upto 2.5 M (from 5M NaCl stock solution) and centrifugation (15000 g for 
10 min at 20 °C). The supernatant was collected and neutralized by addition of HCl and PBS. Then the 
pellet was resuspended in PBS. For analysis, an equal fraction of the wash, elution and pellet fraction was 
loaded on an SDS-PAGE gel, which was then analyzed on a fluorescence imager (Syngene, G:BOX 
Chemi-XT4, blue LEDs/SW06 filter). ImageJ 1.38x was used to quantify the amount of antibody present 
in each fraction. The activity of the purified rabbit anti-mouse IgGs was then assayed by a dot blot in 
which the monoclonal mouse anti αB crystallin IgGs were immobilized on a nitrocellulose membrane. 
The dot blot was performed as described previously. As a negative control, the same procedure was 
performed with ELP[V5L2G3-90].  
To investigate the purification of antibodies from mixtures, the polyclonal FITC-labeled rabbit anti-
mouse IgGs (Dako, F0261) were mixed with four commercially available proteins. The following mixture 
was prepared: polyclonal FITC-labeled rabbit anti-mouse IgGs (1.7 mg/mL), bovine serum albumin 
(BSA, 66 kDa, 3.5 mg/mL), horseradish peroxidase (HRP, 40 kDa, 1.0 mg/mL), Candida antarctica lipase 
B (CalB, 34 kDa, 0.7 mg/mL) and lysozyme (14 kDa, 1.6 mg/mL) in PBS. Then a similar purification 
procedure as described above was employed. However, an additional washing step with PBS was 
performed prior to elution to completely remove the contaminants.  
Recycling of Z33-ELP 
For the recycling experiments, the purification of FITC-labeled polyclonal rabbit anti-mouse IgGs (Dako, 
F0261, 23 µg, 0.15 nmol) was repeated three times. After the elution of the antibody, the pelleted Z33-
ELP was resolubilized in PBS and directly used for the next cycle of antibody purification. For analysis, 
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an equal fraction of the three wash fractions, the three elution fractions and the final pellet fraction was 
loaded on an SDS-PAGE gel, which was then analyzed on a fluorescence imager (Syngene, G:BOX 
Chemi-XT4, blue LEDs/SW06 filter). ImageJ 1.38x was used to quantify the amount of antibody present 
in each fraction. 
Selective purification of human antibodies 
A stock solution containing ELP (125 µM) and Z33-ELP (12.5 µM) was prepared. Human IgG1 (Sigma-
Aldrich, I5029, 12 µg, 0.08 nmol) was mixed with a solution of FITC-labeled bovine IgG (12 µg, 0.08 
nmol) and BSA in PBS (Santa Cruz Biotechnology, sc-2719) to yield a solution with a total volume of 40 
µL. To this mixture, 10 µL of the ELP/Z33-ELP stock solution was added (final quantities: ELP: 50 µg, 
1.25 nmol, Z33-ELP: 5 µg, 0.12 nmol). Then the Z33-ELP was allowed to bind to the IgGs during 
incubation for 20 min at room temperature. After this incubation, NaCl was added to a final 
concentration of 1.7 M (from 5 M NaCl stock solution) and the mixture was centrifuged (15000 g for 5 
min at 20 °C). To remove the non-specifically bound proteins, the pellet was redissolved in 50 µL PBS, 
and the supernatant was stored for SDS-PAGE analysis (wash fraction 1, 2 and 3). Then the antibody-
Z33-ELP complex was again precipitated by addition of NaCl to a final concentration of 1.7 M (from 5 M 
NaCl stock solution) and the mixture was centrifuged (15000 g for 5 min at 20 °C). This washing was 
repeated two more times and eventually the pellet was redissolved in 50 mM NaOH to release the 
antibody from Z33-ELP. After 5 min of incubation at 20 °C, Z33-ELP was precipitated and pelleted by 
addition of NaCl up to 2.5 M (from 5 M NaCl stock solution) and centrifugation (15000 g for 5 min at 20 
°C). The supernatant was collected and neutralized by addition of HCl and PBS (elution fraction). Then 
the pellet was redissolved in PBS. For analysis, the three wash fractions, the elution fraction and the pellet 
fraction were loaded on an SDS-PAGE gel, which was then analyzed on a fluorescence imager (Syngene, 
G:BOX Chemi-XT4, blue LEDs/SW06 filter). ImageJ 1.38x was used to quantify the amount of 
antibody present in each fraction. This quantification was corrected for differences in loading volumes of 
the various fractions. 
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4.1. Introduction 
Nanocapsules and nanoparticles have been used in a wide range of applications, varying 
from drug delivery vehicles to nanoreactors.[1-3] One of the most widely studied methods 
for the construction of these nanostructured materials is the molecular self-assembly of 
amphiphilic block copolymers.[4] Various hydrophobic core-forming polymers have been 
used, and often poly(ethylene glycol) (PEG) is chosen as the hydrophilic polymer block, as 
it efficiently provides stealth and steric protection for encapsulated materials and, because 
of its low toxicity, has been approved for internal applications by regulatory agencies.[1] 
Recently, polypeptide-based nanovehicles have gained much attention. In a number of 
cases, amphiphilic protein–polymer conjugates have been explored. In these biohybrid 
macromolecules, also called giant amphiphiles, the protein is used as the hydrophilic head 
group and the polymer as the hydrophobic tail.[5-8] Polypeptide-based block copolymer 
amphiphiles have also been designed for nanoparticle assembly.[9-11] 
 As we illustrated in the previous chapters, elastin-like polypeptides (ELP) can be 
switched from a water-soluble state to an insoluble hydrophobic state, resulting in 
aggregation. This stimulus-responsive behavior has also been used to create well-defined 
self-assembling protein-based block copolymers. ELP diblock copolymers consisting of 
two ELP blocks with a significantly different transition temperature (Tt) were combined. 
Triggering the phase transition of the ELP-block with the lowest Tt, resulted in the 
formation of an amphiphilic diblock copolypeptide, which self-assembled into spherical 
micelles.[12] Micellar ELP diblock copolymer assemblies were further characterized and 
studied as drug delivery device.[13-17] Also vesicular structures were produced by changing 
block arrangements and lengths.[18] ELPs have also been fused with other protein-based 
blocks, such as poly aspartic acid,[19] viral capsid proteins[20] and targeting domains for 
triggered multivalency,[21-23] to create functional amphiphilic block copolymers which all 
could be assembled upon triggering the ELP.  
 Until now, all examples in which ELP is used to drive assembly rely on a hydrophilic 
protein-based block. And even though many studies with amphiphilic polymers are known 
in which PEG is the hydrophilic corona-forming element, its beneficial properties have 
not yet been combined with the stimulus-responsive ELP-block. One of the reasons that 
such a hybrid system has probably not been reported yet, is that for the conjugation of the 
two macromolecules, highly efficient and specific conjugation chemistry is required.[24] 
Recently, the strain-promoted alkyne–azide cycloaddition (SPAAC) has been developed, 
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which has shown to be highly efficient in bioconjugation reactions, even with 
macromolecular species.[25-26] This reaction demands the two macromolecules to be 
functionalized with azides and strained alkynes. PEG can be straightforwardly end-
modified with a cyclooctyne moiety. For the introduction of azides into the ELP-block, 
we have developed a metal-free and pH-controlled diazotransfer reaction on primary 
amines, which enables the introduction of a well-defined number of azides in the ELP 
(Scheme 4.1).[27] Since we have absolute control over the amino acid sequence of the ELP 
blocks, the position of the conjugation sites is predetermined, which creates the 
opportunity to introduce one or more PEGs for the construction of diblock and 
miktoarm star (star-shaped polymers with multiple polymer arms originating from a core) 
stimulus-responsive block copolymers.[28-29]  
 This chapter describes the synthesis and self-assembly properties of a series of ELP–
PEG block copolymers, in which the length of both the stimulus-responsive ELP block 
and the hydrophilic PEG block and the number of PEG chains are varied.  
 
 
Scheme 4.1. Outline of the synthesis of ELP–PEG block copolymers 
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4.2. Results and discussion 
4.2.1. Production and characterization of elastin-like polypeptides 
To investigate the self-assembly behavior of ELP–PEG conjugates with different block 
lengths for both ELP and PEG, three variants of ELP[V5L2G3-n] with n = 40, 90 and 130 
were produced via protein expression in E. coli (for the protein sequences and ELP 
nomenclature see Experimental section). The expression was performed in E. coli 
BLR(DE3), a recA deficient derivative of the commonly used BL21(DE3) strain, which 
may help in stabilization of plasmids with repetitive sequences. As reported in literature, 
the highest target protein yields were observed after 24 hours of uninduced expression in 
nutrient-rich medium; supplementing the medium with phosphate, glycerol and proline 
did not result in increased yields.[30]  
 After expression the ELPs were purified by inverse transition cycling (ITC), by 
repeated centrifugation while alternating above and below the ELP transition temperature.  
The purification was analyzed by SDS-PAGE analysis; as an illustrative example the 
procedure for ELP[V5L2G3-90] is shown in Figure 4.1a. First the bacterial cells were lysed 
by ultrasonic disruption, and the lysate was obtained (lane 1). In the first “hot spin”, which 
is generally achieved by the addition of NaCl until the solution turns turbid, most of the 
endogenous E. coli proteins were removed (lane 2). It was preferred to precipitate ELP by 
increasing salt concentration over increasing temperature, as at elevated temperatures 
other E. coli proteins also precipitated; moreover, the centrifugation steps could all be 
performed at room temperature. Then, the redissolved pellet was centrifuged to remove 
irreversibly precipitated material, resulting in almost pure ELP in the supernatant with a 
single band around 40 kDa (lane 3). After another cycle of ITC, ELP90 was obtained pure 
(lane 5). Molecular weights (MW) of respectively 20, 40 and 55 kDa were estimated for 
ELP40, ELP90 and ELP130 from the SDS-PAGE analysis of the purified proteins 
(Figure 4.1b). Finally the proteins were freeze-dried and expression yields were determined 
by weight (see Table 4.1). It is noteworthy that determination of yield via BCA protein 
assay or via UV absorbance resulted in underestimated values.[31] 
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Figure 4.1. Purification of ELP (a) Coomassie-stained SDS-PAGE gel of ELP90 purification; total cell lysate (lane 1), 
supernatant of “hot spin 1” (lane 2), supernatant of “cold spin 1” (lane 3), supernatant of “hot spin 2”  (lane 4), 
product after last “cold spin” (lane 5). (b) Coomassie-stained SDS-PAGE gel of purified ELPs; ELP40 (lane 1), ELP90 
(lane 2) and ELP130 (lane 3). 
Table 4.1. Characteristics of the three ELP constructs 
ELP 
construct[a] 
Expression yield  
(mg/L of culture) 
Expected MW[a] 
(Da) 
Detected MW  
(Da) 
Tt in PBS with 
0.5 M NaCl (°C) 
Tt in PBS with 
2.0 M NaCl (°C) 
ELP40 
 
10-25 19687.6 19687.5 53 
 
24 
ELP90 95-120 39670.9 39671.2 34 13 
KK-ELP90 5[c] 39927.2 39929.9 n.d.[d] n.d. 
ELP130 40-75 55614.5 55612.0 30 10 
[a] ELP40, ELP90 and ELP130 contain one lysine residue in their leader sequence, whereas KK-ELP90 contains 
two additional lysine residues in its leader sequence. [b] Expected isotopically averaged molecular weights of 
ELPs after processing of N-terminal methionine. [c] Expression yield was determined by BCA assay, which 
resulted in underestimated value. [d] n.d. = not determined 
 Subsequently, the molecular weight was determined more accurately by electrospay 
ionization time-of-flight (ESI-TOF) mass spectrometry. The multiply-charged ion series 
and the deconvoluted total mass spectra are shown in Figure 4.2. The expected and 
detected MWs, as summarized in Table 4.1, matched very well. For all three ELPs a 
remarkably large number of charges and a broad charge-state distribution were observed. 
This was an indication for the ELPs to be intrinsically disordered, which is expected as 
ELPs below their Tt are believed to adopt a random coil conformation.[32]  
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Figure 4.2. Multiply-charged ion series of ESI-TOF mass spectrometry and deconvoluted total mass spectrum of 
(a) ELP40, (b) ELP90 and (c) ELP130. The observed molecular weights match nicely with the expected values. 
 To compare the Tt of the three ELPs, the LCST behavior was characterized by 
measuring turbidity as a function of temperature. To also investigate the influence of salt 
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on the Tt, this measurement was performed in phosphate buffered saline (PBS) 
supplemented with 0.5 M and 2.0 M sodium chloride. The turbidity profiles for ELP40 
(blue traces), ELP90 (black traces) and ELP130 (red traces) are displayed in Figure 4.3 and 
the Tt-values are summarized in Table 4.1. As expected the largest effect of number of 
pentapeptide repeats on the Tt was observed between ELP40 and ELP90, whereas the 
difference between ELP90 and ELP130 was limited.[33] The increased NaCl concentration 
resulted in an average decrease in Tt of 23 °C. For ELP90 and ELP130 this was sufficient 
to reduce the Tt to below room temperature, whereas ELP40 requires a higher 
concentration of NaCl. 
 
Figure 4.3. Normalized turbidity as function of temperature of ELP[V5L2G3-40] (red traces), ELP[V5L2G3-90] (black 
traces) and ELP[V5L2G3-130] (blue traces) in PBS supplemented with 0.5 M NaCl (solid lines) and in PBS 
supplemented with 2.0 M NaCl (dashed lines) measured at 350 nm.  
4.2.2. Metal-free and pH-controlled introduction of azides into proteins 
As outlined in Scheme 4.1, the ELPs need to be functionalized with an azide for the 
subsequent coupling with PEG. The introduction of such functional handles for the 
modification of proteins has been studied intensively in the past decade for various 
applications in the fields of chemical biology and bionanotechnology and two general 
approaches have been developed: co-translational and post-translational modification.[34-37] 
Co-translational incorporation of azides into ELPs using a genetic engineering approach 
has been reported, however, the scale on which this can be performed is limited and the 
process is laborious.[38] Our group recently developed a post-translational method to 
introduce azides into proteins and peptides by converting primary amines into azides via 
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an aqueous diazotransfer.[39-40] This reaction was performed at pH 11.0 in the presence of 
Cu(II) to introduce the azido-moiety at the α-amine at the N-terminus and the ε-amines of 
lysine residues. For this reaction, the hydrochloric salt of imidazole-1-sulfonyl azide (1) 
was used as a shelf-stable, non-explosive and water-soluble diazotransfer reagent.[41]  
 To explore whether milder and more selective conditions than described before could 
be applied, we examined the aqueous diazotransfer without addition of Cu(II) at pH 11.0 
and at pH 8.5. We initially tested this reaction on two variants of ELP90, with either one 
lysine (ELP90) or with two additional lysine residues (KK-ELP90) in the leader sequence. 
Diazotransfer results for other proteins such as Candida antarctica lipase B (CalB) and hen 
egg-white lysozyme C are discussed in depth elsewhere.[27] 
 
Scheme 4.2. Straightforward conversion of amines into azides using imidazole-1-sulfonyl azide as diazotransfer 
reagent. At pH 11.0 in the presence of Cu(II) multiple azides are introduced, whereas under milder, copper-free 
conditions at pH 8.5 the diazotransfer reaction is selective towards a single amine.[27] 
Diazotransfer at pH 11.0 in presence and absence of Cu(II) 
The two ELPs were incubated overnight at room temperature in the presence of 
diazotransfer reagent 1 (50 – 175 equivalents relative to amines) and sodium carbonate as a 
base, leading to a pH of 11.0 (Scheme 4.2). The conversion of amines into azides could be 
determined by ESI-TOF mass spectrometry, as the conversion of one amine into an azide 
resulted in an increase of molecular weight of 26 Da (Table 4.2). For the two ELP90 
variants, all amines were converted into azides, both in the presence and absence of 
Cu(II), resulting in 2N3-ELP90 and 4N3-KK-ELP90 (Table 4.2).  
 To verify that indeed the α-amine at the N-terminus and all ε-amines of the lysine 
residues were converted into azides, 2N3-ELP90 and 4N3-KK-ELP90 were subjected to 
tryptic digestion. Trypsin is a serine protease, which cleaves peptide bonds on the C-
terminal side of lysine and arginine residues.[42] Conversion of the ε-amine of a lysine 
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residue into an azide will result in inhibition of cleavage. Both ELP variants contained a 
lysine at position 23 and arginine residues at positions 16 and 24. The additional lysines in 
KK-ELP90 were positioned at residue numbers 29 and 30. The obtained fragments were 
then analyzed by ESI-TOF mass spectrometry and compared with the fragments of 
unmodified ELPs (Table 4.3). The peaks of the doubly- and triply-charged fragments that 
corresponded to amino acids 1-16 containing an azide were detected, i. e. [M + 2H]2+ 
being 897.9 instead of 885.4 Da, and [M + 3H]3+ being 599.0 Da instead of 590.6 Da. The 
conversion of lysine with residue number 23, which is present in both ELP variants, was 
expected to result in fragment 17-24, instead of 17-23, because cleavage was inhibited by 
the presence of the azide on the ε-amine. Indeed, the diazotized fragment 17-24 was 
detected for 2N3-ELP90 and for 4N3-KK-ELP90 (983.5 [M + 1H]1+). Conversion of the 
two additional lysines in KK-ELP90 (residue numbers 29 and 30) resulted in the detection 
of tryptic fragment 25-488 with a mass of 37290.0 Da (after deconvolution). 
 Cu(II), Ni(II) and Zn(II) are known to catalyze the diazotransfer reaction.[43] Even 
though imidazole-1-sulfonyl azide (1) was synthesized without using any metal salts, the 
imidazole ring present in this compound might have complexed some of these metal ions. 
To investigate whether this was the case, inductively coupled plasma mass spectrometry 
(ICP-MS) was employed on 1. The amounts of Cu(II), Ni(II) and Zn(II) detected were less 
than 5, 2.5 and 20 pmol per µmol of diazotransfer reagent, respectively. These values 
corresponded to trace amounts of less than 0.002 mol% catalyst relative to amines, and 
indicate that metal ions do not play a significant role in the diazotransfer reaction.[27] 
Table 4.2. Deconvoluted molecular weights based on multiply-charged ion series as observed by ESI-TOF 
Protein Expected MW prior 
to diazotransfer [a] 
(Da) 
Detected MW prior 
to diazotransfer 
(Da) 
pH Cu(II) Detected MW 
(Da) 
ELP90 39670.9 39671.7 8.5 - 39697.6 
   11.0 - 39722.8 
   8.5 + 39697.5, 39722.3 
   11.0 + 39722.8 
KK-ELP90 39927.2 39929.9 8.5 - 39953.5 
   11.0 - 40032.4 
   8.5 + 40005.7, 40031.5 
   11.0 + 40031.2 
[a] Expected isotopically averaged molecular weights of ELPs after processing of N-terminal methionine 
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Table 4.3. Results of tryptic digestion 
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Introduction of single azide at lower pH 
In addition to excluding Cu(II) from the reaction, we investigated the effect of lowering 
the pH. The diazotransfer was performed in diethanolamine-buffered solutions of pH 8.5, 
using 17.5 equivalents of 1, in the presence of Cu(II), resulting in less efficient conversion 
of amines into azides. Performing the diazotransfer at lower pH and in the absence of 
Cu(II), remarkably resulted in the introduction of only one azide for both ELP90 and KK-
ELP90 (Scheme 4.2 and Table 4.2). 
 The selectivity towards a single amine was speculated to be caused by differences in 
reactivity of amines. The reactivity will depend on the pKa, which is influenced by the 
microenvironment of the amine. The pKa values of amines in a protein can vary 
significantly. In general, the α-amine at the N-terminus of a protein (pKa = 7.6 – 8.0) will 
often have a much lower pKa than the primary amines of the lysine side chains (pKa = 9.3 
– 9.5).[44] However, also the solvent accessibility of the amines will influence their 
reactivity.  
 Mono-functionalized ELPs were treated with trypsin to determine which amine had 
been converted. The digests were analyzed by mass spectrometry (Table 4.3). In the tryptic 
digest of 1N3-ELP90 and 1N3-KK-ELP90 a peak of triply charged fragment was detected 
that corresponded to amino acids 1-16 containing an azide, i. e. [M + 3H]3+ being 598.9 
Da (and 599.0 Da for 1N3-KK-ELP90) instead of 590.6 Da (Figure 4.4). Note that for 
ELP90 a small fraction of the unreacted fragment was detected as well. The singly charged 
tryptic fragment 17-23 was detected, and the peak corresponding to amino acids 17-24 
containing a converted lysine at position 23 was only present when Cu(II), a base and/or 
175 equivalents of diazotransfer reagent were added to produce 2N3-ELP90 and 4N3-KK-
ELP90. Furthermore, the protein fragment corresponding to amino acids 30-488 was 
detected, which confirmed that the two additional lysines of 1N3-KK-ELP90 were 
unchanged in the mono-functionalized sample. Therefore it was concluded that in both 
ELP variants, only the α-amine at the N-terminus had been converted at pH 8.5 in the 
absence of Cu(II).  
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Figure 4.4. Mass spectra of N-terminal fragments of mono-functionalized (a) 1N3-ELP90 and (b) 1N3-KK-ELP90. 
The calculated [M + 3H]3+ of the unmodified peptide is 590.6 Da. 
Introduction of azides into ELPs for the synthesis of block copolymers 
For the synthesis of ELP–PEG block copolymers, ELP40, ELP90 and ELP130 were 
modified with 1 or 2 azides by the pH-controlled diazotransfer. Note that all of these 
ELPs contain two amines, the α-amine at the N-terminus and the ε-amine of the single 
lysine residue (for sequences, see Experimental section). The reaction was therefore 
performed at pH 8.5 and pH 11.0, respectively, using 17.5 – 50 equivalents of 
diazotransfer reagent in the absence of Cu(II). Mass spectrometry verified the presence of 
either one or two azides (Table 4.4). 
Table 4.4. Deconvoluted molecular weights based on multiply-charged ion series as observed by ESI-TOF 
ELP 
construct 
Detected MW 
of unmodified 
ELP (Da) 
Expected MW 
One azide 
(Da) 
Detected MW after 
diazotransfer at  
pH 8.5 (Da) 
Expected MW 
Two azides 
(Da) 
Detected MW after 
diazotransfer at  
pH 11.0 (Da) 
ELP40 19687.5 19713.6 19712.3 19739.6 19740.2 
ELP90 39671.2 39696.9 39696.1 39722.9 39722.6 
ELP130 55612.0 55640.5 55641.0 55666.5 55665.0 
 
4.2.3. Synthesis of BCN-poly(ethylene glycol) 
The proposed modular strategy for synthesis of the linear and branched ELP–PEG block 
copolymers required the PEG to be modified with a strained alkyne. Even though 
multiple strained alkynes are currently available,[25-26] we opted for bicyclo[6.1.0]nonyne 
(BCN), because of its commercial availability, the ease of functionalization, limited 
lipophilicity and the favorable reaction kinetics.[45] 
 Two poly(ethylene glycol) methyl ethers with different lengths, mPEG2000 2a and 
mPEG5000 2b, were end-functionalized with a BCN-moiety (Scheme 4.3). In a first step 
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the hydroxyl groups were quantitatively converted into azides via intermediate mesylation, 
resulting in mPEG-N3 (4). Subsequently, the azides were reduced to amines with 
triphenylphosphine giving mPEG-NH2 (5). In order to form the desired mPEG-BCN (7), 
compounds 5 were reacted with the commercially available (1R,8S,9s)-bicyclo[6.1.0]non-4-
yn-9-ylmethyl succinimidyl carbonate (6, BCN-OSu). The reaction was stirred overnight at 
room temperature in the presence of triethylamine as a base. Purification by column 
chromatography gave the PEG-BCN products in yields of 33% (7a) and 44% (7b). 
 
 
Scheme 4.3. Synthesis of BCN-functionalized poly(ethylene glycol). MsCl: mesyl chloride; DCM: dichloromethane; 
DMF: dimethylformamide; THF: tetrahydrofuran; BCN-OSu: (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethyl 
succinimidyl carbonate. Mesylation of alcohol of commercially available mPEG2000 2a and mPEG5000 2b was 
followed by substitution with azide. Subsequently, the azide was reduced with triphenylphosphine to obtain 
compounds 5a and 5b with a respective yield of 82% and 94% over three steps. Subsequent reaction with BCN-
OSu (6) was performed with a yield of 33% and 44% for 7a and 7b, respectively. 
4.2.4. Conjugation of elastin-like polypeptides and poly(ethylene glycol) 
The functionalized building blocks were conjugated via SPAAC. The modular approach 
gave rise to 12 different products with different ELP-block lengths (40, 90, 130), different 
PEG-block lengths (2000, 5000) and architecture (linear or branched). In all reactions a 5 
– 10 fold excess of PEG-BCN was used and size exclusion chromatography (SEC) was 
applied to remove both the excess and the unreacted ELPs. After this purification, the 
products were analyzed by SDS-PAGE (Figure 4.5). The shift of the product band on 
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SDS-PAGE was complete, indicating that all block copolymers were successfully 
synthesized and were obtained pure (>95%) after SEC, except for 1xPEG2000-ELP130 
(>75% pure). This lower purity was due to the difficulty to separate unreacted ELP130 
from 1xPEG2000-ELP130 by SEC, as the difference in size is very small. Determination of 
MW by SDS-PAGE was complex, because the protein standards, which were used as 
molecular weight marker, were difficult to compare with the hybrid (branched) material. 
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry was therefore employed to confirm the molecular weight of the block 
copolymers. Due to the polydisperse nature of PEG, slightly broadened peaks were 
observed. The observed MW of the ELPs increased with 2, 4, 5 and 10 kDa upon 
conjugation of 1 PEG2000, 2 PEG2000, 1 PEG5000 and 2 PEG5000, respectively (Table 4.5). 
 
 
 
Figure 4.5. Coomassie-stained SDS-PAGE analysis of purified ELP–PEG conjugates. Clear shifts were observed for 
the ELP–PEG conjugates compared to the unmodified ELPs. All block copolymers were successfully synthesized 
and were obtained pure (>95%) after SEC, except for 1xPEG2000-ELP130 (>75% pure).  
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Table 4.5. Properties of ELP–PEG block copolymers and self-assembly characteristics 
Construct Detected MW 
(kDa)[a] 
Hydrodynamic 
diameter (nm) 
PDI 
ELP40 (unmodified) 19.6 precipitation - 
ELP40-1xPEG2000 21.9 115 0.100 
ELP40-2xPEG2000 24.0 40 0.221 
ELP40-1xPEG5000 24.9 39 0.245 
ELP40-2xPEG5000 30.1 48 0.100 
    
ELP90 (unmodified) 39.4 precipitation - 
ELP90-1xPEG2000 41.6 353 0.172 
ELP90-2xPEG2000 43.7 284 0.189 
ELP90-1xPEG5000 44.9 53 0.023 
ELP90-2xPEG5000 50.0 41 0.008 
    
ELP130 (unmodified) 55.0 precipitation - 
ELP130-1xPEG2000 57.6 156 0.039 
ELP130-2xPEG2000 59.7 101 0.073 
ELP130-1xPEG5000 60.6 74 0.056 
ELP130-2xPEG5000 65.6 51 0.024 
[a] MW detected by MALDI-TOF. 
 
4.2.5. Self-assembly of ELP–PEG 
The ELP phase transition was triggered to induce self-assembly of the ELP–PEG 
conjugates. As shown in Figure 4.3, ELP90 and ELP130 were triggered to self-assemble at 
room temperature by the addition of NaCl to a concentration of 2.0 M, but a higher 
concentration of 3.5 M was required for ELP40. The addition of NaCl to the unmodified 
ELPs resulted in immediate precipitation, whereas no precipitation was observed for the 
ELP–PEG conjugates. Subsequently, the assemblies were analyzed by dynamic light 
scattering (DLS). The results are summarized in Table 4.5. The PEG5000-conjugates 
resulted in uniform assembly products with diameters around 50 nm, a size range often 
associated with micellar structures. The block copolymers with PEG2000 gave larger and 
less well-defined assemblies, based on the polydispersity index (PDI). Assembly of the 
ELP40-based block copolymers gave rise to even less well-defined particles, potentially 
due to the smaller hydrophobic block. The branched ELP90-2xPEG5000 and ELP130-
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2xPEG5000 gave the best PDI values, indicating monodisperse assembly products. When 
taking into account the diameter of the assemblies, and the length of the block copolymers 
(the hydrophilic to hydrophobic ratio), it is most likely that these ELP–PEG conjugates 
are assembled in a micellar arrangement. Especially the branched miktoarm block 
copolymers have a packing parameter which favors micellar packing.[46] 
 The assembly products of the most interesting (monodisperse) ELP–PEG conjugates 
containing PEG5000 chains were visualized by transmission electron microscopy (TEM). 
TEM data showed spherical-shaped particles for all the samples that were studied, the 
observed particles displayed a diameter of 40 – 70 nm, which nicely matched with the 
diameters observed by DLS (Figure 4.6). Similar to the DLS data, TEM showed smaller 
diameters for the assemblies of the ELP–PEG conjugates with two PEG5000 chains. 
 
Figure 4.6. Uranyl acetate-stained TEM micrographs of self-assembled (a) ELP90-1xPEG5000, (b) ELP130-1xPEG5000, 
(c) ELP90-2xPEG5000 and (d) ELP130-2xPEG5000. The scale bar indicates 200 nm. 
4.2.6. Encapsulation of 1-anilinonapthalene-8-sulfonic acid 
A hydrophobic small-molecule was encapsulated to show the potential of the micelles as 
nanocarriers. The small hydrophobic 1-anilinonapthalene-8-sulfonic acid (1,8-ANS) 
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fluoresces in a hydrophobic environment and has previously been used to study 
encapsulation by amphiphilic block copolymers.[13] Upon binding to hydrophobic sites, a 
blue shift of fluorescence emission maxima and the increase of fluorescence intensity and 
lifetime are observed.[47-48] The fluorescence intensity of 1,8-ANS was measured before 
and after triggering of self-assembly of the ELP-block (Figure 4.7). In all cases, minimal 
fluorescence with a maximum around 505 nm was observed prior to self-assembly. After 
self-assembly and subsequent centrifugation of the solution, indeed a blue shift of 
fluorescence emission maxima to 470 nm and an increase of fluorescence intensity were 
observed (Figure 4.7a, b and c). Moreover, the centrifugation step confirmed that the 
particles are stably dispersed, since the fluorescence was still observed. In the control 
experiment where the phase transition of unmodified ELP was induced in the presence of 
1,8-ANS, no increase in fluorescence was observed, because the aggregated ELP was 
removed from solution by centrifugation (Figure 4.7d, e and f). 
 
Figure 4.7. Fluorescence analysis of encapsulation of 1-anilinonaphthalene-8-sulfonic acid (1,8-ANS) by various 
ELP–PEG block copolymers. The fluorescence intensity is measured prior to self-assembly (solid lines) and after 
self-assembly (dashed lines). To compare fluorescence intensity before and after self-assembly of all block 
copolymers of (a) ELP40, (b) ELP90 and (c) ELP130, the spectra have been normalized. ELP40-1xPEG5000 and 
ELP130-1xPEG2000 were omitted because no clear increase in fluorescence was observed after self-assembly. The 
absolute fluorescence intensity is shown to compare the ELP–PEG conjugates with the unmodified (d) ELP40, (e) 
ELP90 and (f) ELP130. 
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4.3. Conclusion 
We have described a modular approach for the synthesis of a series of ELP–PEG block 
copolymers, in which the length of the stimulus-responsive ELP-block (ELP40, ELP90 
and ELP130), the length of the hydrophilic PEG-block (PEG2000 and PEG5000) and 
architecture (linear or branched) were varied. To this end, PEG was straightforwardly end-
functionalized with a cyclooctyne and ELP was functionalized via a newly developed 
metal-free and pH-controlled diazotransfer reaction, which allowed control over the 
number of azides in the ELP. These two macromolecules were then conjugated via the 
highly efficient and specific SPAAC reaction. Triggering the phase transition of the ELP-
block resulted in the formation of an amphiphilic block copolymer, which self-assembled 
into micelles. This is the first example, in which PEG as the hydrophilic corona-forming 
block was combined with the stimulus-responsive ELP-block for the formation of 
nanocarriers. We furthermore showed that a hydrophobic fluorescent dye could easily be 
encapsulated, which demonstrates the potential of these hybrid polymers to form 
stimulus-responsive nanocarriers for hydrophobic drugs, with a PEG corona which 
provides stealth and steric protection for the encapsulated materials.  
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4.5. Experimental section  
Materials 
Unless stated otherwise all chemicals were obtained from Sigma-Aldrich and used without further 
purification. Restriction enzymes (BsmFI, FokI, XhoI and BamHI) and Antarctic Phosphatase were 
obtained from New England Biolabs. Ligase (T4 DNA Ligase) was obtained from Promega. Ampicillin 
was purchased from MP Biomedicals. Sulfuryl chloride, sodium azide and diethanolamine were obtained 
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from Acros. CuSO4·5H2O and Na2CO3 were purchased from Merck and Baker, respectively. Trypsin 
(mass spectrometry grade) was acquired from Promega. (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethyl 
succinimidyl carbonate was purchased from SynAffix BV. Ultrapure Milli-Q water (MQ) was purified 
using a WaterPro PS polisher (Labconco, Kansas City, MO) set to 18.2 MΩ/cm.  
Elastin-like polypeptide nomenclature 
ELP constructs are usually described using the notation ELP[XiYjZk-n], where the capital letters between 
the brackets indicate the single letter amino acid code for the residues at the Xaa position in the 
pentapeptide Val-Pro-Gly-Xaa-Gly. The subscript stands for the ratio of the guest residues and the n 
represents the total number of pentapeptide repeats. 
Construction of expression vectors 
The vectors pET15b-ELP[V5L2G3-40], pET15b-ELP[V5L2G3-90] and pET15b-KK-ELP[V5L2G3-90] for 
expression of ELP[V5L2G3-40], ELP[V5L2G3-90] and KK-ELP[V5L2G3-90] were prepared as 
described.[49] pET15b-ELP[V5L2G3-130] was prepared by elongation of the ELP[V5L2G3-90] construct by 
recursive directional ligation (RDL). The cloning vector containing ELP90, pMTL23-δ-BsaI-adapter-
ELP[V5L2G3-90], was linearized using BsmFI digest and subsequently dephosphorylated, using Antarctic 
Phosphatase. The insert was obtained from pMTL23- δ-BsaI-aIII-ELP[V5L2G3-40] by a double digest 
using BsmFI and FokI and ligated into the dephosphorylated vector, using T4 DNA Ligase. Sequences 
were verified by DNA sequencing. However, as a consequence of cloning, mutations resulting in the loss 
of one glycine and the replacement of a valine for an alanine of another amino acid were observed; these 
modifications did however not affect the ELP properties. Elongated ELP was then digested out of the 
cloning vector, using XhoI/BamHI digest, and inserted into XhoI/BamHI linearized pET15b vector.  
Protein sequences 
ELP40 
GSS HHHHHH SSGLVPRGSHMLEKREAEAGP [VPGGG VPGVG VPGVG VPGGG 
VPGLG VPGVG VPGVG VPGVG VPGGG VPGLG]4 VPGGGA 
ELP90  
GSS HHHHHH SSGLVPRGSHMLEKREAEAGP [VPGGG VPGVG VPGVG VPGGG 
VPGLG VPGVG VPGVG VPGVG VPGGG VPGLG]9 VPGGGA 
KK-ELP90 
GSS HHHHHH SSGLVPRGSHMLEKREAEAKKGP [VPGGG VPGVG VPGVG VPGGG 
VPGLG VPGVG VPGVG VPGVG VPGGG VPGLG]9 VPGGGA 
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ELP130  
GSS HHHHHH SSGLVPRGSHMLEKREAEAGP [VPGGG VPGVG VPGVG VPGGG 
VPGLG VPGVG VPGVG VPGVG VPGGG VPGLG]4 VPAG VPGVG VPGVG VPGGG 
VPGLG VPGVG VPGVG VPGVG VPGGG VPGLG [VPGGG VPGVG VPGVG VPGGG 
VPGLG VPGVG VPGVG VPGVG VPGGG VPGLG]8 VPGGGA 
Expression of ELPs 
ELP40, ELP90, ELP130 
The pET15b-ELP[V5L2G3-n] (n = 40, 90 or 130) expression vector was transformed into the BLR(DE3) 
E. coli strain. A single colony was used to inoculate 50 mL 2xYT medium supplemented with ampicillin 
(100 mg/L). The culture was grown overnight at 37 °C while shaking (200 RPM). The next day the 
culture was used to inoculate 1 L 2xYT medium supplemented with ampicillin (100 mg/L) for uninduced 
expression at 37 °C.[30] After 24h of expression, the cells were harvested by centrifugation (4 °C, 30 min, 
2700 g). Subsequently the cell pellet was resuspended in 50 mL cold phosphate buffered saline (PBS, 137 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·2H2O, 1.0 mM KH2PO4, pH 7.4) and incubated with 
lysozyme (1 mg/mL) for 30 min on ice. The cells were further lysed by ultrasonic disruption. The cell 
lysate was centrifuged (15000 g at 4 °C for 30 min, Sorvall HB-4) and the cleared lysate was obtained. 
The protein was purified from the cleared lysate via two cycles of inverse transition cycling,[50] which is 
achieved by repeated centrifugation while alternating the temperature above and below the transition 
temperature (Tt) of the elastin-like polypeptide. The phase transition temperature was decreased by the 
addition of salt. For this purpose NaCl was added to the cleared lysate from a 5 M stock solution until a 
turbid solution was obtained. In “hot spin 1”, this solution was centrifuged at 15000 g for 15 min at 20 
°C. The pellet was redissolved in 15 mL cold PBS and then centrifuged at 15000 g for 15 min at 4 °C 
(“cold spin 1”). NaCl was added to the supernatant and the resulting turbid solution was centrifuged at 
15000 g for 15 min at 20 °C (“hot spin 2”). The pellet was then redissolved in 6.5 mL cold PBS and 
centrifuged at 15000 g for 15 min at 4 °C (“cold spin 2”). An SDS-PAGE analysis was performed to 
check the purification (Figure 4.1). After purification the protein was freeze-dried. First the salts were 
removed by two more cycles of ITC and resuspension in water (MilliQ). The protein yields were 
determined by weight and the molecular weights were determined by ESI-TOF mass spectrometry (Table 
4.1).  
KK-ELP90 
pET15b-KK-ELP[V5L2G3-90] was transformed into BLR(DE3)pLysS (Novagen) and the expression was 
performed as described.[49] The protein was purified by inverse transition cycling and the protein yield 
was determined by BCA assay (Pierce). The purity was confirmed by SDS-PAGE.  
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Diazotransfer reactions for introduction of azides in ELP 
Stock solutions of diazotransfer reagent 1 (20 mg/mL, 95.2 mM), Na2CO3 (20 mg/mL, 188.7 mM) and 
CuSO4·5H2O (1 mg/mL, 4.0 mM) in MQ were prepared. NaOH was added to the stock solution of 1 to 
neutralize the pH to 7. 
pH 11.0 
To 1 mg of ELP in MQ (at a concentration of 10 mg/mL), 50 – 175 equivalents of diazotransfer reagent 
per amine and 50 µL of Na2CO3 stock solution was added. For the reactions in the presence of copper, 
50 µL of CuSO4·5H2O stock solution was added. MQ was added to a final volume of 1 mL. After 
overnight incubation at room temperature while shaken on an Eppendorf Thermomixer, the excess of 
diazotransfer reagent was removed by two cycles of inverse transition cycling. 
pH 8.5 
To 1 mg of ELP in MQ (at a concentration of 10 mg/mL), 17.5 – 50 equivalents of diazotransfer reagent 
per amine and a 50 mM diethanolamine buffer of pH 8.5 was added to obtain a final volume of 1 mL. 
For the reactions in the presence of copper, 50 µL of CuSO4·5H2O stock solution was added. After 
overnight incubation at room temperature while shaken on an Eppendorf Thermomixer, the excess of 
diazotransfer reagent was removed by two cycles of inverse transition cycling. 
Mass spectrometry 
Protein mass characterization was performed by electrospray ionization time-of-flight (ESI-TOF) on a 
JEOL AccuTOF. Deconvoluted mass spectra were obtained using MagTran 1.03b2. Isotopically averaged 
molecular weights were calculated using the “Protein Calculator v3.3” at 
http://www.scripps.edu/~cdputnam/protcalc.html. 
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry 
measurements on the whole proteins and the conjugates were performed on a Bruker Biflex III 
spectrometer with 2,5-dihydroxyacetophenone (DHAP) as matrix.[51] To detect tryptic digest fragments 
by MALDI-TOF, analysis was performed with α-cyano-4-hydroxycinnamic acid as matrix. 
Tryptic digest 
Tryptic digest analysis of the ELPs was performed by adding 0.5 μg trypsin to 7 μg ELP in 12 μL 20 mM 
NH4HCO3. After 5 hours of incubation at 37 °C the samples were purified using ZipTip-C18 (Millipore) 
and eluted in 20 μL 75 % acetonitrile in 0.1 % trifluoroacetic acid / MQ. The digest was then analyzed by 
MALDI-TOF and ESI-TOF mass spectrometry. 
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Synthesis of imidazole-1-sulfonyl azide hydrochloride (1)  
 The hydrochloric salt of imidazole-1-sulfonyl azide was synthesized as described 
by Goddard-Borger et al.[41] Sulfuryl chloride (4.0 mL, 50 mmol) was added 
dropwise to an ice-cooled suspension of NaN3 (3.3 g, 50 mmol) in MeCN (50 mL) 
and the mixture was stirred overnight, allowing it to warm up to room 
temperature. Then the mixture was recooled on ice and imidazole (6.5 g, 95 mmol) was added portion-
wise. After the addition, the reaction mixture was stirred for 3h while the temperature was allowed to 
warm up to room temperature. Subsequently, the mixture was diluted with EtOAc (100 mL), washed 
twice with MilliQ water (2x 100 mL) and twice with saturated NaHCO3 (2x 100 mL) and then dried over 
MgSO4. Then the HCl salt was formed via dropwise addition of 4 M HCl in EtOAc (40 mL) to the ice-
cooled mixture. The resulting precipitate was filtered and washed with EtOAc (3x50 mL) to obtain 
imidazole-1-sulfonyl azide hydrochloride in a yield of 59%. LRMS: (m/z) [MCl]+ calculated for 
C3H3N5O2S 174.0, found: 173.9. 1H-NMR (400 MHz, D2O): δ9.22 (s, 1H), δ7.99 (s, 1H), δ7.57 (s, 1H). It 
should be noted that diazotransfer reagent 1 is shelf stable, but should not be kept as a concentrated 
aqueous solution for prolonged time due to risk of decomposition.[52] 
Synthesis of α-methoxy ω-mesyl poly(ethylene glycol)44 (3a)  
 Monomethoxy PEG2000 (2 g, 1 mmol) was co-evaporated with 
toluene (3 × 30 mL) and loaded into a flame-dried Schlenk-flask under 
Argon atmosphere. The monomethoxy PEG2000 was dissolved in THF 
(25 mL) and NEt3 (0.55 mL, 4 mmol) was added. The resulting solution was added to a solution of 
mesylchloride (0.248 mL, 3.2 mmol) in THF (25 mL) under argon atmosphere. The reaction mixture was 
stirred overnight at room temperature whereupon the THF was removed under reduced pressure. The 
resulting oil was dissolved in H2O (50 mL) and the aqueous layer was extracted with CH2Cl2 (3 × 50 mL). 
The combined organic layers were dried over Na2SO4 and the solvents were removed under reduced 
pressure. The crude product was taken up in THF (10 mL) and the solution was added to Et2O (400 mL). 
Upon storing the mixture at -20 °C for 1 hour, the solid was collected by filtration. Compound 3a was 
obtained as a white solid (2 g, 100%). 1H-NMR (400 MHz, CDCl3): δ4.40 – 4.35 (m, 2H, 
CH2CH2OSO2CH3), δ3.84 –3.74 t, 3H), δ3.64 (br s, 168H, CH2CH2O), δ3.57 – 3.52 (m, 2H), δ3.47 – 
3.45 (m, 1H), δ3.37 (s, 3H, OCH3), δ3.08 (s, 3H, OSO2CH3). 
Synthesis of α-methoxy ω-mesyl poly(ethylene glycol)114 (3b) 
 Commercially available monomethoxy PEG5000 (5.07 g; 1.01 mmol) 
was dissolved in toluene (25 mL). Toluene was evaporated under 
reduced pressure to remove any remaining water. The monomethoxy 
PEG5000 was then dissolved in dry THF (50 mL) and transferred to a flame-dried Schlenk flask. Dry 
triethylamine (0.55 mL; 4.0 mmol) and mesylchloride (0.248 mL; 3.20 mmol) were added and the reaction 
mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo, 
redissolved in water (50 mL) and extracted three times with DCM (50 mL). The combined organic phases 
were dried over Na2SO4 and concentrated in vacuo. The product was then dissolved in a minimal volume 
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of DCM and added to ice cold diethyl ether (500 mL). The resulting mixture was stored at -20 °C for 1 
hour after which the resulting precipitate was filtered off over a glass funnel and collected in a yield of 
4.97 g (0.99 mmol; 98%). 1H-NMR (400 MHz, CDCl3): δ4.38 (m, 2H, CH2CH2OSO2CH3), δ3.83 – 3.45 
(m, 454H, CH2CH2O), δ3.38 (s, 3H, OCH3), δ3.08 (s, 3H, OSO2CH3). 
Synthesis of α-methoxy ω-azido poly(ethylene glycol)44 (mPEG2000-N3, 4a) 
 Compound 3a (2 g, 1 mmol) was dissolved in DMF (50 mL) and NaN3 (1.3 
g, 20 mmol) was added. The reaction mixture was stirred for 2 days at 30 °C. 
The reaction mixture was diluted with CH2Cl2 (100 mL) and the organic layer 
was washed with H2O (3 × 100 mL) and brine (100 mL) and the organic layer was dried over MgSO4. 
The organic solvents were removed under reduced pressure. The resulting oil was redissolved in THF (10 
mL) and added to Et2O (400 mL). Upon storing the mixture at -20 °C for 1 hour, the solid was collected 
by filtration. Compound 4a was obtained as a white solid (1.9 g, 95%). 1H-NMR (400 MHz, CDCl3): 
δ3.82 – 3.80 (m, 1H), δ3.73 – 3.56 (m, 170H, CH2CH2O), δ3.60 – 3.53 (m, 2H), δ3.48 – 3.46 (m, 1H, 
CHH-OMe), δ3.41 – 3.38 (m, 2H, CH2CH2N3), δ3.38 (s, 3H, OCH3). 
Synthesis of α-methoxy ω-azido poly(ethylene glycol)114 (mPEG5000-N3, 4b) 
 Compound 3b (5.0 g; 1.0 mmol) was dissolved in DMF (60 mL) and heated 
to 30 °C. Sodium azide (1.31g; 20.2 mmol) was added and the reaction 
mixture was stirred at 30 °C for 3 days. Water (100 mL) was added and the 
resulting mixture was extracted three times with DCM (50 mL). The combined organic layers were dried 
over Na2SO4 and concentrated in vacuo. The resulting oil was dissolved in little DCM and added to ice 
cold diethyl ether (500 mL). The resulting mixture was stored at -20 °C for 1 hour after which the 
resulting precipitate was filtered off and collected in a yield of 4.79 g (0.96 mmol; 96%). 1H-NMR (400 
MHz, CDCl3): δ3.83 – 3.39 (m, 454H, CH2CH2O), δ3.39 (m, 2H, CH2CH2N3) δ3.38 (s, 3H, OCH3). FT-
IR (ATR): 2872, 2103 (νazide), 1466, 1343, 1280, 1242, 1103 cm-1. 
Synthesis of α-methoxy ω-amino poly(ethylene glycol)44 (mPEG2000-NH2, 5a) 
 Compound 4a (1.0 g; 0.50 mmol) was dissolved in THF (10 mL). Then 
PPh3 (0.66 g; 2.50 mmol) was added and the reaction mixture was stirred at 
room temperature overnight. Water (15 mL) was added and the mixture 
was stirred at room temperature for another 2 hours. THF was removed from the reaction mixture under 
reduced pressure. The resulting mixture was extracted three times with ethyl acetate and the combined 
organic layers were washed once with water. The combined aqueous layers were extracted three times 
with chloroform and NaCl was added to promote phase separation. The combined chloroform layers 
were dried over Na2SO4 and concentrated in vacuo. The resulting product was precipitated from 
diethylether. This gave the desired product in a yield of 0.85 g (0.43 mmol; 86%). 1H-NMR (400 MHz, 
CDCl3): δ3.83 – 3.45 (m, 180H, CH2CH2O), δ3.38 (s, 3H, OCH3), δ3.04 (t, 2H, CH2CH2NH2). 
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Synthesis of α-methoxy ω-amino poly(ethylene glycol)114 (mPEG5000-NH2, 5b) 
 Compound 4b (4.8 g; 0.96 mmol) was combined with THF (50 mL) and 
heated to 40 °C. After all solids were completely dissolved, the mixture was 
allowed to cool to room temperature. PPh3 (1.34 g; 5.11 mmol) was added 
and the reaction mixture was stirred at room temperature overnight. Water (25 mL) was added and the 
mixture was stirred at room temperature for another 2 hours. THF was removed from the reaction 
mixture under reduced pressure and more water (100 mL) was added. The resulting mixture was 
extracted three times with ethyl acetate (100 mL) and the combined organic layers were washed once with 
water (100 mL). The combined aqueous layers were extracted three times with chloroform (100 mL). The 
combined chloroform layers were dried over Na2SO4 and concentrated in vacuo. The resulting product 
was dissolved in dioxane (15 mL) and freeze-dried overnight. This gave the desired product in a yield of 
4.8 g (0.96 mmol; 100%). 1H-NMR (400 MHz, CDCl3): δ3.83 – 3.45 (m, 454H, CH2CH2O), δ3.38 (s, 3H, 
OCH3), δ3.04 (t, 2H, CH2CH2NH2). FT-IR (ATR): 2884, 1467, 1343, 1280, 1146, 1113 cm-1. 
Synthesis of α-methoxy ω-(bicyclo[6.1.0]non-4-yn-9-ylmethyl carbamate) poly(ethylene 
glycol)44 (mPEG2000-BCN, 7a) 
 Commercially available (1R,8S,9S)-bicyclo[6.1.0]non-4-
yn-9-ylmethyl succinimidyl 6 (44.7 mg; 153 μmol) was 
dissolved in DCM (15 mL). Compound 5a (201 mg; 
101 μmol) and triethylamine (41.6 μL; 0.3 mmol) were 
added and the reaction mixture was stirred overnight at 
room temperature for 4 days. The reaction mixture was washed twice with 2 M HCl solution (20 mL) and 
three times with water (20 mL). The organic layer was then dried over Na2SO4 and concentrated in vacuo. 
The product was purified by column chromatography (elution with 5-10% MeOH in DCM). The pure 
fractions were combined and the solvent was evaporated under reduced pressure to obtain the product in 
a yield of 75 mg (33 μmol; 33 %). 1H-NMR (400 MHz, CDCl3): δ5.28 (bs, 1H, carbamate), δ4.15 (m, 2H, 
NH(CO)OCH2CH), δ3.87 – 3.37 (m, 180H, CH2CH2O), δ3.38 (s, 3H, OCH3), δ2.26 (m, 6H, 
cyclooctyne), δ1.60 (m, 3H, (CO)OCH2CH + cyclooctyne), δ0.94 (m, 2H, cyclopropane-cyclooctyne ring 
fusion).  
Synthesis of α-methoxy ω-(bicyclo[6.1.0]non-4-yn-9-ylmethyl carbamate) poly(ethylene 
glycol)114 (mPEG5000-BCN, 7b) 
 Commercially available (1R,8S,9S)-bicyclo[6.1.0]non-4-
yn-9-ylmethyl succinimidyl 6 (21 mg; 72 μmol) was 
dissolved in DCM (15 mL). Compound 5b (229 mg; 
45.8 μmol) and triethylamine (19 μL; 0.14 mmol) were 
added and the reaction mixture was stirred overnight at 
room temperature. The reaction mixture was washed twice with 2 M HCl solution (20 mL) and three 
times with water (20 mL). The organic layer was then dried over Na2SO4 and concentrated in vacuo. The 
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product was purified by column chromatography (elution with 10% MeOH in DCM). The pure fractions 
were combined and the solvent was evaporated under reduced pressure to obtain the product in a yield of 
107 mg (20.4 μmol; 44%). 1H-NMR (400 MHz, CDCl3): δ5.26 (bs, 1H, carbamate), δ4.15 (d, 2H, 
NH(CO)OCH2CH), δ3.88 – 3.35 (m, 456H, CH2CH2O), δ3.38 (s, 3H, OCH3), δ2.25 (m, 6H, 
cyclooctyne), δ1.60 (m, 3H, (CO)OCH2CH + cyclooctyne), δ0.94 (m, 2H, cyclopropane-cyclooctyne ring 
fusion). 
Strain-promoted alkyne azide cycloaddition for synthesis of ELP–PEG 
Twelve different cycloaddition reactions were performed, using purified 1N3-ELP40, 2N3-ELP40, 1N3-
ELP90, 2N3-ELP90, 1N3-ELP130 and 2N3-ELP130. For a typical reaction, 5 – 10 equivalents of 7a or 
7b was added to 100 µL solution of azido-ELP (10 mg/mL in MQ). The reaction mixture was shaken for 
72 h at room temperature. Then the cycloaddition product was purified using size exclusion 
chromatography performed on an Amersham Ettan LC system (GE Healthcare, Diegem, Belgium) 
equipped with a Superdex 200 10/300 GL column (GE Healthcare) and a fraction collector. The 
purification was performed at room temperature with a flow rate of 0.5 mL/min of 500 mM NaCl as 
eluent, while collecting 300 µL fractions. The fractions containing pure ELP–PEG conjugate were used 
for self-assembly experiments (as analyzed by SDS-PAGE).  
Self-assembly and encapsulation 
Self-assembly was induced by addition of NaCl (from a 5 M stock solution) to the purified ELP–PEG 
conjugate solution. NaCl was added upto a concentration of 2.0 M for the ELP90 and ELP130 
conjugates. For ELP40 conjugates, NaCl was added upto a concentration of 3.5 M. For the encapsulation 
experiments, 1-anilinonapthalene-8-sulfonic acid (upto 0.1 mM) was added to the ELP–PEG conjugate 
solution. The fluorescence was measured on a Perkin Elmer LS55 Fluorescence Spectrometer (excitation 
at 370 nm, emission 350 – 650 nm, 5 nm emission slit, 5 nm excitation slit, 150 nm/min) using a quartz 
cuvette (3 mm path length) at 23 °C. To induce self-assembly the NaCl concentration was increased using 
a 5 M NaCl stock solution containing 0.1 mM 1-anilinonapthalene-8-sulfonic acid. The solution was 
centrifuged (2 min at 13000 g) and again the fluorescence was measured. 
Dynamic light scattering 
DLS experiments were performed on a Zetasizer Nano S (Malvern Instruments Ltd, England). Prior to 
measurements, the self-assembled samples were centrifuged (1 min at 13000 g). 
Transmission electron microscopy (TEM) 
TEM grids (CF200-Cu, EMS) were glow-discharged using a Cressington Carbon coater and power unit. 5 
µL sample of self-assembled ELP–PEG was applied to the glow-discharged grid and was incubated for 1 
minute. Then the sample was removed carefully using a filter paper and the grid was allowed to dry for at 
least 15 min. Subsequently, the grid was negatively stained by applying 5 µL of 2% uranyl acetate in water. 
The staining solution was removed after 15 seconds and the grid was again allowed to dry for at least 15 
min. The samples were analyzed on a JEOL JEM-1010 TEM (Jeol, Japan). 
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5.1. Introduction 
Self-assembled nanocapsules have been studied intensively because of their controlled 
assembly and disassembly behavior and storage capacity. Nanocapsules have a range of 
applications, varying from drug delivery vehicles to nanoreactors. Different materials have 
been used to generate these capsules, including lipids, synthetic polymers,[1] proteins,[2-4] 
and combinations thereof.[2, 5] Protein-based building blocks have gained much interest, as 
these structures permit the formation of perfectly defined capsules due to the intricate 
three-dimensional folding of the protein constituents.[6-8] Many examples of protein cages 
in nature are known, including nanovaults,[9] viruses,[10] and ferritin.[11] Spherical viruses 
generally consist of several hundreds of subunits that self-assemble to encapsulate their 
genetic material for storage and transport. However, many virus capsid proteins (CPs) can 
be induced to assemble even without their natural cargo.[12-15] 
 Cowpea chlorotic mottle virus (CCMV) is an excellent example of a virus whose 
assembly can be exquisitely controlled in the absence of its viral RNA. It can be 
disassembled and reassembled by adjusting the pH. At high pH (7.5) empty CCMV 
capsids dissociate into CP dimers, and at low pH (5.0) they reassemble.[16-17] These virus-
like particles (VLPs) are composed of 90 CP dimers arranged with Caspar and Klug 
triangulation number[18] (T) = 3 symmetry, though T = 1 and pseudo T = 2 forms have 
also been observed.[19] VLPs of CCMV have been used as nanoreactors or as templates for 
constrained syntheses of nanomaterials.[20-25] However, they are stable only at lower pH, 
which limits their applications. 
 Templated assembly has been described as an approach to generate VLPs under 
different conditions.[26-27] However, nanoparticle-templated capsids are already filled, and 
thus, it is more challenging to accommodate additional material. Therefore, we need to 
develop additional methods to control the assembly. In a recent study, a CP with an N-
terminal histidine tag (H6CP) was produced in Escherichia coli. This histidine tag was 
capable of binding nickel ions and was positioned on the inside of the VLPs in proximity 
to the N-termini of other CPs. It was shown that the H6CP could be assembled and 
stabilized by the addition of nickel ions.[28] We realized that if the assembly of the CPs 
could be controlled by an external trigger (e.g., in a thermally responsive manner), this 
would allow another level of control over the assembly of CPs in addition to changing the 
pH or adding other substances. 
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 A well-defined protein-based class of stimulus-responsive polymers are the elastin-like 
polypeptides (ELPs). ELPs consist of repeating Val-Pro-Gly-Xaa-Gly pentapeptides, 
where Xaa is any natural amino acid except proline. ELPs can be switched from an 
extended water-soluble state to a collapsed hydrophobic state in response to an increase in 
temperature. This completely reversible phenomenon is also known as lower critical 
solution temperature (LCST) behavior, and the transition temperature (Tt) can be varied 
by changing the fourth residue of the pentapeptide repeat, the number of repeats, and the 
protein and salt concentrations.[29-30] 
 In this chapter we report the construction and assembly properties of a block 
copolymer in the form of a fusion protein, ELP-CP, consisting of the CP of CCMV and 
an N-terminal short ELP block. This design combines the properties of the two blocks: 
the ability of CP to form well-defined VLP morphologies and the stimulus-responsive 
character of the ELP fragment. Amazingly, two types of highly homogeneous self-
assembled structures can be formed using a single protein: (1) pH-induced assembly leads 
to 28 nm VLPs and (2) ELP-induced assembly yields 18 nm VLPs (Scheme 5.1). The latter 
can only be accessed via the emergent properties of the ELP-CP. 
 
Scheme 5.1. Representation of the ELP-CP and its self-assembly products 
5.2. Results and discussion 
5.2.1. Protein design, production and purification 
We expressed CCMV CPs with an N-terminal stimulus-responsive ELP domain in E. coli. 
The ELP was placed at the N-terminus of the CP, as it was expected that this would 
position the ELP tags on the interior of the VLPs. The ELP design was based on our 
estimate that ELP[V4L4G1-9] would have a transition temperature within the temperature 
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and salt concentration ranges where the CP is stable (for ELP nomenclature, see 
Experimental section).[30] The ELP block replaced the RNA-binding domain — the first 
26 amino acids — of the wild-type CP (WT-CP), which ensured that the length of the new 
N-terminal domain would not interfere with the assembly of the CPs into VLPs.[19, 31] The 
ELP-CP constructs were also equipped with an N-terminal histidine tag to facilitate 
purification via affinity chromatography. The resulting plasmid encoded H6-ELP-[V4L4G1-
9]-CP(ΔN26) (for the protein sequences, see Experimental section). The expressed protein 
was purified via affinity chromatography and analyzed by SDS-PAGE (Figure 5.1a). This 
showed relatively pure protein in the elution fractions. Fractions containing the purified 
protein were combined and dialyzed against a pH 7.5 buffer with 0.5 M NaCl. The 
expected product molecular weight of 22253.4 Da was verified by electrospray ionization 
time-of-flight (ESI-TOF) mass spectrometry (Figure 5.1b and c). The CPs were produced 
with a yield of 60−80 mg/L of culture.  
 
Figure 5.1. (a) Coomassie-stained SDS-PAGE analysis of affinity purification of H6-ELP-[V4L4G1-9]-CP(ΔN26); flow 
through (lane 1), wash fraction 1 (lane 2), wash fraction 2 (lane 3), elution fraction 1 (lane 4), elution fraction 2 
(lane 5), elution fraction 3 (lane 6), elution fraction 4 (lane 7). (b) Multiply-charged ion series of ESI-TOF mass 
spectrometry of purified H6-ELP-[V4L4G1-9]-CP(ΔN26) (c) deconvoluted total mass spectrum of purified H6-ELP-
[V4L4G1-9]-CP(ΔN26). 
5.2.2. pH-induced assembly of virus-like particles 
First it was investigated whether the modified CPs would still assemble into VLPs in 
response to pH changes under conditions where the ELP domain would not undergo its 
phase transition. To induce assembly, the CPs were dialyzed against a pH 5.0 acetate 
buffer and visualized by transmission electron microscopy (TEM). The ELP-CPs formed 
VLPs with a diameter of 28 nm (Figure 5.2 left). Dynamic light scattering (DLS) showed 
that these assembly conditions yielded a uniform assembly product with an estimated 
diameter of 31 nm (Figure 5.3a), with minimal aggregation. Size exclusion chromatography 
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(SEC) inline with multi-angle laser light scattering (MALLS) indicated that the VLPs, 
which eluted at 10.2 mL on a Superose 6 10/300 GL column (Figure 5.4a), had a 
molecular weight of 4.0 MDa, in line with 180 CPs of 22253.4 Da (theoretically 4.0 MDa). 
These results are consistent with VLPs resembling native-like T = 3 particles. The 
assembly at pH 5.0 was of high affinity, as no peak corresponding to dimers (expected at 
17.0 mL; Figure 5.4a) was observed, and had high fidelity, as no other aggregates or 
assembly products were observed. Asymmetric-flow field-flow fractionation (AF4) 
coupled to MALLS was used to further support the results observed by SEC-MALLS 
(Figure 5.4b). AF4 also showed a highly effective assembly process and a molecular weight 
that corresponded to T = 3 VLPs. In comparison, assembly of WT-CP under similar 
conditions occurred with lower efficiency and always left some residual dimer.[32] 
 
 
 
 
Figure 5.2. Uranyl acetate-stained TEM micrographs of CPs assembled into VLPs. Overviews (top) and enlarged 
views (bottom) of VLPs under (left) pH-induced and (right) ELP induced assembly conditions. 
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 To ascertain the particle geometry and understand the disposition of the ELP blocks, 
we performed cryogenic electron microscopy (cryo-EM) and three-dimensional 
reconstruction of the pH-induced H6-ELP-[V4L4G1-9]-CP(ΔN26) VLPs (Figure 5.5a and 
b). It was observed that the VLPs consisted of two shells (Figure 5.5c and e). As the 
morphology of the outer shell was identical to that of the empty T = 3 CCMV capsid,[19, 33] 
the electron density of the inner shell could only be explained by the presence of the 
ELPs, indicating that the ELP domain indeed was in the interior of the VLPs. Moreover, 
it tentatively appeared that in this environment the ELPs self-assembled because of their 
high local concentration. 
 
 
Figure 5.3. DLS measurements of SEC-purified assembled H6-ELP-[V4L4G1-9]-CP(ΔN26) under (a) pH-induced 
conditions and (b) ELP-induced conditions. Three measurements were performed for each sample. 
 
Figure 5.4. (a) SEC-MALLS chromatograms of H6-ELP-[V4L4G1-9]-CP(ΔN26). The solid lines show the normalized 
differential refractive index signals, and the dotted lines show the molecular masses of the complexes. (b) AF4-
MALLS chromatograms of H6-ELP-[V4L4G1-9]-CP(ΔN26). The solid lines show the normalized absorbance at 280 
nm, and the dotted lines show the molecular masses of the complexes. It is noteworthy that the larger VLPs elute 
in front of the CP dimers by SEC, whereas, as expected, this elution behavior is reversed in case of AF4. 
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5.2.3. ELP-induced assembly of virus-like particles 
After it was established that the ELP-CPs assembled into T = 3 VLPs under pH-induced 
conditions, ELP-induced assembly was assayed. The ELP Tt can be tuned by several 
factors, such as molecular weight, amino acid composition and salt and protein 
concentration. As the polymer length and the amino acids at the fourth positions in the 
pentapeptide repeat were already determined by the design of the polypeptide, the salt 
concentration was used to adjust Tt into a range suitable for the CCMV CP. Increasing the 
NaCl concentration to 2.5 M lowered the Tt of the ELP of the fusion protein to below 
room temperature. Therefore, to induce assembly, ELP-CP dimers were dialyzed against a 
pH 7.5 buffer containing 2.5 M NaCl, and then the samples were analyzed by TEM. 
Similar to the pH-induced assembly, we again observed assembly of the ELP-modified 
capsid proteins into monodisperse VLPs, but these had a diameter of 18 nm (Figure 5.2 
right). These assemblies were then analyzed by DLS, and a diameter of 25 nm was 
estimated (Figure 5.3b). These smaller VLPs were also analyzed by SEC-MALLS and 
AF4-MALLS (Figure 5.4a and b). Triggering the stimulus response of the ELPs led to 
assembly of the dimers into 1.3 MDa VLPs with no residual dimers, indicating again high 
assembly efficiency. This mass corresponds to 60 CPs of 22253.4 Da, suggesting a T = 1 
architecture (theoretically 1.3 MDa). 
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Figure 5.5. Cryo-EM micrographs and reconstructions of H6-ELP-[V4L4G1-9]-CP(ΔN26) VLPs. Selected images of the 
frozen-hydrated specimens of the (a) pH-induced VLPs and (b) ELP-induced VLPs. The inserts show the 
translationally-aligned averaged images. Note that both VLPs appear to have the morphology of two concentric 
shells. Cryo-EM reconstructions of VLPs viewed along the icosahedral twofold axis: (c, e) pH-induced assembly 
yielded 90-dimer T = 3 particles; (d, f) ELP-induced assembly yielded 30-dimer T = 1 particles. The top panels (c, 
d) depict surface views, and the bottom panels (e, f) present equatorial views to show the interior. Ovals, 
triangles, and pentagons indicate locations of twofold, threefold, and fivefold axes, respectively. 
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 Cryo-EM and image reconstruction were employed to verify that the ELP-induced 
assembly yielded T = 1 icosahedra (Figure 5.5d and f). Again, two shells surrounding a 
small unoccupied inner volume were observed. The outer shell showed the pentameric 
turrets expected for CCMV,[19] and the electron density of the inner shell was again 
attributable to ELP. In our construct, the ELP domain was designed to interact with 
neighboring ELP domains. This could explain the tighter packing that resulted in smaller 
VLPs after ELP-induced assembly. This hypothesis was corroborated by previous reports 
in the literature showing that CPs lacking both the positively charged RNA-binding 
domain and the β-hexamer (residues 3-36) could be assembled into mainly pseudo T = 2 
and T = 1 and a small fraction of T = 3 icosahedrons in a pH-dependent manner.[19] 
Formation of T = 1 particles was also observed for truncated CPs lacking the N-terminal 
region and for full length WT-CPs via kinetic trapping upon addition of short 
oligonucleotides or anionic polymers.[32, 34-36] However, the quantitative formation of T = 
1 particles reported here is unprecedented. 
 A NaCl concentration of 2.5 M was applied initially to ensure that all of the ELP-CPs 
were assembled. Next, a series of NaCl concentrations was used to investigate the 
minimum concentration required to obtain assembly at room temperature and pH 7.5. It 
was found that a concentration of 1.8 M NaCl in the pH 7.5 buffer was enough to induce 
full assembly of the ELP-CPs (Figure 5.6 and Figure 5.7). 
 
 
Figure 5.6. Size exclusion chromatograms for assembly of H6-ELP-[V4L4G1-9]-CP(ΔN26) in pH7.5 buffer with 
varying NaCl concentrations. The assembly was analyzed in pH 7.5 buffer with 1.4 M NaCl (red line), 1.5 M NaCl 
(blue line) and 1.6 M NaCl (black line) at 20 °C. 
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 To demonstrate that the ELP was responsible for the assembly at high salt 
concentrations, we investigated whether CPs lacking the stimulus-responsive peptide 
could self-assemble under similar conditions. WT-CP and H6CP[21] were dialyzed into pH 
7.5 buffer with 1.8 M NaCl. However, under these conditions, the control proteins were 
detectable only as dimers (Figure 5.7). 
 At NaCl concentrations below 1.8 M, only a fraction of the ELP-CPs assembled, 
resulting in a bimodal distribution of capsid and dimer consistent with virus assembly 
theory (Figure 5.6).[37] This is notable because when free ELP undergoes a phase 
transition, it leads to complete aggregation. This difference is probably a result of the fact 
that the ELPs are sequestered on the inside of the VLPs, thus limiting the number of 
ELPs that can participate in a given nucleation event. To verify that this was the reason 
for incomplete assembly, a sample was diluted twice and measured again by SEC after 
overnight incubation. As expected, the VLP:dimer ratio changed from 0.39:1 to 0.17:1 
(based on the areas under the peaks; Figure 5.8). This showed that relatively more ELP-
CP is present as dimers at lower protein concentrations and that the assembly is reversible. 
 In the previous experiments, the assembly of ELP-CP was induced by starting from 
CP dimers and applying either the ELP or the pH-based assembly trigger. When both 
pathways were triggered simultaneously (pH 5.0 with 2.5 M NaCl), the ELP-CP assembled 
into T = 1 VLPs (Figure 5.9a). Interestingly, sequential triggering of the stimuli resulted in 
detection of the product of the first trigger; i.e. pH-induced, followed by ELP-induced 
assembly led to T = 3 particles, whereas ELP-induced, followed by pH-induced particle 
formation yielded T = 1 particles. When pH-induced T = 3 VLPs were exposed to a 
simultaneous increase of pH and NaCl concentration a mixture of T = 1 and T = 3 
icosahedra was obtained. Potentially, longer incubation could result in complete transition 
towards T = 1 particles. Notably, immediate switching from conditions for ELP-induced 
VLPs to pH-induced conditions resulted in precipitation. The diagram in Figure 5.9b 
summarizes the observed assembly products under various conditions.  
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Figure 5.7. Size exclusion chromatograms for assembly of control proteins and SDS-PAGE of the CPs. (a) The 
assembly of H6-ELP-[V4L4G1-9]-CP(ΔN26) (blue solid line), H6CP (red solid line) and WT-CP (black dashed line) in a 
pH 7.5 buffer with 1.8 M NaCl. (b) Coomassie-stained SDS-PAGE depicts the CPs used in this study: H6-ELP-
[V4L4G1-9]-CP(ΔN26) (lane 1), H6CP (lane 2) and WT-CP (lane 3). 
 
 
 
Figure 5.8. SEC chromatogram for self-assembly at two different concentrations of protein. The assembly of H6-
ELP-[V4L4G1-9]-CP(ΔN26) at 1.0 mg/mL was analyzed in pH 7.5 buffer with 1.3 M NaCl (black line) and after 
dilution of the sample to 0.5 mg/mL and overnight incubation (red line). The areas under the peak were 
determined to calculate the ratio between the VLPs and the dimers. 
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Figure 5.9. (a) SEC-MALLS chromatograms of H6-ELP-[V4L4G1-9]-CP(ΔN26). The solid lines show the differential 
refractive index signals, and the dotted lines show the molecular masses of the complexes. (b) H6-ELP-[V4L4G1-9]-
CP(ΔN26) diagram for assembly under various conditions. 
 Finally, the temperature-responsive assembly of ELP-CPs was examined. As 
concluded from the previous experiments, only a minor fraction of ELP-CPs was 
assembled at room temperature in the 1.3 M NaCl buffer at pH 7.5. Therefore, a sample 
of ELP-CPs under these conditions was incubated at 35 °C for 15 min and then again 
analyzed by SEC at this temperature. The higher temperature resulted in efficient assembly 
of the dimers into T = 1 particles (Figure 5.10). From this experiment it can also be 
concluded that the assembly is a rather fast process, as it was completed within 15 min.  
 
 
Figure 5.10. SEC chromatogram of H6-ELP-[V4L4G1-9]-CP(ΔN26) in 1.3 M NaCl at pH 7.5 at different temperatures 
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 Temperature-responsive assembly was also confirmed by TEM. TEM grids were 
prepared of ELP-CP at room temperature in pH7.5 buffer with 2.0 M and 2.3 M NaCl 
(Figure 5.11a and c, respectively). Next, the CP solutions were cooled and incubated for 30 
min at 4 °C and then again TEM grids were prepared (Figure 5.11b and d). TEM analysis 
at 20 °C for ELP-CP in pH 7.5 with 2.0 M NaCl showed VLPs with a diameter of 18 nm, 
whereas these disappeared after cooling to 4 °C. In the pH 7.5 buffer with 2.3 M NaCl, no 
temperature effect was observed between 4 °C and 20 °C, and in both cases VLPs with a 
diameter of 18 nm were detected, probably because the salt concentration decreased the Tt 
to below 4 °C. 
 
 
Figure 5.11. Uranyl acetate-stained TEM micrographs of H6-ELP-[V4L4G1-9]-CP(ΔN26) prepared at different 
temperatures and NaCl concentrations. The assembly was analyzed in pH 7.5 buffer: (a) 2.0 M NaCl at 4 °C; (b) 
2.0 M NaCl at 20 °C; (c) 2.3 M NaCl at 4 °C; (d) 2.3 M NaCl at 20 °C. 
5.3. Conclusion 
This work shows the feasibility of combining two structural protein elements to generate a 
system with emergent properties. We constructed a capsid protein fusion that can be self-
assembled via two mechanisms into two different, well-defined structures. To construct 
such a system, thermally responsive ELPs were genetically combined with CCMV CPs. 
Under pH-induced assembly conditions, the modified CPs assembled into 28 nm diameter 
VLPs with a T = 3 icosahedral architecture. Thermally responsive ELP-induced assembly 
resulted in the efficient production of 18 nm diameter T = 1 icosahedra. This architecture 
is accessible only because of the combined properties of ELPs and CPs in one system, as 
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the assembly was induced by triggering the phase transition of ELP, but the architecture 
was controlled by the CPs. The present system could find application in switchable 
encapsulation of enzymes to control their activity. The VLPs could also be used as a 
capture and release system for therapeutics. The confined internal volume with a relatively 
high ELP concentration could also lead to a better understanding of ELP structural 
characteristics. 
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5.5. Experimental section 
Materials 
Restriction enzymes, ligase and kinase were obtained from New England Biolabs. The DNA oligos were 
synthesized by Biolegio (Nijmegen, The Netherlands). The wild-type capsid protein (WT-CP) was 
provided by J.J.L.M. Cornelissen from University of Twente, The Netherlands. Ampicillin and 
chloroamphenicol were purchased from MP Biomedicals. Lysozyme and isopropyl β-D-1-
thiogalactopyranoside (IPTG) were obtained from Sigma-Aldrich. 
Two types of buffers were used, a pH 5.0 buffer (50 mM NaOAc, 500 mM NaCl, 10 mM MgCl2, 1 mM 
EDTA, pH 5.0 set with HCl) and a pH 7.5 buffer (50 mM TrisHCl, 500-2500 mM NaCl, 10 mM MgCl2, 
1 mM EDTA, pH 7.5 set with HCl). The NaCl concentration in the latter buffer was varied between 500 
and 2500 mM. Prior to use, all buffers were filtered over a Millipore 0.2 µm filter and for the SEC-
MALLS analysis, the buffers were also degassed. 
Elastin-like polypeptide nomenclature 
ELP constructs are usually described using the notation ELP[XiYjZk-n], where the capital letters between 
the brackets indicate the single letter amino acid code for the residues at the Xaa position in the 
pentapeptide Val-Pro-Gly-Xaa-Gly. The subscript stands for the ratio of the guest residues and the n 
represents the total number of pentapeptide repeats. 
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Construction of expression vector 
The pET-15b-H6-CP vector coding for bacterial expression of the histidine-tagged CCMV capsid protein 
was previously constructed as described by Minten et. al.[21] For the insertion of the ELP and the removal 
of the RNA-binding domain, two sets of DNA oligos with a complementary overhang were designed (see 
Table 5.1). These two sets of oligos were annealed and the resulting insert encoded for a histidine-tag, the 
ELP[V4L4G1-9] and a short fragment of the CP with a 5’ NcoI and a 3’ AgeI restriction site. First, the 
pET-15b-H6-CP vector was digested with NcoI-HF™ and AgeI-HF™, and then the product was 
purified by agarose gel electrophoresis. Subsequently, the annealed inserts were ligated into the digested 
vector. The linear product was again purified by agarose gel electrophoresis and then it was 
phosphorylated and ligated to yield the pET-15b-H6-ELP[V4L4G1-9]-CP(ΔN26). This plasmid was 
transformed into E. coli XL1-Blue cells, the DNA was extracted and the sequence was confirmed by 
DNA sequencing. The plasmid was transformed into E. coli BLR(DE3)pLysS cells (Novagen, MERCK), 
which were used for the expression of H6-ELP[V4L4G1-9]-CP(ΔN26). 
Table 5.1. DNA sequence of oligos used for construction of expression vector 
Name Sequence 
Forward-1 5'- CATGGGCCATCATCATCATCATCACGTTCCGGGCGTCGGTGTTCCTGGATTAGGTGTTCC … … 
Reverse-1 3'-     CCGGTAGTAGTAGTAGTAGTGCAAGGCCCGCAGCCACAAGGACCTAATCCACAAGG … … 
    (continued) Forward-1    … … AGGTGTAGGTGTTCCAGGACTCGGTGTTCCTGGTGTAGGTGTTCCTGGTTTAGGTG     -3' 
(continued) Reverse-1   … … TCCACATCCACAAGGTCCTGAGCCACAAGGACCACATCCACAAGGACCAAATCCACAAGG -5' 
    
Forward-2 5'- TTCCAGGTGGCGGTGTTCCTGGTGTGGGAGTTCCTGGTTTAGGTCTCGAGGTGGTCCAAC … … 
Reverse-2 3'-     TCCACCGCCACAAGGACCACACCCTCAAGGACCAAATCCAGAGCTCCACCAGGTTG … … 
    (continued) Forward-2     … … CTGTTATTGTAGAACCCATCGCTTCAGGCCAAGGCAAGGCTATTAAAGCATGGA     -3' 
(continued) Reverse-2     … … GACAATAACATCTTGGGTAGCGAAGTCCGGTTCCGTTCCGATAATTTCGTACCTGGCC -5' 
  
Protein sequences 
WT-CP 
MSTVGTGKLTRAQRRAAARKNKRNTRVVQPVIVEPIASGQGKAIKAWTGYSVSKWTASCAA
AEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSCVTETQTTAAASFQV
ALAVADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVEHVRPTFD
DSFTPVY 
H6-CP 
GSSHHHHHHSSGLVPRGSHMMSTVGTGKLTRAQRRAAARKNKRNTRVVQPVIVEPIASGQG
KAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVS
GTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAA
LTEGDVIVHLEVEHVRPTFDDSFTPVY 
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H6-ELP[V4L4G1-9]-CP(ΔN26) 
GHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVIV
EPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLW
LGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTADLT
IYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY 
Expression and purification of capsid proteins 
For a typical expression, 100 mL 2xYT medium, supplemented with ampicillin (100 mg/L) and 
chloroamphenicol (50 mg/L), was inoculated with a single colony of E. coli BLR(DE3)pLysS containing 
pET-15b-H6-CP or pET-15b-H6-ELP[V4L4G1-9]-CP(ΔN26) and was incubated at 30 °C overnight. This 
overnight culture was used to inoculate 900 mL of 2xYT medium supplemented with ampicillin (100 
mg/L) and chloroamphenicol (50 mg/L). The culture was grown at 30 °C and protein expression was 
induced during logarithmic growth (OD600 = 0.4-0.6) by addition of IPTG up to 1 mM. After 5 h of 
expression, the cells were harvested by centrifugation (4000 g at 4 °C for 15 min) and the pellet was 
stored at -20 °C overnight.  
After thawing, the cell pellet was resuspended in 15 mL lysis buffer (50 mM NaH2PO4, 10 mM imidazole 
and 1300 mM NaCl, pH 8.0) and incubated with lysozyme (1 mg/mL) for 30 min on ice. The cells were 
then lysed by ultrasonic disruption (5 times 5 s, 100% duty cycle and output control 3, Branson Sonifier 
250, Marius Instruments Nieuwegein, the Netherlands). The lysate was centrifuged (13000 RPM at 4 °C 
for 15 min, Microcentrifuge, Heraeus Pico) to remove the cellular debris. The supernatant was incubated 
with 1 mL Ni-NTA agarose beads for 1 h at 4 °C. Subsequently, the suspension was loaded onto a 
column, the flow-through was collected and the column was washed twice with 5 mL wash buffer (50 
mM NaH2PO4, 20 mM imidazole and 1300 mM NaCl, pH 8.0). Finally, the CPs were eluted from the 
column using 10 times 1 mL elution buffer (50 mM NaH2PO4, 250 mM imidazole and 1300 mM NaCl, 
pH 8.0). The purification was analyzed by SDS-PAGE (Figure 5.1a). The fractions containing the CPs 
were combined and dialyzed against a capsid buffer of pH 7.5 (50 mM Tris, 500 mM NaCl, 10 mM 
MgCl2, 1 mM EDTA, pH 7.5) to obtain the protein dimers. For storage the proteins were assembled by 
dialysis against a pH 5.0 buffer (50 mM NaOAc, 500 mM NaCl, 10 mM MgCl, 1 mM EDTA, pH 5.0). 
Protein concentrations were determined using a Cary 50 Conc (Varian, Middelburg) UV-VIS 
spectrophotometer using a quartz cuvette with a path length of 0.3 cm. The protein concentrations were 
calculated using the theoretical extinction coefficients.[38] The proteins were produced with a yield of 60-
80 mg/L of culture and the purity was verified by SDS-PAGE. ESI-TOF (JEOL AccuTOF): H6-CP 
calculated 22506.6 Da, found 22507.4 Da and H6-ELP[V4L4G1-9]-CP(ΔN26) calculated 22253.4 Da, 
found 22253.2 Da (Figure 5.1b and c). 
Mass spectrometry 
Protein mass characterization was performed by electrospray ionization time-of-flight (ESI-TOF) on a 
JEOL AccuTOF. Deconvoluted mass spectra were obtained using MagTran 1.03b2. Isotopically averaged 
molecular weights were calculated using the “Protein Calculator v3.3” at 
http://www.scripps.edu/~cdputnam/protcalc.html. 
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Assembly experiments 
For the pH-induced and salt-induced
For 
 assembly of CPs, dialysis was used to change buffer composition. 
Therefore, 400 µL of CP-dimer solution (1.0 mg/mL in 50 mM Tris, 500 mM NaCl, 10 mM MgCl2, 1 
mM EDTA, pH 7.5) was inserted into a dialysis membrane (Spectra/Por 4 dialysis tubing, 12-14 kDa 
MWCO, 10 mm flat width) and dialyzed against 100 mL of the desired buffer. After 30 min the buffer 
solution was refreshed and the solution was incubated for another 30 min. All these steps were 
performed at room temperature (20 °C). 
temperature-induced
For 
 assembly analyzed by SEC, a solution of CP-dimer (1.0 mg/mL in 50 mM Tris, 
500 mM NaCl, 10 mM MgCl, 1 mM EDTA, pH 7.5) was inserted into the dialysis membrane and 
dialyzed against a pH 7.5 capsid buffer with an increased NaCl concentration (50 mM Tris, 1300 mM 
NaCl, 10 mM MgCl, 1 mM EDTA, pH 7.5) as described above. Then the sample was incubated at the 
desired temperature (20 °C or 35 °C) for 15 min prior to injection onto the SEC-column.  
temperature-induced
Size exclusion chromatography (SEC) 
 assembly analyzed by TEM, a solution of CP-dimer (1.0 mg/mL in 50 mM Tris, 
500 mM NaCl, 10 mM MgCl, 1 mM EDTA, pH 7.5) was inserted into the dialysis membrane and 
dialyzed against a pH 7.5 capsid buffer with an increased NaCl concentration (50 mM Tris, 500-2500 mM 
NaCl, 10 mM MgCl, 1 mM EDTA, pH 7.5) as described above. Then the protein solution was used to 
prepare TEM grids at 4 °C (cold room) and 20 °C (room temperature). For this purpose, the sample was 
diluted five-fold with the same buffer at the desired temperature (4 °C and 20 °C) and after the sample 
was incubated at that temperature for 30 min, it was applied to the TEM grid. 
The SEC measurements were performed on a Superose 6 10/300 GL column from GE Healthcare. For a 
typical analysis, 100 µL sample (100 µg) was separated on the column with a flow rate of 0.5 mL/min. All 
SEC measurements, except for the temperature-variation and multi-angle laser light scattering 
measurements, were performed at room temperature (20 °C) on an Amersham Ettan LC system (GE 
Healthcare, Diegem, Belgium) equipped with a fraction collector. For the temperature-variation 
measurements, a Shimadzu LC-20A Prominence system (Shimadzu, ‘s Hertogenbosch, The Netherlands) 
was used. Here, the column, the injection loop and the buffer were positioned in the column oven and 
were equilibrated until the desired temperature was reached. The size exclusion chromatography - multi 
angle laser light scattering (SEC-MALLS) experiments were conducted at room temperature using the 
Superose 6 10/300 GL column in-line with a Wyatt DAWN HELEOS II light scattering detector using a 
laser operating at 658 nm and a Wyatt Optilab Rex refractive index detector. Overnight flushing of the 
system was performed to pre-equilibrate for every buffer followed by normalization using Bovine Serum 
Albumin. Weight-averaged molecular weight calculations were performed using ASTRA 5.3.4.14, using a 
dn/dc value of 0.170 for pH 7.5, 2.5 M NaCl buffer (50 mM Tris, 2500 mM NaCl, 10 mM MgCl2, 1 mM 
EDTA, pH 7.5) and a dn/dc value of 0.185 for pH 7.5, 0.5 M NaCl buffer (50 mM Tris, 500 mM NaCl, 
10 mM MgCl2, 1 mM EDTA, pH 7.5) and for pH 5.0, 0.5 M NaCl buffer (50 mM NaOAc, 500 mM 
NaCl, 10 mM MgCl2, 1 mM EDTA, pH 5.0). 
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Asymmetric-flow field-flow fractionation (AF4) 
The asymmetric-flow field-flow fractionation - multi-angle laser light scattering (AF4-MALLS) 
experiments were performed using a Shimadzu LC-20A Prominence system, with Shimadzu CTO20A 
injector, and a Wyatt Eclipse AF4 equipped with the short channel with a regenerated cellulose 10 kDa 
membrane (Millipore) and wide spacer of 350 µm, connected to a Wyatt DAWN HELEOS II light 
scattering detector using a laser operating at 658 nm, a Wyatt Optilab Rex refractive index detector and a 
Shimadzu SPD20A. The channel was pre-equilibrated for every buffer followed by normalization using 
Bovine Serum Albumin. Weight-averaged molecular weight calculations were performed using ASTRA 
6.0.6.13, using a dn/dc value of 0.170 for pH 7.5, 2.5 M NaCl buffer (50 mM Tris, 2500 mM NaCl, 10 
mM MgCl2, 1 mM EDTA, pH 7.5) and a dn/dc value of 0.185 for pH 7.5, 0.5 M NaCl buffer (50 mM 
Tris, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5) and for pH 5.0, 0.5 M NaCl buffer (50 mM 
NaOAc, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 5.0). Typically, 10 µL sample (10 µg) of 1.0 
mg/mL was analysed using the following flow rates and method (Table 5.2): 
Table 5.2. AF4 method 
Duration (min) Mode Cross flow rate  
start (mL/min) 
Cross flow rate  
end (mL/min) 
2 Elution 2.00 2.00 
1 Focus - - 
2 Focus + inject - - 
1 Focus - - 
15 Elution 2.00 0.30 
4 Elution 0.00 0.00 
4 Elution + inject 0.00 0.00 
1.00 mL/min detector flow, 1.50 mL/min focus flow, 0.20 mL/min inject flow 
 
Dynamic light scattering 
DLS experiments were performed on a Zetasizer Nano S (Malvern Instruments Ltd, England). All 
samples were first purified by SEC. 
Transmission electron microscopy (TEM) 
TEM grids (FCF200-Cu, EMS) were glow-discharged using a Cressington Carbon coater and power unit. 
5 µL sample (0.2 mg/mL) was applied to the glow-discharged grid and was incubated for 1 minute. Then 
the sample was removed carefully using a filter paper and the grid was allowed to dry for at least 15 min. 
Subsequently, the grid was negatively stained by applying 5 µL of 2% uranyl acetate in water. The staining 
solution was removed after 15 seconds and the grid was again allowed to dry for at least 15 min. The 
samples were analyzed on a JEOL JEM-1010 TEM (Jeol, Japan).  
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Cryo-electron microscopy (cryo-EM) 
To prepare cryo-EM specimen, 4 μL aliquots of sample were applied on a glow-discharged holey carbon-
coated grid (Quantifoil, R2/2), and blotted with filter papers from both sides for 4.5 s. Subsequently the 
grid was plunged into liquid ethane bath cooled by liquid nitrogen using an FEI VitrobotTM. The grid was 
quickly transferred into a Gatan 626DH cryo-holder (Gatan Inc., Oxford, UK) and examined in a 300-kV 
JEM-3200FS transmission electron microscope (JEOL Ltd., Japan) operated under low dose conditions 
(<14 e-/Å2). Images were recorded at a nominal magnification of 80,000 x on a 4k x 4k CCD camera 
(Gatan UltraScanTM 4000) yielding a pixel size is 1.48 Å at the specimen space. 
Only images that exhibited minimum astigmatism, specimen drift, and charging were processed using 
AUTO3DEM (version 4.01.11) software packages.[39] Individual particles were semi-automatically 
extracted from the digital micrographs using e2boxer.pyprogram.[40] The defocus level of each 
micrograph was estimated to be from 0.5 μm to 4.0 μm under focus by RobEM. The random model 
reconstruction method was employed to generate the initial low-resolution 3-D models for both VLPs.[41] 
The determination of the origins and orientations was started with the PPFT program and further refined 
by the PO2R program. The final 3-D models for pH-induced (T = 3) VLPs and ELP-induced (T = 1) 
VLPs were computed from 6910 and 8775 particles using P3DR, respectively. The estimated resolution 
for pH-induced VLPs was 10.9 Å and for ELP-induced VLPs was 10.2 Å using standard Fourier shell 
correlation at a 0.5 threshold. The 3-D density maps were visualized and analyzed using Chimera.[42] 
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6.1. Introduction 
Compartmentalization of biological processes is crucial for life, as many metabolic 
pathways are regulated by spatial control. The importance of compartmentalization can be 
observed on the cellular level, as well as on the level of organelles, where enzymatic 
processes are spatially confined by a membrane.[1-2] On an even smaller scale, protein-
based compartments, such as[3] carboxysomes and proteasomes are prominent examples 
of supramolecular architectures with a specialized enzymatic function.[4-5] Encapsulation of 
enzymatic cascades in supramolecular architectures is advantageous as it can result in 
enhanced efficiency; fragile processes are protected from the environment and, vice versa, 
the environment is protected from unstable and toxic intermediates.[6-7] 
 Protein cages have been shown to be interesting materials for mimicking the function 
of subcellular architectures.[7-11] Multiple examples of artificial nanoreactors are based on 
virus-derived spherical protein cages, so-called virus-like particles (VLPs).[6, 12-19] These 
protein capsules are assemblies of tens to hundreds of capsid protein (CP) subunits. 
Various encapsulation strategies have been demonstrated for VLPs of cowpea chlorotic 
mottle virus (CCMV).[20-21] Encapsulation of cargo was achieved via statistical 
entrapment,[13] and also through controlled positioning of cargo prior to self-assembly of 
the CPs.[14, 22] For the latter approach, the cargo was anchored both non-covalently[14] and 
covalently[22] to the internal side of the CP.  
 In the previous chapter we have described a block copolymer in the form of a fusion 
protein, consisting of the CP of CCMV and an N-terminal short stimulus-responsive 
elastin-like polypeptide (ELP) block.[23] This protein-based block copolymer could be self-
assembled via two mechanisms into two different, well-defined nanocapsules: (1) pH-
induced assembly yielded 28 nm VLPs (T = 3 particles), and (2) ELP-induced assembly 
led to the formation of 18 nm VLPs (T = 1 particles). Next, we were interested whether 
the smaller VLPs can still be used to create a nanoreactor by accommodating an enzyme 
in the internal void. 
 This chapter discusses the development of a nanoreactor based on the T = 1 assembly 
of ELP-CP. This was first attempted via covalently linking enzymes to the N-terminus of 
the ELP-CP. In a second approach the formation of nanoreactors was achieved using a 
modular supramolecular method, in which his-tagged proteins were non-covalently linked 
to the N-terminus of the ELP-CPs via complexation with nickel ions. The feasibility of 
this approach was demonstrated by measuring the enzymatic activity of these 
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nanoreactors. Furthermore, the nickel-induced assembly pathway of ELP-CPs proved to 
be an unexpectedly efficient route to the formation of T = 1 particles. 
6.2. Results and discussion 
6.2.1. Covalent modification of capsid proteins 
The first route to construct nanoreactors using VLPs of ELP-CP was based on a covalent 
approach. It was hypothesized that encapsulation of enzymes could be performed by 
covalently linking the enzymes to the N-terminus of the capsid proteins, which is 
positioned on the inside of the VLPs. To enable this in a modular fashion, we aimed to 
use the strain-promoted alkyne-azide cycloaddition (SPAAC).[24-25] To this end, the capsid 
protein needed to be functionalized with an azide in the N-terminal region. Azides have 
been introduced into proteins in multiple ways: co-translationally using a genetic 
engineering approach,[26-29] or post-translationally via chemical or enzymatic 
modification.[30-35] 
  
Figure 6.1. Structures of imidazole-1-sulfonyl azide (1), BCN-lissamine-rhodamine B (2), methionine (3) and 
azidohomoalanine (4). 
Diazotransfer 
Initially, post-translational chemical modification was attempted by applying the pH-
controlled diazotransfer reaction. This reaction can be used to convert primary amines in 
proteins into azides, and in Chapter 4 we showed that under pH-controlled conditions in 
the absence of metal-catalyst this reaction can be selective towards the amine with the 
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lowest pKa, which is often the α-amine at the N-terminus.[31] Therefore, H6-ELP-[V4L4G1-
9]-CP(ΔN26) was expressed, purified and its characteristics were confirmed as described 
in Chapter 5.[23] Then the diazotransfer reaction was performed in a diethanolamine buffer 
of pH 8.5 using imidazole-1-sulfonyl azide (1). Unfortunately the reaction resulted in 
partial precipitation of the protein, and we were unable to detect the product by whole 
protein mass spectrometry. Nonetheless, the soluble fraction was analyzed by matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry after 
tryptic digestion. Figure 6.2a depicts the N-terminal tryptic fragment before and after 
diazotransfer, which revealed a mass shift of 26 Da.  Most of the other lysine-containing 
fragments were detected and did not show a mass shift. Subsequently, the azido-ELP-CP 
was reacted with a fluorescently-labeled cyclooctyne (BCN-lissamine-rhodamine B, 2). 
From fluorescently-imaged SDS-PAGE analysis of this reaction it was concluded that 
labeling was successful (Figure 6.2b). However, again precipitation occurred during the 
reaction, resulting in major loss of material. This prompted us to explore alternative 
options for the introduction of azides. 
 
Figure 6.2. Diazotransfer and subsequent SPAAC with BCN-functionalized rhodamine. (a) MALDI-TOF mass 
spectra of N-terminal tryptic fragment before (top panel) and after diazotransfer (bottom panel). The theoretical 
mass shift of +26 Da is observed, which confirms the occurrence of the diazotransfer reaction. (b) Coomassie-
stained (top) and fluorescently-imaged (bottom) SDS-PAGE analysis of the SPAAC reaction; negative control of 
reaction with unmodified ELP-CP (lane 1), azido-ELP-CP with BCN-rhodamine (lane 2). 
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Incorporation of azidohomoalanine 
Alternatively, we attempted to N-terminally functionalize the capsid proteins via 
biosynthetic incorporation of an azide moiety. Residue-specific incorporation of an 
unnatural amino acid by using azidohomoalanine (Aha, 4) as a methionine (Met, 3) 
surrogate was investigated.[26] The ELP-modified capsid protein initially contained one 
methionine residue, Met137, which is positioned in the capsid protein part of the fusion 
protein. Because we aimed to introduce the azide in the N-terminal region of the ELP-CP, 
a novel construct was designed, in which Met137 was mutated into an alanine residue and 
a new methionine codon was placed at the N-terminus, followed by an arginine to prevent 
processing of the N-terminal residue. The exact sequence of MR-H6-ELP-[V4L4G1-9]-
CP(ΔN26, M137A) is given in the Experimental section. 
 To confirm that the adjustments to the construct did not alter the ELP-CP properties 
and that indeed the N-terminal methionine is not processed by methionine 
aminopeptidase, the new construct was expressed under standard conditions in the 
presence of methionine (Met, 3). Met-ELP-CP was purified via affinity chromatography 
and analyzed by SDS-PAGE and mass spectrometry. The protein was obtained relatively 
pure with a yield of ~20 mg/L of bacterial culture (Figure 6.3a, lane 1). The expected 
molecular weight of 22570.7 Da was validated by electrospray ionization time-of-flight 
(ESI-TOF) mass spectrometry (Figure 6.4a), confirming the presence of the N-terminal 
methionine. Then pH-induced assembly was investigated by size exclusion 
chromatography coupled to multi-angle laser light scattering (SEC-MALLS). This showed 
that the VLPs, which eluted at 10 mL, had a molecular weight of 4.1 MDa (Figure 6.3b). 
This mass was in good agreement with T = 3 particles (180 CPs of 22570.7 Da). From 
transmission electron microscopy (TEM) monodisperse spherical particles with a diameter 
of 28 nm were observed (Figure 6.3c). 
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Figure 6.3. Characterization of Met-ELP-CP and Aha-ELP-CP. (a) Coomassie-stained SDS-PAGE analysis of Met-
ELP-CP (lane 1), and Aha-ELP-CP (lane 2). (b) SEC chromatograms of pH-induced assembly of ELP-CP variants. 
Uranyl acetate-stained TEM micrographs of (c) Met-ELP-CP and (d) Aha-ELP-CP VLPs after pH-induced assembly. 
  
 After it was established that the properties of the new ELP-CP construct were 
indistinguishable from the previously studied ELP-CP, expression with Aha (4) was 
performed in methionine auxotrophic E. coli. Similarly, Aha-ELP-CP was purified by 
affinity chromatography. ESI-TOF mass spectrometry confirmed the efficient 
incorporation of Aha, as only a mass of 22565.3 Da was observed, which corresponded to 
the expected 5 Da mass difference upon Aha-Met replacement (Figure 6.4b). Even though 
SDS-PAGE analysis revealed that the obtained Aha-ELP-CP was not entirely pure (Figure 
6.3a, lane 2), pH-induced assembly was investigated. TEM clearly demonstrated the 
presence of 28 nm diameter particles for Aha-ELP-CP (Figure 6.3d). SEC showed a small 
peak for assembly at 10 mL, but the majority of the CPs eluted at 17 mL, which 
corresponded to dimers (Figure 6.3b).[23] Probably the concentration of Aha-ELP-CP was 
too low for efficient assembly. Moreover, the presence of a large amount of impurities 
may have interfered with assembly. To investigate the reactivity of Aha-ELP-CP, a 
SPAAC reaction using BCN-lissamine-rhodamine B (2) was performed. SDS-PAGE 
analysis of this reaction confirmed the presence and reactivity of the azide (Figure 6.4c). 
Due to limited expression yield and low purity of Aha-ELP-CP, it was decided to use a 
completely different approach for the construction of nanoreactors. 
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Figure 6.4. ESI-TOF mass spectrometry analysis of (a) Met-ELP-CP, and (b) Aha-ELP-CP showing multiply-charged 
ion series and deconvoluted total mass spectrum (insets). (c) SDS-PAGE analysis of Aha-ELP-CP after reaction 
with 2, coomassie-stained (lane 1) and fluorescently-imaged (lane 2). 
 
6.2.2. Non-covalent approach for encapsulation of enzymes in VLPs 
As the covalent modular approach was hampered due to difficulties in obtaining sufficient 
quantities of the reactive ELP-PC constructs, a non-covalent approach was followed. We 
argued that encapsulation could be performed via nickel complexation of the 
hexahistidine-tags (his-tag) of ELP-CP and the target protein. The his-tag at the N-
terminus of ELP-CP, which is positioned on the inside of the VLPs, is capable of 
coordinating various metal ions, such as nickel and cobalt. Recently, the metal 
coordinating properties of his-tagged CPs of CCMV were used to stabilize VLPs.[36] This 
non-covalent strategy retains the modular approach towards the creation of nanoreactors 
and avoids time-consuming cloning, because many proteins have been expressed with a 
his-tag to aid purification. Non-covalent anchoring has previously been shown to be a 
viable strategy to create protein-based nanoreactors; electrostatic interactions and coiled-
coil motifs were used to encapsulate materials in CCMV VLPs,[14, 16, 37] and fusions to the 
scaffolding protein of the bacteriophage P22 were prepared to encapsulate proteins.[6, 17-18, 
38]  
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Figure 6.5. (a) SEC chromatograms of Ni-induced assembly of VLPs in buffer of pH 7.5 with 0.3 M NaCl. (b) Uranyl 
acetate-stained TEM micrographs of Ni-induced VLPs of H6-ELP-[V4L4G1-9]-CP(ΔN26). 
Ni2+-induced self-assembly 
First the effect of Ni2+ ion addition on ELP-CP assembly was studied. Interestingly, the 
addition of 1 equivalent NiCl2 (i.e. 1 nickel ion per capsid protein monomer) to 
unmodified H6-ELP-[V4L4G1-9]-CP(ΔN26) in buffer of pH 7.5 with 300 mM NaCl 
resulted in almost complete assembly, as shown by SEC (Figure 6.5a). The majority of 
sample eluted at 11.5 mL, indicating T = 1 VLPs, and a small peak was observed at 17 mL, 
corresponding to CP dimers. A diameter of 20 nm could be determined by TEM analysis 
(Figure 6.5b), which is slightly larger than observed for ELP-induced T = 1 VLPs.[23] 
However, strong evidence for particles with T = 1 symmetry was provided by asymmetric-
flow field-flow fractionation coupled to MALLS (AF4-MALLS), which showed a 
molecular weight of 1.3 MDa, in line with 60 CPs of 22253.4 Da (theoretically 1.3 MDa) 
(Figure 6.6). Also AF4 showed a small peak for CP dimers (at 9 min). The nearly complete 
assembly was unexpected, because this was not observed for the CCMV CPs without 
ELP.[36] This could possibly be explained by a decrease of the Tt of the ELP upon addition 
of NiCl2, as the complexation of nickel influences the effective molecular weight and the 
local concentration of the ELPs. Similarly, it was recently shown that controlled non-
covalent dimerization of ELPs indeed affected the Tt.[39] The level of assembly in pH 7.5 
buffer with 0.3 M NaCl is then a result of the synergistic effect of ELP-induced assembly 
and the Ni2+-induced assembly. 
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Figure 6.6. AF4-MALLS chromatogram of Ni-induced assembly of VLPs in buffer of pH 7.5 with 0.3 M NaCl. The 
solid line shows the absorbance at 280 nm, and the dotted line shows the molecular mass of the complex. 
Encapsulation of proteins 
Next the nickel-mediated encapsulation of two his-tagged proteins was investigated, i.e. 
enhanced green fluorescent protein (H6-EGFP) and Candida antarctica lipase B (H6-CalB). 
These proteins were produced by bacterial expression and purified via Ni-NTA affinity 
chromatography, followed by preparative SEC purification. The purity of these proteins 
was confirmed by SDS-PAGE analysis (Figure 6.7a). The molecular weights were 
measured by ESI-TOF mass spectrometry: H6-EGFP 30946.7 Da (expected: 30950.8) and 
H6-CalB 34267.9 Da (expected: 34269.7). 
 
Figure 6.7. Analysis of purified proteins. (a) SDS-PAGE analysis of H6-CalB (lane 1), H6-EGFP (lane 2) and H6-ELP-
[V4L4G1-9]-CP(ΔN26) (lane 3). ESI-TOF mass spectrometry analysis of (b) H6-CalB, and (c) H6-EGFP showing 
multiply-charged ion series and deconvoluted total mass spectrum (insets). 
 First the encapsulation of H6-EGFP was examined while varying the amount of NiCl2 
(0.1 – 100.0 equivalents of nickel ions to CP monomers). To ensure complete and stable 
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assembly of CPs, the NaCl concentration was increased from 0.3 M to 2.0 M after 1 hour 
incubation of ELP-CP and H6-EGFP with NiCl2 in pH 7.5 buffer. The assemblies were 
investigated by SEC and the fluorescence of the collected peak fractions was measured 
(Figure 6.8). The VLPs eluted at 11-12 mL and the non-encapsulated H6-EGFP eluted at 
17 mL. Only in the case of 1.0 and 10.0 equivalents of NiCl2, significant increase in 
fluorescence signal was observed in the fractions containing the VLPs (Figure 6.8b). In the 
case of 100.0 equivalents, the his-tags were probably completely saturated with nickel, 
which prevented complexation of multiple proteins around one nickel ion, whereas 0.1 
equivalent is not enough to mediate encapsulation. This demonstrated that encapsulation 
of his-tagged proteins is possible with just 1.0 equivalent of NiCl2. Preliminary 
experiments suggested that on average less than 1 protein was encapsulated in the T = 1 
capsules. The low encapsulation efficiency could potentially be explained by the limited 
volume of the internal cavity. This could also explain the observation that a similar 
amount of fluorescence was detected after encapsulation of H6-EGFP with 1.0 and 10.0 
equivalents of NiCl2. 
 
Figure 6.8. (a) SEC chromatograms of Ni-mediated encapsulation of H6-EGFP in VLPs in buffer of pH 7.5 with 2.0 
M NaCl. The number of molar equivalents of Ni2+ to ELP-CP (monomers) was varied. (b) The fluorescence 
intensity of the fractions containing the VLPs were measured.  
 Ni2+-mediated encapsulation of H6-CalB was performed for the construction of a 
nanoreactor. Therefore H6-CalB and ELP-CP were incubated with 1 equivalent of NiCl2, 
and then the ELP-induced assembly was triggered by increasing the salt concentration. As 
a negative control, the same procedure was performed, without the addition of NiCl2. The 
assemblies were again analyzed by SEC, which showed the VLP-peak at 11-12 mL and the 
CalB-peak at 21 mL (Figure 6.9a). In the presence of NiCl2, the VLP-peak was slightly 
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shifted, indicating larger particles. The particles were studied by TEM, which showed 
uniform spherical particles with a diameter of 20 nm in the absence and presence of NiCl2 
(Figure 6.9b and c, respectively). The molecular mass of the self-assembled particles after 
encapsulation of CalB was studied by AF4-MALLS. This showed that the molecular 
weight did not increase significantly when CalB was encapsulated (Figure 6.10).  
 
Figure 6.9. (a) SEC chromatograms of VLPs assembled in the presence of CalB with and without NiCl2. TEM 
micrographs of purified VLPs which were assembled in the presence of CalB (b) without NiCl2 and (c) with NiCl2. 
The asterisk indicates a spike in the chromatogram as a result of an HPLC system error. 
 
Figure 6.10. AF4-MALLS chromatograms of VLPs assembled in the presence of CalB with and without NiCl2. The 
solid lines show the normalized absorbance at 280 nm, and the dotted lines show the molecular masses of the 
complexes. 
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 The enzymatic activity of the nanoreactors containing CalB was analyzed by hydrolysis 
of 4-nitrophenyl acetate (Figure 6.11). The observed activity provided proof-of-principle 
for the formation of catalytically active capsules. To validate the necessity of NiCl2 to 
encapsulate CalB, the enzymatic activity of nanoreactors formed in the absence of NiCl2 
was also investigated (Figure 6.11). No activity was observed in this case, indicating the 
requirement of NiCl2 for the encapsulation of CalB. Furthermore, this showed that in this 
case, the hydrolytic activity was not caused by the histidines.[40] 
 
Figure 6.11. Enzymatic activity of CalB nanoreactors. Enzymatic hydrolysis of 4-nitrophenyl acetate resulted in 
formation of 4-nitrophenol which was monitored by detecting absorbance at 405 nm. The reactions were 
performed in triplicate and were corrected for autohydrolysis. 
6.3. Conclusion and outlook 
We have designed a methodology for encapsulation of enzymes into T = 1 VLPs based on 
ELP-CP. In our approach to construct nanoreactors we first attempted to introduce 
azides in the N-terminal region of the ELP-CP for the covalent linking of cyclooctyne-
functionalized enzymes via the strain-promoted alkyne-azide cycloaddition. To this end, 
the pH-controlled diazotransfer was used to convert the α-amine at the N-terminus into 
an azide, which unfortunately resulted in precipitation. Alternatively, incorporation of 
azidohomoalanine at the N-terminus of ELP-CP as a methionine surrogate was performed 
successfully. The reactivity of the azide was confirmed in a SPAAC reaction with a 
fluorescently-labeled cyclooctyne, but low expression yield and limited purity forced us to 
attempt other options. 
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 In a second attempt a non-covalent approach was followed. It was hypothesized that 
encapsulation could be performed via nickel complexation of the his-tags of ELP-CP and 
the target protein. This Ni2+-mediated strategy for encapsulation was shown for two 
different his-tagged functional proteins into VLPs of 20 nm diameter. As a proof-of-
principle, nanoreactors containing H6-CalB were produced and their enzymatic activity 
was shown by the hydrolysis of 4-nitrophenyl acetate. The amount of encapsulation still 
needs to be quantified to be able to comment on encapsulation efficiency and to compare 
the enzyme activity. Preliminary experiments suggested that on average less than 1 protein 
is encapsulated in the T = 1 capsules. Potentially, the low encapsulation efficiency could 
be indicating that the size of the internal cavity is selective towards the encapsulation of 1 
protein. This was in line with the absence of increase in molecular mass for VLPs with 
CalB and the comparable amount of fluorescence observed after encapsulation of H6-
EGFP with 1.0 and 10.0 equivalents of NiCl2. Furthermore, the diameter of the internal 
volume of the T = 1 VLPs was previously shown to be less than 5 nm,[23] which suggests 
that only 1 or 2 proteins would be allowed inside. This limited encapsulation efficiency can 
be very interesting for studying single enzyme molecules.[13]  
 Furthermore, nickel-induced self-assembly was found as an alternative stimulus to 
ELP-induced assembly for the formation of VLPs with presumably T = 1 symmetry. Even 
though Ni2+-mediated assembly was reported before for his-tagged CPs of CCMV, this is 
the first time that almost complete assembly was observed. This could possibly be 
explained by a synergistic effect of the ELP-induced assembly and the Ni2+-induced 
assembly. The observed self-assembly at neutral pH and low salt concentration enables the 
application of CCMV VLPs in a wider range of conditions. 
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Materials 
Restriction enzymes and ligase were obtained from New England Biolabs. E. coli M15MA pREP4 cells 
were a kind gift by David A. Tirrell. Rosalie Teeuwen is acknowledged for kindly providing pET15b-H6-
EGFP. Ampicillin, kanamycin and chloroamphenicol were purchased from MP Biomedicals. Natural 
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amino acids, lysozyme, imidazole and isopropyl β-D-1-thiogalactopyranoside (IPTG) were obtained from 
Sigma-Aldrich. 4-Azido-L-homoalanine was obtained from Iris Biotech GmbH (Germany). BCN-
lissamine-rhodamine B was purchased from SynAffix BV (The Netherlands). Trypsin (mass spectrometry 
grade) was acquired from Promega. Synthesis of imidazole-1-sulfonyl azide hydrochloride was described 
in Chapter 4.  
Construction of expression vector 
For the construction of the expression vector for azidohomoalanine incorporation, a synthetic gene was 
ordered (GenScript, Piscataway, USA). The gene was optimized for codon usage of E. coli and the 
M137A mutation was introduced (for gene sequence, see below). Both the gene and the pQE80L 
expression vector (QIAGEN) were sequentially digested with HindIII and BamHI. The linearized vector 
and the insert were purified by agarose gel electrophoresis and subsequently ligated to yield pQE80L-
MR-H6-ELP-[V4L4G1-9]-CP(ΔN26, M137A). This plasmid was transformed into E. coli XL1 Blue cells, 
the DNA was extracted and the sequence was confirmed by DNA sequencing.  
Synthetic gene sequence for construction of pQE80L-MR-H6-ELP-[V4L4G1-9]-CP(ΔN26, M137A) 
GGATCCGTTCCGGGCGTCGGTGTTCCTGGCCTGGGTGTACCAGGTGTAGGTGTTCCAGGCC
TGGGTGTTCCTGGTGTAGGTGTGCCTGGTCTGGGCGTGCCAGGCGGCGGTGTTCCTGGTGT
GGGGGTTCCTGGTTTAGGTACCGTGGTCCAACCTGTTATTGTAGAACCAATCGCTAGCGGC
CAAGGCAAGGCTATTAAAGCATGGACCGGTTACAGCGTATCTAAGTGGACCGCCTCTTGTG
CGGCTGCCGAAGCTAAAGTAACCAGCGCTATTACTATCTCTCTGCCTAATGAGCTGTCGTC
CGAACGTAACAAGCAGCTGAAGGTAGGTCGTGTTCTGCTGTGGCTGGGTTTGCTGCCGTCT
GTTAGCGGCACTGTGAAATCCTGTGTTACCGAGACGCAGACTACTGCTGCTGCCTCCTTTC
AGGTGGCATTAGCTGTGGCCGACAACTCGAAAGATGTTGTCGCTGCTGCGTACCCGGAGGC
GTTTAAGGGTATTACCCTGGAACAACTGACCGCGGATCTGACGATCTACTTGTACAGCTCT
GCGGCTCTCACTGAGGGCGACGTCATCGTGCATTTGGAGGTTGAGCATGTCCGTCCTACGT
TTGACGACTCTTTCACTCCGGTGTATTAGAAGCTT  
Protein sequences 
H6-ELP[V4L4G1-9]-CP(ΔN26) 
GHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLE 
VVQPVIVEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNK 
QLKVGRVLLWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAF 
KGITLEQLTADLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY 
MR-H6-ELP-[V4L4G1-9]-CP(ΔN26, M137A) 
MRGSHHHHHHGSVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGT 
VVQPVIVEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNK 
QLKVGRVLLWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAAYPEAF 
KGITLEQLTADLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY 
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EGFP 
MGSSHHHHHHSSGLVPRGSHMLEKREAEAGRLGAGGPVATMVSKGEELFTGVVPILVE 
LDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYP 
DHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKED 
GNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDG 
PVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK 
CalB 
MGLPSGSDPAFSQPKSVLDAGLTCQGASPSSVSKPILLVPGTGTTGPQSFDSNWIPLS 
AQLGYTPCWISPPPFMLNDTQVNTEYMVNAITTLYAGSGNNKLPVLTWSQGGLVAQWG 
LTFFPSIRSKVDRLMAFAPDYKGTVLAGPLDALAVSAPSVWQQTTGSALTTALRNAGG 
LTQIVPTTNLYSATDEIVQPQVSNSPLDSSYLFNGKNVQAQAVCGPLFVIDHAGSLTS 
QFSYVVGRSALRSTTGQARSADYGITDCNPLPANDLTPEQKVAAAALLAPAAAAIVAG 
PKQNCEPDLMPYARPFAVGKRTCSGIVTPLEHHHHHH 
Expression of purification of proteins 
H6-ELP[V4L4G1-9]-CP(ΔN26) 
Expression and purification of H6-ELP[V4L4G1-9]-CP(ΔN26) was performed as described in Chapter 5.  
Aha-ELP-CP  
For a typical expression, 60 mL LB medium, supplemented with ampicillin (100 mg/L) and kanamycin 
(25 mg/L), was inoculated with a single colony of E. coli M15MA pREP4 containing pQE80L-MR-H6-
ELP-[V4L4G1-9]-CP(ΔN26, M137A) and was incubated at 37 °C overnight. This overnight culture was 
used to inoculate 1L of M9 minimal medium, supplemented with all 20 natural amino acids (40 mg/L 
each), glucose (0.4 %), CaCl2 (0.1 mM), MgSO4 (5 mM), thiamine·HCl (35 mg/L), ampicillin (100 mg/L) 
and kanamycin (25 mg/L). The culture was grown at 37 °C until an OD600 of 0.6 was reached. Then the 
culture was sedimented by centrifugation (4000 g at 4 °C for 15 min). After washing the cells twice with 
cold 0.9 % NaCl solution, the cells were resuspended in M9 minimal medium supplemented with 19 
natural amino acids (40 mg/L each, no methionine), azidohomoalanine (100 mg/L), glucose (0.4 %), 
CaCl2 (0.1 mM), MgSO4 (5 mM), thiamine·HCl (35 mg/L), ampicillin (100 mg/L) and kanamycin (25 
mg/L). Expression was induced by addition of IPTG up to 1 mM. After 5 h of expression at 30 °C, the 
cells were harvested by centrifugation (4000 g at 4 °C for 15 min) and the pellet was stored at -20 °C 
overnight. The protein was purified as described for H6-ELP[V4L4G1-9]-CP(ΔN26) in Chapter 5. For 
storage the proteins were assembled by dialysis against a pH 5.0 buffer (50 mM NaOAc, 500 mM NaCl, 
10 mM MgCl, 1 mM EDTA, pH 5.0). The protein was produced with a yield lower than 1 mg/L of 
culture and the purity was investigated by SDS-PAGE. ESI-TOF (JEOL AccuTOF): Aha-ELP-CP 
calculated 22565.7 Da, found 22565.3 Da (Figure 6.4b). 
Met-ELP-CP 
For a typical expression, 20 mL 2xYT medium, supplemented with ampicillin (100 mg/L) and kanamycin 
(25 mg/L), was inoculated with a single colony of E. coli M15MA pREP4 containing pQE80L-MR-H6-
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ELP-[V4L4G1-9]-CP(ΔN26, M137A) and was incubated at 37 °C overnight. This overnight culture was 
used to inoculate 500 mL of 2xYT medium supplemented with ampicillin (100 mg/L) and kanamycin (25 
mg/L). The culture was grown at 37 °C and protein expression was induced during logarithmic growth 
(OD600 = 0.4-0.6) by addition of IPTG up to 1 mM. After 5 h of expression at 30 °C, the cells were 
harvested by centrifugation (4000 g at 4 °C for 15 min) and the pellet was stored at -20 °C overnight. The 
protein was purified as described for H6-ELP[V4L4G1-9]-CP(ΔN26) in Chapter 5. For storage the 
proteins were assembled by dialysis against a pH 5.0 buffer (50 mM NaOAc, 500 mM NaCl, 10 mM 
MgCl, 1 mM EDTA, pH 5.0). The protein was produced with a yield of 10 mg/L of culture and the 
purity was verified by SDS-PAGE. ESI-TOF (JEOL AccuTOF): Met-ELP-CP calculated 22570.7 Da, 
found 22569.0 Da (Figure 6.4a). 
H6-EGFP 
For a typical expression, 20 mL LB medium, supplemented with ampicillin (100 mg/L), was inoculated 
with a single colony of E. coli BLR(DE3) containing pET15b-H6-EGFP and was incubated at 37 °C 
overnight. This overnight culture was used to inoculate 500 mL of 2xYT medium supplemented with 
ampicillin (100 mg/L). The culture was grown at 37 °C and protein expression was induced during 
logarithmic growth (OD600 = 0.6) by addition of IPTG up to 1 mM. After 7 h of expression, the cells 
were harvested by centrifugation (4000 g at 4 °C for 15 min) and the pellet was stored at -20 °C 
overnight. After thawing, the cell pellet was resuspended in 20 mL lysis buffer (50 mM NaH2PO4, 10 mM 
imidazole and 300 mM NaCl, pH 8.0). The cells were then lysed by ultrasonic disruption (3 times 30 s, 
100% duty cycle and output control 3, Branson Sonifier 250, Marius Instruments Nieuwegein, the 
Netherlands). The lysate was centrifuged (15000 g at 4 °C for 15 min) to remove the cellular debris. The 
supernatant was incubated with 1 mL Ni-NTA agarose beads (QIAGEN) for 1 h at 4 °C. Subsequently, 
the suspension was loaded onto a column, the flow-through was collected and the column was washed 
twice with 5 mL wash buffer (50 mM NaH2PO4, 20 mM imidazole and 300 mM NaCl, pH 8.0). Finally, 
the H6-EGFP was eluted from the column using 5 mL elution buffer (50 mM NaH2PO4, 250 mM 
imidazole and 300 mM NaCl, pH 8.0). The volume of the protein solution was reduced to 1 mL using 
centrifugal filtration (Amicon Ultra-0.5 mL, 10 kDa). The protein was then further purified and the 
buffer was exchanged to phosphate buffered saline (PBS) via size exclusion chromatography (Superdex 
200 10/300 GL). 300 μL fractions were collected and analyzed by SDS-PAGE. The fractions containing 
pure H6-EGFP were combined and 3 mg aliquots were flash frozen and stored at -20 °C. The protein 
was produced with a yield of 24 mg/L of culture and the purity was verified by SDS-PAGE (Figure 6.7a, 
lane 2). ESI-TOF: calculated 30950.8 Da, found 30946.7 Da (Figure 6.7c).  
CalB-H6 
Construction of pET22b-CalB-H6 has been previously described.[27] For a typical expression, 20 mL LB 
medium, supplemented with ampicillin (100 mg/L) and chloroamphenicol (50 mg/L), was inoculated 
with a single colony of E. coli B834(DE3)pLysS containing pET22b-CalB-H6 and was incubated at 37 °C 
overnight. This overnight culture was used to inoculate 500 mL of 2xYT medium supplemented with 
ampicillin (100 mg/L) and chloroamphenicol (50 mg/L). The culture was grown at 37 °C and protein 
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expression was induced during logarithmic growth (OD600 = 0.6) by addition of IPTG up to 1 mM. After 
overnight expression at 25 °C, the cells were harvested by centrifugation (4000 g at 4 °C for 15 min) and 
the pellet was stored at -20 °C overnight. After thawing, the cell pellet was resuspended in 20 mL lysis 
buffer (50 mM NaH2PO4, 10 mM imidazole and 300 mM NaCl, pH 8.0). The cells were then lysed by 
ultrasonic disruption (3 times 30 s, 100% duty cycle and output control 3, Branson Sonifier 250, Marius 
Instruments Nieuwegein, the Netherlands). The lysate was centrifuged (15000 g at 4 °C for 15 min) to 
remove the cellular debris. The supernatant was incubated with 1 mL Ni-NTA agarose beads (QIAGEN) 
for 1 h at 4 °C. Subsequently, the suspension was loaded onto a column, the flow-through was collected 
and the column was washed twice with 5 mL wash buffer (50 mM NaH2PO4, 20 mM imidazole and 300 
mM NaCl, pH 8.0). Finally, the CalB-H6 was eluted from the column using 5 mL elution buffer (50 mM 
NaH2PO4, 250 mM imidazole and 300 mM NaCl, pH 8.0). The volume of the protein solution was 
reduced to 200 μL using centrifugal filtration (Amicon Ultra-0.5 mL, 10 kDa). The protein was then 
further purified and the buffer was exchanged to phosphate buffered saline (PBS) via size exclusion 
chromatography (Superdex 200 10/300 GL). 300 μL fractions were collected and analyzed by SDS-
PAGE. The fractions containing pure CalB-H6 were combined and stored at 4 °C. The protein was 
produced with a yield of 4 mg/L of culture and the purity was verified by SDS-PAGE (Figure 6.7a, lane 
1). ESI-TOF: calculated 34269.7 Da, found 34267.9 Da (Figure 6.7b).  
Mass spectrometry 
Protein mass characterization was performed by electrospray ionization time-of-flight (ESI-TOF) on a 
JEOL AccuTOF. Deconvoluted mass spectra were obtained using MagTran 1.03b2. Isotopically averaged 
molecular weights were calculated using the “Protein Calculator v3.3” at 
http://www.scripps.edu/~cdputnam/protcalc.html. 
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry 
measurements on the tryptic digest fragments were performed on a Bruker Biflex III spectrometer with 
α-cyano-4-hydroxycinnamic acid  as matrix.  
Tryptic digestion 
Tryptic digest analysis of the ELP-CPs was performed by adding 1.0 μg trypsin to 14 μg of protein in 24 
μL 20 mM NH4HCO3. After 5 hours of incubation at 37 °C the samples were purified using ZipTip-C18 
(Millipore) and eluted in 20 μL 75 % acetonitrile in 0.1 % trifluoroacetic acid / MQ. The digest was then 
analyzed by MALDI-TOF mass spectrometry. 
Cycloadditions 
5 equivalents of BCN-lissamine-rhodamine B (2) were added to 20 μg of azide-containing ELP-CP in pH 
7.5  buffer with 500 mM NaCl (50 mM Tris, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5). The 
reaction was analyzed by SDS-PAGE, after incubation at room temperature for 3 h while shaking. 
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Self-assembly 
Two types of buffers were used for self-assembly experiments, a pH 5.0 buffer (50 mM NaOAc, 500 mM 
NaCl, 10 mM MgCl2, 1 mM EDTA, pH 5.0 set with HCl) and a pH 7.5 buffer (50 mM TrisHCl, 300-
2000 mM NaCl, 10 mM MgCl2, pH 7.5 set with HCl). The NaCl concentration in the latter buffer was 
varied between 300 and 2000 mM. Prior to use, all buffers were filtered over a Millipore 0.2 µm filter.  
For ELP-induced
For 
 assembly of CPs, dialysis was used to change buffer composition. Therefore, CP-dimer 
solution (44 µM in 50 mM Tris, 300 mM NaCl, 10 mM MgCl2, pH 7.5) was inserted into a dialysis 
membrane (Spectra/Por 4 dialysis tubing, 12-14 kDa MWCO, 10 mm flat width) and dialyzed against 100 
mL of pH 7.5 buffer with 2 M NaCl (50 mM Tris, 2000 mM NaCl, 10 mM MgCl2, pH 7.5). After 60 min 
the buffer solution was refreshed and the solution was incubated for another 60 min. All these steps were 
performed at room temperature (20 °C).  
nickel-induced
 
 assembly of CPs, NiCl2 was added up to 44 µM to CP-dimer solution (44 µM in 50 
mM Tris, 300 mM NaCl, 10 mM MgCl2, pH 7.5). This mixture was incubated on ice for 1 h. 
Nickel-mediated encapsulation 
Encapsulation of H6-EGFP was performed in the presence of 0.1, 1.0, 10.0, 100.0 equivalents of NiCl2 
(i.e. nickel ions per capsid protein monomer). Therefore, 200 µL of H6-EGFP (10 µM) and CP-dimer (44 
µM) in pH 7.5 buffer with 300 mM NaCl (50 mM Tris, 300 mM NaCl, 10 mM MgCl2, pH 7.5) were 
incubated in the presence of the desired amount of NiCl2 for 1 h at room temperature. Subsequently, 
ELP-induced assembly was induced by dialysis against pH 7.5 buffer with 2 M NaCl. 
For encapsulation of CalB-H6, 200 µL of CalB-H6 (12 µM) and CP-dimer (44 µM) in pH 7.5 buffer with 
300 mM NaCl (50 mM Tris, 300 mM NaCl, 10 mM MgCl2, pH 7.5) were incubated in the presence of the 
44 µM of NiCl2 for 30 min on ice. For the negative control, incubation was performed in the absence of 
NiCl2. Subsequently, ELP-induced assembly was induced by dialysis against pH 7.5 buffer with 2 M 
NaCl. 
Size exclusion chromatography (SEC) 
The SEC measurements were performed on a Superose 6 10/300 GL column from GE Healthcare. For a 
typical analysis, 100 µL sample (100 µg) was separated on the column. All SEC measurements, except for 
multi-angle laser light scattering measurements, were performed on an Amersham Ettan LC system (GE 
Healthcare, Diegem, Belgium) equipped with a fraction collector. The size exclusion chromatography – 
multi-angle laser light scattering (SEC-MALLS) experiments were performed on a Shimadzu LC-20A 
Prominence system (Shimadzu, ‘s Hertogenbosch, The Netherlands) at room temperature using the 
Superose 6 10/300 GL column in-line with a Wyatt DAWN HELEOS II light scattering detector using a 
laser operating at 658 nm and a Wyatt Optilab Rex refractive index detector. Overnight flushing of the 
system was performed to pre-equilibrate the buffer followed by normalization using Bovine Serum 
Albumin. Weight-averaged molecular weight calculations were performed using ASTRA 6.0.6.13, using a 
dn/dc value of 0.185 for pH 5.0, 0.5 M NaCl buffer (50 mM NaOAc, 500 mM NaCl, 10 mM MgCl2, 1 
mM EDTA, pH 5.0). 
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Asymmetric-flow field-flow fractionation (AF4) 
The asymmetric-flow field-flow fractionation - multi-angle laser light scattering (AF4-MALLS) 
experiments were performed using a Shimadzu LC-20A Prominence system, with Shimadzu CTO20A 
injector, and a Wyatt Eclipse AF4 equipped with the short channel with a regenerated cellulose 10 kDa 
membrane (Millipore) and wide spacer of 350 µm, connected to a Wyatt DAWN HELEOS II light 
scattering detector using a laser operating at 658 nm, a Wyatt Optilab Rex refractive index detector and a 
Shimadzu SPD20A. The channel was pre-equilibrated for every buffer followed by normalization using 
Bovine Serum Albumin. Weight-averaged molecular weight calculations were performed using ASTRA 
6.0.6.13, using a dn/dc value of 0.170 for pH 7.5, 2.0 M NaCl buffer (50 mM Tris, 2000 mM NaCl, 10 
mM MgCl2, pH 7.5) and a dn/dc value of 0.185 for pH 7.5, 0.5 M NaCl buffer (50 mM Tris, 300 mM 
NaCl, 10 mM MgCl2, pH 7.5). Typically, 10 µL sample (10 µg) of 1.0 mg/mL were analysed using the 
following flow rates and method (Table 6.1): 
Table 6.1. AF4 method 
Duration (min) Mode Cross flow rate  
start (mL/min) 
Cross flow rate  
end (mL/min) 
2 Elution 2.00 2.00 
1 Focus - - 
2 Focus + inject - - 
1 Focus - - 
15 Elution 2.00 0.30 
4 Elution 0.00 0.00 
4 Elution + inject 0.00 0.00 
1.00 mL/min detector flow, 1.50 mL/min focus flow, 0.20 mL/min inject flow 
 
TEM 
TEM grids (FCF200-Cu, EMS) were glow-discharged using a Cressington Carbon coater and power unit. 
5 µL sample (0.2 mg/mL) was applied to the glow-discharged grid and incubated for 1 minute. Then the 
sample was removed carefully using a filter paper and the grid was allowed to dry for at least 15 min. 
Subsequently, the grid was negatively stained by applying 5 µL of 2% uranyl acetate in water. The staining 
solution was removed after 15 seconds and the grid was again allowed to dry for at least 15 min. The 
samples were analyzed on a JEOL JEM-1010 TEM (Jeol, Japan).  
Enzyme activity assay 
Lipase activity was analysed by the hydrolysis of 4-nitrophenyl acetate (4-NPA). Therefore 1 µL of 50 
mM 4-NPA in 50 % isopropanol in MQ was added to 59 µL of peak fraction of nanoreactors in a quart 
cuvette. The production of 4-nitrophenol was monitored for 5 minutes at room temperature by 
measuring absorbance at 405 nm in a UV-VIS spectrophotometer (Varian). The reactions were 
performed in triplicate and were corrected for autohydrolysis of 4-NPA. 
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7.1. Elastin-like polypeptides: from structural elucidation to 
application 
The materials science community has been inspired by Nature’s ability to create materials 
based on structural proteins such as collagen, keratin, silk fibroin and elastin. The 
unraveling of their function has been the topic of numerous investigations. The structure-
function relationship of elastin, an elastic protein-based cross-linked material, which can 
be found in the extracellular matrix of mammalian tissue, could not be explained until the 
discovery of its soluble precursor, tropoelastin, and the deciphering of its amino acid 
sequence.[1-2] The highly repetitive nature of the hydrophobic domains observed in 
tropoelastin initiated the development of elastin-like polypeptides (ELPs). These 
polypeptides, which mimic tropoelastin in its ability to self-assemble by demonstrating a 
lower critical solution temperature (LCST) behavior, were first reported by Urry and 
coworkers.[3] ELPs can be switched from a water-soluble state to an insoluble 
hydrophobic state, resulting in aggregation. At low temperatures ELPs are soluble in 
aqueous solution; upon raising the temperature above the transition temperature of the 
ELPs, the solution becomes cloudy due to aggregation. This phenomenon is completely 
reversible.  
 Over the last decades, the view on ELPs has changed from a tool to explain the 
structure-function relationship of elastin, into a unique class of stimulus-responsive 
materials. Biosynthetic production of these protein-based polymers enables an unrivaled 
level of control over sequence and polymer length, resulting in a tailor made transition 
temperature. The biosynthesis furthermore provides the opportunity to introduce 
biologically-active peptide sequences. The easy access to a wide variety of ELPs has paved 
the road for the application of these stimulus-responsive polypeptides in various fields of 
materials science. The low toxicity and potential biocompatibility make these polymers 
particularly interesting for biomedical applications.[4]  
 The following sections give an overview on the development of the two main areas in 
which ELPs are applied and our contributions to these developments. In the last section 
an outlook for the application of ELPs is presented and the expectations for the field of 
protein nanotechnology are discussed. 
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7.1.1 Protein purification 
The research group of Chilkoti was the first to recognize the applicability of ELPs for the 
purification of proteins by directly fusing the target protein to this stimulus-responsive 
polypeptide.[5] Chen and coworkers expanded this principle to ELP-mediated affinity 
precipitation for bioseparation of DNA and proteins.[6-7] The most recent developments in 
this field have been directed to the construction of a generic ELP-based purification 
platform for antibodies, which would overcome the limitations of the industrial state-of-
the-art purification. Alternative methods for purification of antibodies are particularly 
interesting as these immunoglobulins have become one of the fastest growing classes of 
therapeutics, with currently more than 25 FDA-approved therapeutic antibodies for 
treatment of diseases.[8] Both the Chen and our group have developed purification 
procedures relying on ELP-fusions with antibody-binding domains that bind to the 
constant region of antibodies.[9] We observed a difference in binding affinity of the Z33 
antibody-binding domain for antibodies from various origins, which allowed us to 
separate human from bovine antibodies (Chapter 2 and 3). The Chen-group is currently 
collaborating with Bristol-Myers Squibb (BMS) in an attempt to industrially integrate their 
newly developed antibody purification process, and they have furthermore extended this 
methodology to a set-up for high-throughput screening.[10] The involvement of 
pharmaceutical industry clearly illustrates the potential of this methodology. 
7.1.2. Nanocarriers 
Another promising application of ELPs can be found in the field of drug delivery, where 
ELPs have been used as carriers for drugs. The research into ELP-based carriers can be 
divided into two subclasses: macromolecular carriers, where drugs are attached to ELPs, 
and nanocarriers, in which drugs are encapsulated in ELP-based particles. This latter class 
is generally the product of self-assembly of amphiphilic ELP diblock copolymers, 
consisting of hydrophilic and hydrophobic blocks.[11-12] 
 The work described in Chapters 4, 5 and 6 of this thesis contributes to the field of 
ELP-induced nanocarriers by designing novel ELP-based block copolymers. In our first 
approach we developed an amphiphilic block copolymer consisting of a stimulus-
responsive ELP block and a hydrophilic corona-forming poly(ethylene glycol) (PEG) 
block. PEG was chosen as the hydrophilic block, as it efficiently provides stealth and 
steric protection for encapsulated materials and, because of its low toxicity, has been 
approved for internal applications by regulatory agencies.[13] The synthesis of ELP–PEG 
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required alternative production procedures to the previously described ELP nanocarriers, 
which were produced biosynthetically by genetically encoded ELP block copolypeptides. 
We chose to use the recently developed strain-promoted alkyne–azide cycloaddition to 
conjugate the two end-functionalized macromolecules. This conjugation chemistry also 
enabled us to produce miktoarm star polymers, which consisted of one ELP-block with 
multiple PEG blocks. Such block copolymer architectures were shown to be valuable to 
control the structure and stability of the self-assembly product. 
 In an attempt to obtain even higher control over the self-assembly product we were 
inspired by naturally occurring protein cages that generally consist of a distinct number of 
protein subunits organized into perfectly defined capsules. To this end, we constructed a 
block copolymer in the form of a fusion protein, consisting of a viral capsid protein and a 
short ELP block. This design combined the properties of the two blocks: the ability of 
capsid proteins to form well-defined nanocapsule morphologies and the stimulus-
responsive character of the ELP fragment. To our knowledge this ELP–CP block 
copolymer provides the highest control over ELP-induced self-assembled structures that 
have been reported until today. Of course, the toxicity of these ELP-based nanocarriers 
needs to be assayed and the targeting and drug release have to be investigated. In order to 
further expand this concept towards the application in drug delivery, it would be very 
interesting to use non-viral shell-forming blocks, such as ferritin, nanovaults and 
carboxysomes. 
7.2. Outlook 
The view from the materials science community on ELPs has changed from a source of 
inspiration to a protein-based polymer which can be applied in many materials. This 
protein-based polymer has been thoroughly characterized and many fundamental studies 
on their potential applicability in purification and drug delivery have been reported. In the 
past 10-15 years, studies into ELP-based purification platforms have made exciting steps 
forward, resulting in ELP-mediated purification of biotherapeutics. This methodology is 
now ready for industrial application and the future will tell its feasibility. Therefore, it is 
interesting to see that pharmaceutical industry is collaborating on implementing this 
technology. Of course, several more practical issues, such as scalability of the process and 
recyclability of the ELP-scaffold, need to be studied in a more industrial setting. 
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 The use of ELPs for the bottom-up synthesis of self-assembled nanovehicles for drug 
delivery is a very interesting concept.[14] The hydrophobic interior of such nanocarriers can 
be employed to accommodate hydrophobic drugs, which have previously shown to be 
potent therapeutics, but lack efficacy due to their unfavorable pharmacokinetic properties. 
Even though promising progress towards the application of ELPs into drug delivery has 
been reported,[15-16] this has not yet resulted in clinical application. Commercialization is 
expected to require more fundamental understanding of these polypeptides and more 
thorough examination of their toxicity and immunogenicity. This is not surprising as also 
the development of liposomal drug delivery systems until their first clinical application 
took several decades.[17] The biodegradability of ELPs can be an advantage over other 
drug delivery systems, however, the fate of the ELP degradation products also needs to be 
examined, as it is known that elastin-derived peptides (EDP) can function as signaling 
peptides.  
 The research into ELP-based materials is part of the much broader field of protein 
nanotechnology. Protein-based materials are not limited to materials based on structural 
proteins, such as silk, collagen and elastin, but also enzymes and binding-domains are 
integrated in protein materials for the construction of sensors and nanoreactors.[18-19] In 
the last couple of years exciting progress has been made in this relatively new field of 
protein nanotechnology and many new developments are to be expected.[20-21] Designer 
polypeptides for self-assembled protein structures are of particular interest as the 
biosynthetic production allows incorporation of any naturally occurring functionality, 
ranging from structural components to more advanced functionalities such as catalytic 
activity or complex structural features. In this thesis we have also shown that modular 
combination of protein elements can result in new materials with emergent properties. 
Also de novo design of proteins[22-23] and short peptide sequences[24] has recently resulted in 
self-assembling cage-like polypeptide-based nanomaterials. 
 It is envisioned that in the future protein nanotechnology could be combined with 
other materials as the most recent developments in bioorthogonal chemistry enable highly 
efficient and specific functionalization of proteins.[25-26] Some very interesting 
advancement has already been made using thiol-maleimide chemistry. This has resulted in 
hybrid systems for controlled polymerization inside protein cages,[27] supramolecular 
polymerization of protein complexes to form nanotubes,[28-29] and light-gated 
nanocages.[30] The rapid development of custom-designed protein materials is promising 
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and the combination with other materials using state-of-the-art conjugation chemistry 
could lead to even more sophisticated molecular machines. 
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Summary 
The materials science community has been inspired by Nature’s ability to employ 
structural proteins such as elastin for the preparation of materials with well-defined 
properties. The unraveling of elastin’s structure-function relationship resulted in the 
development of elastin-like polypeptides (ELPs). These polypeptides mimic elastin’s 
soluble precursor, tropoelastin, in its ability to self-assemble by displaying a lower critical 
solution temperature (LCST) behavior; ELPs can be switched reversibly upon raising the 
temperature from a water-soluble to an insoluble hydrophobic state, resulting in 
aggregation. Chapter 1 describes both the biosynthesis and the biological role of elastin, 
and the development and characteristics of elastin-like polypeptides, followed by an 
overview of elastin-like polypeptide-based materials. As illustrated in this chapter, the view 
on ELPs has changed from a tool to explain the structure-function relationship of elastin, 
into a unique class of stimulus-responsive materials. This useful property has motivated 
their application in a wide variety of materials and biological applications.  
 In the rest of the thesis we explore the stimulus-responsive character of hybrid ELP-
based block copolymers for the development and characterization of materials with novel 
emergent functionalities. We focus on the application of ELPs for the purification of 
antibodies and for the formation of well-defined ELP-induced nanocarriers.  
 In Chapter 2 and 3 we explored the use of ELPs in the purification of antibodies. 
This research was motivated by the growing demand for purified immunoglobulins, which 
are widely applied as detection probes, purification ligands and targeting moieties in 
research and medicine. The increasing production of antibodies requires new 
straightforward and cost efficient processes for their purification. Currently, antibodies are 
purified by several column chromatography steps. The bottleneck in this downstream 
processing is found in the Protein A-based affinity capture chromatography. Purification 
by affinity precipitation, using ELPs, is an interesting alternative to affinity 
chromatography. This requires an antibody-binding domain to be coupled to the ELP. 
Chapter 2 describes the thermodynamic investigation of the interaction between 
antibodies and Z33, a minimized antibody-binding domain derived from Protein A of only 
33 amino acids. A difference in Z33 binding affinity of several orders of magnitude was 
observed between human and bovine antibodies. This finding was further explored in 
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Chapter 3, in which the application of the Z33-ELP fusion protein in the purification of 
antibodies by affinity precipitation is described. The observed selectivity towards human 
IgGs was employed for the efficient and selective ELP-mediated purification of human 
IgGs from mixtures containing bovine IgGs and other proteins. 
 Chapters 4, 5 and 6 of this thesis discuss the ELP-induced formation of nanocarriers 
by employing especially designed ELP-based block copolymers. Such stimulus-responsive 
carriers are promising for their potential application in the field of controlled drug release. 
 In our first approach, which is described in Chapter 4, we developed a series of 
amphiphilic block copolymers consisting of a stimulus-responsive ELP block and a 
hydrophilic corona-forming poly(ethylene glycol) (PEG) block. PEG was chosen as the 
hydrophilic block, as it efficiently provides stealth and steric protection for encapsulated 
materials and, because of its low toxicity, has been approved for internal applications by 
regulatory agencies. The synthesis of ELP–PEG required a production procedure in which 
a biosynthetically produced ELP block was conjugated to the synthetic PEG chain. We 
chose to use the recently developed strain-promoted alkyne–azide cycloaddition to 
conjugate the two end-functionalized macromolecules. This conjugation chemistry also 
enabled us to produce miktoarm star polymers, which consisted of one ELP-block with 
multiple PEG blocks. Such block copolymer architectures were shown to be valuable to 
control the structure and stability of the self-assembly product. 
 In order to obtain even higher control over the self-assembly product we were inspired 
by naturally occurring protein cages that generally consist of a distinct number of protein 
subunits organized into perfectly defined capsules. To this end, we constructed a block 
copolymer in the form of a fusion protein, consisting of a viral capsid protein and a short 
ELP block (Chapter 5). This design combined the properties of the two blocks: the ability 
of capsid proteins (CP) to form well-defined nanocapsule morphologies and the stimulus-
responsive character of the ELP fragment. Interestingly, this protein-based block 
copolymer could be self-assembled via two mechanisms into two different, well-defined 
nanocapsules: (1) pH-induced assembly yielded 28 nm virus-like particles, and (2) ELP-
induced assembly led to the formation of 18 nm virus-like particles. The latter were a 
result of the emergent properties of the fusion protein.  
 In Chapter 6 we describe the development of nanoreactors based on the ELP–CPs 
nanocapsules. Furthermore, we discovered an unexpectedly efficient nickel-induced  
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assembly pathway for ELP–CPs as route to the formation of 18 nm nanocapsules. This 
was probably the result of the synergistic effect of nickel complexation by the 
hexahistidine-tags of the CPs and interactions between the ELP domains. 
 Chapter 7 concludes the work described in this thesis and reflects on the progress in 
the field of ELP-based materials. An outlook for the application of ELPs is provided and, 
in a broader view, the expectations for the development of protein nanotechnology are 
discussed. 
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Samenvatting 
In de materiaalwetenschappen is men geïnspireerd door hoe de natuur structurele eiwitten, 
zoals elastine, gebruikt voor het maken van materialen met goed gedefinieerde 
eigenschappen. Het ontrafelen van de relatie tussen de structuur en de functie van elastine, 
heeft geleid tot de ontwikkeling van elastine-achtige polypeptiden (ELPs). Deze 
polypeptiden imiteren de kritische oplossingstemperatuur van de voorloper van elastine, 
genaamd tropoelastine. Dit betekent dat de ELPs reversibel geschakeld kunnen worden 
tussen een hydrofiele wateroplosbare staat en een hydrofobe niet-wateroplosbare staat, die 
leidt tot aggregatie. Hoofdstuk 1 beschrijft zowel de biosynthese als de biologische functie 
van elastine. Daarnaast worden de ontwikkeling en de eigenschappen van ELPs 
besproken, gevolgd door een overzicht van ELP-gebaseerde materialen. Zoals naar voren 
komt in dit hoofdstuk, is de kijk op ELPs door de jaren heen veranderd van een 
gereedschap om de structuur-functie relatie van elastine te verklaren, in een unieke klasse 
van stimulus-responsieve polymeren. Deze zeer nuttige eigenschap heeft geleid tot een 
scala aan toepassingen in de materiaalwetenschappen en de biologie. 
 In dit proefschrift onderzoeken wij dit stimulus-responsieve gedrag in ELP-gebaseerde 
blokcopolymeren voor de ontwikkeling en karakterisatie van materialen met nieuwe 
functionaliteiten. Hierbij concentreren wij ons op twee toepassingen van ELPs:  de 
zuivering van antilichamen en de formatie van goed gedefinieerde ELP-geïnduceerde 
nanocarriers. 
 In Hoofdstuk 2 en 3 bekijken we het gebruik van ELPs voor de zuivering van 
antilichamen (ook wel immunoglobulinen, Ig). Dit is interessant vanwege de toenemende 
vraag naar zuivere antilichamen, omdat deze worden gebruikt als detectoren, liganden 
voor zuivering en target moleculen in fundamenteel onderzoek en medicijnstudies. De 
toenemende productie van antilichamen vereist nieuwe, eenvoudige en kostenefficiënte 
methodes voor hun zuivering. Op dit moment worden antilichamen gezuiverd met behulp 
van enkele kolom chromatografische scheidingen. De bottleneck in deze aanpak zit in de 
‘Protein A’-gebaseerde affiniteitschromatografie stap. Hiervoor is zuivering door 
affiniteitsprecipitatie met behulp van ELPs een interessant alternatief. Hiervoor moeten de 
ELPs worden uitgerust met een antilichaam bindingsdomein. Hoofdstuk 2 beschrijft de 
thermodynamische studie van de interactie tussen antilichamen en Z33, een 
geminimaliseerd antilichaam-bindingsdomein. Dit domein bestaat uit slechts 33 
aminozuren en is gebaseerd op Protein A. In deze studie werd een verschil van enkele 
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orde van grootte in bindingsaffiniteit gevonden. Dit resultaat werd gebruikt in Hoofdstuk 
3, waarin we de toepassing van Z33-ELP beschrijven voor het zuiveren van 
immunoglobinen door middel van affiniteitsprecipitatie. De gevonden selectiviteit voor 
humane IgGs werd gebruikt om deze op een efficiënte en selectieve manier te zuiveren 
van runder IgGs en andere eiwitten. 
 Hoofdstukken 4, 5 en 6 van dit proefschrift bediscussiëren de ELP-geïnduceerde 
formatie van nanocarriers door gebruik te maken van speciaal ontworpen ELP-gebaseerde 
blokcopolymeren. Zulke stimulus-responsieve dragers zijn veelbelovend voor mogelijke 
toepassing in gecontroleerde medicijn afgifte.  
 In onze eerste aanpak, die beschreven is in Hoofdstuk 4, hebben we een serie 
amfifiele blokcopolymeren ontwikkeld. Deze bestaan uit een stimulus-responsief ELP-
blok en een hydrofiel poly(ethyleen glycol) (PEG) blok. PEG werd gekozen als hydrofiel 
blok, omdat het sterische bescherming levert voor geëncapsuleerde materialen en omdat 
het de nanocarriers onherkenbaar maakt voor het lichaam. Daarnaast is het vanwege zijn 
lage toxiciteit door de regelgevende instanties goedgekeurd voor inwendig gebruik. Voor 
de synthese van ELP–PEG, werd een biosynthetisch geproduceerd ELP-blok gekoppeld 
met een synthetische PEG-keten. Voor deze koppeling hebben wij gekozen gebruik te 
maken van de ‘strain-promoted alkyn–azide cycloadditie’. Deze conjugatie chemie gaf ons 
ook de mogelijkheid om zogenaamde miktoarm ster polymeren te maken, die bestaan uit 
één ELP-blok en meerdere PEG-ketens. Wij hebben laten zien dat dit soort architecturen 
van blokcopolymeren waardevol kunnen zijn voor de controle over de structuur en 
stabiliteit van het product na zelfassemblage. 
 Om nog meer controle te krijgen over het product na zelfassemblage zijn we 
geïnspireerd door in de natuur voorkomende eiwitcapsules. Deze bestaan normaal 
gesproken uit een exact aantal eiwitten die gepakt zijn tot een perfect gedefinieerde 
capsule. Daarom hebben we een blokcopolymeer in de vorm van een fusie-eiwit 
ontwikkeld, bestaande uit een viraal capside eiwit en een kort ELP-blok (Hoofdstuk 5). 
Dit ontwerp combineert de eigenschappen van beide blokken: het vermogen van de 
capside eiwitten (CP) om goed gedefineerde nanocapsules te vormen en het stimulus-
responsieve gedrag van het ELP-fragment. Dit bijzondere eiwit gebaseerde 
blokcopolymeer kon aangezet worden tot zelfassemblage middels twee verschillende 
mechanisme leidend tot twee verschillende goed gedefinieerde producten: (1) pH-
geïnduceerde assemblage resulteerde in nanocapsules van 28 nm, en (2) ELP-geïnduceerde 
assemblage leidde tot formatie van nanocapsules van 18 nm.  
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 In Hoofdstuk 6 beschrijven we de ontwikkeling van nanoreactoren die gebaseerd zijn 
op de ELP–CPs nanocapsules. Verder ontdekten we een onverwacht efficiënte nikkel-
geïnduceerde assemblage voor de ELP–CPs als manier om nanocapsules van 18 nm te 
produceren. Deze assemblage was waarschijnlijk het resultaat van een synergestisch effect 
van de complexatie van nikkel door de hexahistidine fragmenten en de interactie tussen de 
ELP-blokken. 
 Tot slot wordt er in Hoofdstuk 7 een algemene conclusie gegeven over het werk in dit 
proefschrift.  Daarnaast wordt er gereflecteerd op de voortgang op het gebied van ELP-
gebaseerde materialen. Uiteindelijk wordt afgesloten met een verwachting voor de 
toekomstige toepassing van ELPs en in een breder perspectief worden de verwachting 
voor de ontwikkeling van eiwit nanotechnologie besproken. 
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Dankwoord 
Vele mensen hebben op verschillende manieren bijgedragen aan mijn promotieonderzoek 
en de tijd die hieraan voorafgegaan is. En nu het proefschrift klaar is wil ik graag gebruik 
maken van de mogelijkheid om iedereen die heeft bijgedragen te bedanken. Hiervoor wil 
ik graag een aantal mensen in het bijzonder bedanken. 
 Ten eerste mijn promotor Jan van Hest. Jan, jouw brede interesse in de wetenschap en 
je inspirerende enthousiasme hebben mij enorm gemotiveerd. Ik waardeer het vertrouwen 
en de vrijheid die je me hebt gegeven om aan veel verschillende (soms ongerelateerde) 
projecten te werken. Ik heb veel van je geleerd tijdens mijn opleiding en 
promotieonderzoek, bedankt hiervoor. 
 Daarnaast wil ik de manuscriptcommissie bestaande uit prof. Ger Pruijn, prof. Martien 
Cohen Stuart en dr. Maarten Merkx bedanken voor het kritisch lezen van mijn 
proefschrift en voor hun deelname aan mijn promotiecommissie. Ook ben ik prof. Jeroen 
Cornelissen en prof. Roeland Nolte dankbaar voor de nuttige discussies en hun deelname 
aan mijn promotiecommissie. 
 Mijn werk bij de afdeling Bio-organische Chemie begon met een stage aan peptiden en 
eiwitten bij Dennis. Deze ervaring heeft mijn interesse in het onderzoek op het grensvlak 
van scheikunde en biologie aangewakkerd. In deze eerste onderzoeksstage heb ik van 
Sanne geleerd over productie en analyse van recombinante eiwitten. Sanne, jou expertise 
en inzet en hebben mij geïnspireerd. Ik heb het altijd erg leuk gevonden om met je samen 
te werken tijdens mijn stages en later ook als collega’s. Nanda, nadat ik ongeveer één jaar 
bezig was met mijn onderzoek, begon jij ook met een promotieonderzoek aan de 
‘amazing’ ELPs. Ik heb enorme waardering voor jouw inzet en doorzettingsvermogen. 
Bedankt dat je altijd tijd had om samen resultaten te delen en te bespreken. Sanne en 
Nanda, ik ben blij dat ik tijdens mijn verdediging door jullie als paranimfen wordt 
bijgestaan. 
 Tijdens mijn promotieonderzoek heb ik met verschillende mensen samengewerkt. 
Deze vele samenwerkingsprojecten hebben mij de kans gegeven om bij veel verschillende 
projecten betrokken te zijn en daardoor veel nieuwe dingen te leren. Sander, ik wil je graag 
bedanken voor je motiverende enthousiasme en voor de prettige samenwerking aan de 
verschillende chemical biology projectjes. Marjoke, bedankt voor je hulp bij de synthetisch 
organisch chemische projecten, en nog heel veel succes in Berkeley! Morten, thanks for 
the peptide synthesis and the hyggelig coffees. Inge, bedankt dat je mij hebt  
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geïntroduceerd in de wereld van de eiwit capsules. Jasmin, thank you for the fruitful 
collaboration on the CS2 hydrolase project. Angelique en Rinske, ook jullie bedankt voor 
de samenwerking en de gezellige tijd op het werk. Anhe, Annika, Nanda, Lise, Ryan, 
Sander, Sanne en Zhipeng met jullie heb ik jarenlang in hetzelfde kantoor gedeelte 
gezeten. Bedankt voor jullie suggesties, gezelligheid en voor de snoepjes en koekjes! 
 Naast de samenwerking met collega’s heb ik ook verschillende studenten mogen 
begeleiden. Jaleesa, bedankt voor jouw enthousiasme en gezelligheid in het lab. Heel veel 
succes en geluk in Mexico! Fleur, ik ben blij dat je uiteindelijk besloot om je eerste 
masterstage bij mij te komen doen. Bedankt voor je enorme inzet en heel veel succes met 
je eigen promotieonderzoek! Jan Pille, jij begon je bachelorstage met je eigen zeer 
ambitieuze project, en dankzij jouw inzet en enthousiasme is dit een succes geworden. 
Dani and Ahmet, I would also like to thank you for your contribution to my project. 
 During my PhD-project I also collaborated with several people outside the Radboud 
University Nijmegen. I’m grateful to prof. Adam Zlotnick for giving me the opportunity 
to come to Indiana University Bloomington. I really enjoyed the two weeks in your lab, 
and I’m grateful to Joe Wang and Chengli Li for their help with the characterization of the 
VLPs during this period. Furthermore, I would also like to thank Jun Qiu and Jens Thies 
for their interest and ideas and also for helping me with my experiments at DSM. 
 Marieke, Desiree en Peter van Dijk, ik ben jullie dankbaar voor de administratieve 
ondersteuning en de hulp met bestellingen. Daarnaast wil ik Peter van Galen, Helene en 
Geert-Jan bedanken voor de technische ondersteuning van de massa spectrometrie, de 
HPLC apparatuur en de electronenmicroscopie.  
 Ook ben ik prof. Ger Pruijn dankbaar dat ik een deel van mijn werkzaamheden heb 
mogen uitvoeren in zijn lab in het Nijmegen Centre of Molecular Life Sciences. Hier kon 
ik altijd rekenen op de hulp en interesse van Bas, Carla, Els, Ilmar, Joyce, Nicole, Remon, 
Sanne, Siebe, Vincent, Wilbert en Wilma. 
 Uiteraard wil ik ook de overige collega’s en studenten van de Van Hest-groep en de 
rest van de afdeling Organische Chemie bedanken voor de goede sfeer en prettige 
werkomgeving zowel op het lab als tijdens de pauzes, borrels en feestjes. Ik denk ook met 
plezier terug aan de leuke momenten tijdens de verschillende congressen. Iria, Mariëlle, 
Stijn, Matthijs, Nanda, Ruud en Zhipeng, bedankt voor jullie gezelligheid tijdens de ACS 
meetings.  
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 Naast het onderzoek was er natuurlijk ook nog tijd voor ontspanning, hiervoor wil ik 
mijn familie en vrienden bedanken. De vriendenweekenden, het sporten en de feestjes 
hebben gezorgd voor de nodige afleiding, zodat ik er daarna weer fris tegenaan kon. 
 Ten slotte wil ik ook graag mijn ouders en zusjes bedanken. Papa, mama, Nikki en 
Tessa bedankt voor jullie interesse in alles wat ik doe, en voor de steun die ik altijd heb 
gekregen. Tessa, bedankt voor het ontwerpen van de omslag. Mijn laatste woorden van 
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